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ABSTRACT 
 
SELF-ASSEMBLING BIOAFFINITY HYDROGELS FOR LOCALIZED ANTIBODY 
DELIVERY  
 
 
 
By 
Wen Liu 
August 2018 
 
Dissertation supervised by Wilson S. Meng, Ph.D. 
The scope of illnesses that are being treated using monoclonal antibodies (mAbs) 
has been expanding from cancers to autoimmune diseases due to their high specificity to 
their molecular target.  Because many of the new mAbs are aimed to modulate the 
immune system, an emerging concern is that patients with chronic illnesses are subjected 
to immune-related Adverse Events (irAEs).  Loss of immunological tolerance to self-
antigens or increased susceptibility to infections have been documented in some mAb 
treatments.  Localized sustained release of mAb at disease sites might mitigate the risk of 
such toxicities.  Antibody drugs are formulated typically for parenteral delivery because 
of degradative mechanisms in gastrointestinal tract.  The assumption has been that 
systemic administration via the vascular compartment is the best or only option in 
achieving therapeutic drug concentrations at diseased tissues.  This paradigm is being 
 v 
challenged as the benefit to risk ratio of exposing non-targeted tissues or organs is lower 
in many of the new mAb drugs.  Direct local mAb administration to target tissues is 
enabled by biomaterials scaffolds in which drug retention at the intended sites can be 
modulated.  This dissertation is focused on two bioaffinity hydrogels designed for 
administering mAbs locally.  One was built on a fluorescent-based module: fluorogen 
activating protein dL5 and its fluorogenic partner malachite green (MG) for immobilizing 
IgG Fc binding molecule protein A/G into the hydrogel matrix.  This design was shown 
to render sustained release of mAbs and detectable binding sites in vivo through a built-in 
imaging feature.  The second design was built upon pG_EAK, a bifunctional polypeptide 
in which the IgG-binding domain was genetically fused to the self-assembling sequence 
(AEAEAKAK)3 (single amino acid code; hereafter “EAK”).  The rationale was that 
reducing the number of interactions would enhance the translational prospect of the 
bioaffinity hydrogel.  Sustained release and prolonged retention of IgG delivered in the 
pG_EAK gel were observed in vitro and in vivo in skin allografts.  In conclusion, 
bioaffinity hydrogels built on dL5_EAK and pG_EAK are two injectable platforms on 
which IgG mAbs of different specificities can be localized and sustained in diseased 
tissues. 
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Chapter 1  
Introduction 
Monoclonal antibody therapeutics 
Antibodies (Abs), also known as immunoglobulins (Igs), are glycoproteins 
produced by activated B lymphocytes in response to antigens (Ags).  The Ags often 
originate from bacteria, viruses and other microorganisms, but can also arise from 
endogenous proteins.  While the body generates Ab with diverse specificities, each Ab 
binds to its cognate Ag in a specific way, with the paratope from Ab interacting with the 
epitope from the Ag by spatial complementarity like lock and key.  Electrostatic forces, 
hydrogen bonding, hydrophobic interactions and van der Waal forces constitute the 
reversible interaction between Ab and Ag.  The basic structural unit of Ab is typically a 
Y shaped molecule composed of two large heavy chains and two small light chains 
(Figure 1-1).  Light chains, comprising λ or κ peptide subunits, are connected to heavy 
chains by disulfide bonds, giving rise to a symmetrical molecule with two identical 
antigen-binding sites.  The two heavy chains are also connected together through 
disulfide bonds which constitute the hinge region providing various flexibility to each 
antigen binding site in different subclasses of antibodies.  The antigen-binding fragment 
(Fab) is located on the tip of the “Y”.   It is composed of heavy and light chains and is 
made up of six hypervariable loops known as hypervariable region with each variable 
region binding to the specific Ag.  The hypervariable regions are also called 
complementarity-determining regions (CDRs).  The enormous diversity of Fab allows the 
immune system to recognize a wide variety of Ags.  On the other hand, crystallizable 
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fragment (Fc) of the Ab is located at the base of "Y” composed of only heavy chains.  Fc 
is a constant region that can be used to distinguish between the five different subtypes of 
Igs because the constant heavy chain can bind to its specific Fc receptor to communicate 
with other components of the immune system, helping generate appropriate immune 
response for different foreign objects the body may encounter.  Thus, the general 
structure of Ab is embedded with multiple functionalities [1]. 
  
Figure 1-1 the Y shaped structure of antibody.  
 
There are five Ab classes in mammals: IgA, IgD, IgE, IgG and IgM, named 
according to the type of their heavy chain types in α, γ, δ, ε, and μ respectively.  They 
differ in their biological properties, distribution and functions.  IgA, usually present in 
dimer, is mostly found in mucosal area, preventing colonization by pathogens [2].  IgE is 
mainly involved in allergy by binding to allergens and triggers histamine release from 
other immune cells.  Both IgM (in the form of monomer) and IgD are expressed on the 
surface of naive B cells, rendering the B cells ready to respond to Ag.  IgM also exists as 
a pentamer with very high avidity when in a secreted form and eliminates pathogens in 
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the early stages of humoral immunity before sufficient IgG is produced [3].  After 
activation through the binding to Ag, B cells can divide and differentiate into Ab 
producing cell (plasma cells).  As the most abundant isotype of Ab (~75% of serum Ab), 
IgG provides the majority of Ab based immunity protecting the body from infection.  It is 
also the only isotype that has receptors to facilitate passage through human placenta to 
provide protection to the fetus in utero before its own immune system develops [1]. 
As the major component of humoral immunity, IgG plays its role by several 
mechanisms including neutralizing binding to pathogens, immobilization and 
agglutination of pathogens, coating of pathogen surfaces for the recognition and ingestion 
by phagocytic immune cells (opsonization, phagocytosis and clearance), intracellular 
antibody-mediated proteolysis, activation of classical pathway of complement system 
(complement-dependent cytotoxicity, CDC) and antibody-dependent cell-mediated 
cytotoxicity (ADCC) [4].  There are four subclasses of IgG in human: IgG1, IgG2, IgG3 
and IgG4, named in order of their abundance in serum.  IgG1 is the most abundant 
subclass, comprising about two thirds of all IgG molecules.  The four subclasses of IgG 
differ mainly in the structure of hinge regions, leading to unique biological properties of 
each class.  They emerge at different stages of immune response and vary in segmental 
flexibility, binding affinity to Fc receptor on phagocytic cells as well as the ability to 
activate complement system [5]. 
Because of the high specificity of Ab to their cognate Ag, Ab has risen as the 
leading molecular platform in the development of therapeutics for autoimmune diseases, 
cancer, and inflammatory disease.  While polyclonal antibodies (pAbs) are a collection of 
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Ig molecules that react against different epitopes on a specific antigen, monoclonal 
antibodies (mAbs) are produced by a unique parent cell, binding to the same epitope of 
an antigen.  Serum-pooled human pAb treatment provides wide population diversity of 
Ab families against many possible targets, but suffers from the disadvantages including 
nonspecific Ab components with possible side effects and no rational efficacy against 
diseases, diluting effector functions specific to desired targets and effectors.  Cost, 
inconsistent efficacy and questionable reliability, toxicity and safety issues for a pooled 
human blood-derived protein product hinders its clinical acceptance as an Ab therapy [6].  
After mAb technique was first created in 1975 by using mouse x mouse hybridoma 
(fusion of myeloma cell lines with B cells), the production of mAb at bulk quantity have 
become possible [7].  Since FDA approved the first therapeutic mAb in 1986 to reduce 
acute rejection after organ transplants [8], there has been over 70 therapeutic mAb 
approved in the US as of March 29, 2018 (Table 1-1).  The approval rate of mAb drugs is 
historically high recently, with more than 10 therapeutic mAb products approved in 2017 
alone.  The global sales revenue for all mAb products constitutes approximately half of 
the total sales of all biopharmaceutical products.  The continuous growth in sales of the 
approved mAb products, along with hundreds of mAb product candidates currently in 
clinical trials, will lead to sustained growth in sales of mAb products and an expanding 
market share of mAb in biopharmaceutical industry. 
Table 1-1 FDA approved mAb. Information is up to date as of March 29, 2018. 
Drug 
Name 
 Active Ingredients Initial U.S 
Approval 
Company Target* Therapeutic 
indications* 
Ilumya Tildrakizumab-
Asmn 
3/20/2018 Merck Sharp 
Dohme 
IL-23 Ps 
Trogarzo Ibalizumab-
Uiyk 
3/6/2018 Taimed 
Biologics USA 
CD4 HIV-1 
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Ixifi Infliximab-Qbtx 12/13/2017 Pfizer Inc TNFα CD; UC; RA; AS 
etc 
Ogivri Trastuzumab-
Dkst 
12/1/2017 Mylan Gmbh HER2 breast cancer 
Hemlibra Emicizumab 11/16/2017 Genentech Inc Factor Ixa- 
& Factor X 
bleeding episodes 
Fasenra Benralizumab 11/14/2017 Astrazeneca Ab IL5Rα asthma 
Mvasi Bevacizumab-
Awwb 
9/14/2017 Amgen Inc VEGF Metastatic 
Colorectal Cancer 
etc. 
Cyltezo Adalimumab-
Adbm 
8/25/2017 Boehringer 
Ingelheim 
TNFα RA; JIA; PsA; AS; 
CD; UC; Ps 
Besponsa Inotuzumab 
Ozogamicin 
8/17/2017 Wyeth Pharms 
Inc 
CD22 ALL 
Tremfya Guselkumab 7/13/2017 Janssen Biotech IL-23 Ps 
Rituxan 
Hycela 
Hyaluronidase; 
Rituximab 
6/22/2017 Genentech Inc CD20 FL; DLBCL; CLL 
Kevzara Sarilumab 5/22/2017 Sanofi 
Synthelabo 
IL-6R RA 
Imfinzi Durvalumab 5/1/2017 Astrazeneca Uk 
Ltd 
PD-L1 urothelial 
carcinoma 
Renflexis Infliximab-
Abda 
4/21/2017 Samsung 
Bioepsis Co Ltd 
TNFα CD; UC; RA etc 
Dupixent Dupilumab 3/28/2017 Regeneron 
Pharmaceuticals 
Il-4Rα atopic dermatitis 
Ocrevus Ocrelizumab 3/28/2017 Genentech Inc CD20 MS 
Bavencio Avelumab 3/23/2017 Emd Serono Inc Pd-L1 MCC 
Siliq Brodalumab 2/15/2017 Valeant 
Luxembourg 
Il-17Ra Ps 
Zinplava Bezlotoxumab 10/21/2016 Merck Sharp 
Dohme 
Clostridium 
Difficile  
Toxin B 
CDI 
Lartruvo Olaratumab 10/19/2016 Eli Lilly And Co PDGFR-α STS 
Amjevita Adalimumab-
Atto 
9/23/2016 Amgen Inc TNFα RA etc. 
Zinbryta Daclizumab 5/27/2016 Biogen IL-2Rα 
(CD25) 
MS 
Tecentriq Atezolizumab 5/18/2016 Genentech Inc PD-L1 urothelial 
carcinoma 
Inflectra Infliximab-
Dyyb 
4/5/2016 Celltrion Inc TNFα CD; UC; RA etc 
Cinqair Reslizumab 3/23/2016 Teva Respiratory 
LLC 
IL-5 asthma 
Taltz Ixekizumab 3/22/2016 Eli Lilly And Co IL-17A Ps 
Anthim Obiltoxaximab 3/18/2016 Elusys 
Therapeutics Inc 
PA 
component  
of B. 
anthracis 
toxin 
Inhalational 
Anthrax 
Empliciti Elotuzumab 11/30/2015 Bristol Myers 
Squibb 
SLAMF7 multiple myeloma 
Portrazza Necitumumab 11/24/2015 Eli Lilly Co EGFR lung cancer 
Darzalex Daratumumab 11/16/2015 Janssen Biotech CD38 multiple myeloma 
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Nucala Mepolizumab 11/4/2015 Glaxosmithkline 
LLC 
IL-5 asthma 
Praxbind Idarucizumab 10/16/2015 Boehringer 
Ingelheim 
direct 
thrombin  
inhibitor 
dabigatran 
bleeding 
Repatha Evolocumab 8/27/2015 Amgen Inc PCSK9 HeFH; HoFH 
Praluent Alirocumab 7/24/2015 Sanofi Aventis PCSK9  HeFH etc 
Unituxin Dinutuximab 3/10/2015 United Therap glycolipid 
GD2 
neuroblastoma 
Cosentyx Secukinumab 1/21/2015 Novartis Pharms 
Corp 
IL-17A Ps 
Opdivo Nivolumab 12/22/2014 Bristol Myers 
Squibb 
PD-1 melanoma; lung 
cancer 
Blincyto Blinatumomab 12/3/2014 Amgen CD19                    ALL                                              
Keytruda Pembrolizumab 9/4/2014 Merck Sharp 
Dohme 
PD-1 melanoma 
Entyvio Vedolizumab 5/20/2014 Takeda Pharms 
USA 
integrin 
receptor 
UC; CD 
Sylvant Siltuximab 4/23/2014 Janssen Biotech IL-6 MCD 
Cyramza Ramucirumab 4/21/2014 Eli Lilly And Co VEGFR2 Gastric Cancer 
Gazyva Obinutuzumab 11/1/2013 Genentech CD20 chronic 
lymphocytic 
leukemia 
Kadcyla Ado-
Trastuzumab 
Emtansine 
2/22/2013 Genentech HER2 breast cancer 
Raxibacumab Raxibacumab 12/14/2012 Human Genome 
Sciences Inc 
PA 
component  
of B. 
anthracis 
toxin 
inhalational 
anthrax 
Perjeta Pertuzumab 6/8/2012 Genentech HER2 breast cancer 
Adcetris Brentuximab 
Vedotin 
8/19/2011 Seattle Genetics CD30 Hodgkin 
Lymphoma 
Yervoy Ipilimumab 3/25/2011 Bristol Myers 
Squibb 
CTLA-4 melanoma 
Benlysta Belimumab 3/9/2011 Human Genome 
Sciences Inc. 
BLyS or 
BAFF 
 SLE 
Prolia Denosumab 6/1/2010 Amgen RANK 
ligand 
osteoporosis 
Xgeva Denosumab 6/1/2010 Amgen 
 
Actemra Tocilizumab 1/8/2010 Genentech IL-6R RA 
Arzerra Ofatumumab 10/26/2009 Glaxo Grp Ltd CD20 CLL 
Stelara Ustekinumab 9/25/2009 Centocor Ortho 
Biotech Inc 
IL-12 & 
IL-23 
Ps 
Stelara Ustekinumab 9/25/2009 Janssen Biotech IL-12 & 
IL-23 
Ps; PsA; CD 
Ilaris Canakinumab 6/17/2009 Novartis Pharms IL-1β CAPS; FCAS; 
MWS 
Simponi Golimumab 4/24/2009 Centocor Ortho 
Biotech Inc 
TNFα RA; PsA; AS 
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Simponi Aria Golimumab 4/24/2009 Janssen Biotech TNFα RA 
Cimzia Certolizumab 
Pegol 
4/22/2008 Ucb Inc TNFα CD 
Soliris Eculizumab 3/16/2007 Alexion Pharm C5 PNH 
Vectibix Panitumumab 9/27/2006 Amgen EGFR colorectal carcinom 
Lucentis Ranibizumab 6/30/2006 Genentech VEGF-A macular 
degeneration 
Tysabri Natalizumab 11/23/2004 Biogen Idec α4-integrin MS 
Avastin Bevacizumab 2/26/2004 Genentech VEGF carcinoma of the 
colon & rectum 
Erbitux Cetuximab 2/12/2004 Imclone EGFR colorectal 
carcinoma 
Xolair Omalizumab 6/20/2003 Genentech human IgE asthma 
Humira Adalimumab 12/31/2002 Abbvie Inc TNF RA 
Zevalin Ibritumomab 
Tiuxetan 
2/19/2002 Spectrum 
Pharms 
CD20 non-Hodgkin's 
lymphoma 
Campath Alemtuzumab 5/7/2001 Genzyme CD52 
 
 B-CLL 
Lemtrada Alemtuzumab 5/7/2001 Genzyme CD52 B-CLL 
Mylotarg Gemtuzumab 
Ozogamicin 
5/17/2000 Wyeth Pharms 
Inc 
CD33  myeloid leukemia 
Herceptin Trastuzumab 9/25/1998 Genentech HER2 metastatic breast 
cancer 
Remicade Infliximab 8/24/1998 Centocor Inc TNFα CD 
Synagis Palivizumab 6/19/1998 Medimmune RSV F 
protein 
lower respiratory 
tract disease 
Simulect Basiliximab 5/12/1998 Novartis IL-2Rα 
(CD25) 
acute organ 
rejection 
Rituxan Rituximab 11/26/1997 Genentech CD20 lymphoma. 
Prostascint Capromab 
Pendetide 
10/28/1996 Cytogen PSMA diagnostic imaging 
agent. 
Myoscint Imciromab 
Pentetate 
7/3/1996 Centocor Inc human 
myosin 
cardiac imaging 
agent 
Reopro Abciximab 12/22/1994 Centocor Inc GP IIb/IIIa 
receptor  
of human 9 
platelets 
cardiac ischemic 
complications 
   Summarized from FDA website [9]. 
* Abbreviations: Interleukin: IL; Cluster of differentiation: CD; tumor necrosis factor 
alpha: TNFα; human epidermal growth factor receptor 2: HER2; receptor: R; vascular 
endothelial growth factor: VEGF; human programmed death receptor-1: PD-L1; platelet-
derived growth factor receptor alpha: PDGFR-α; Signaling Lymphocytic Activation 
Molecule Family member 7: SLAMF7; epidermal growth factor receptor: EGFR; 
proprotein convertase subtilisin kexin type 9: PCSK9; protective antigen: PA; human 
vascular endothelial growth factor receptor 2: VEGFR2; soluble human B lymphocyte 
stimulator protein: BLyS or BAFF; cytotoxic T lymphocyte antigen-4: CTLA-4; 
complement protein C5: C5; respiratory syncytial virus: RSV; prostate specific 
membrane antigen: PSMA; glycoprotein: GP; acute lymphoblastic leukemia: ALL; 
Crohn’s Disease: CD; Ulcerative Colitis: UC; Rheumatoid Arthritis: RA; Merkel cell 
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carcinoma: MCC; Follicular Lymphoma: FL; Clostridium difficile infection: CDI; soft 
tissue sarcoma: STS; multiple sclerosis: MS; Juvenile Idiopathic Arthritis: JIA; Psoriatic 
Arthritis: PsA; Ankylosing Spondylitis: AS; Plaque Psoriasis: Ps; Diffuse Large B-cell 
Lymphoma: DLBCL; Chronic Lymphocytic Leukemia: CLL; multicentric Castleman’s 
disease: MCD; systemic lupus erythematosus: SLE; heterozygous familial 
hypercholesterolemia: HeFH; hypercholesterolemia: HoFH; active psoriatic arthritis: 
PsA; CryopyrinAssociated Periodic Syndromes: CAPS; Familial Cold Autoinflammatory 
Syndrome: FCAS; Muckle-Wells Syndrome: MWS; paroxysmal nocturnal 
hemoglobinuria: PNH; B-cell chronic lymphocytic leukemia: B-CLL. 
 
The first mAb drug OKT3 (Ortho Biotech) is murine-derived which brought acute 
immunogenicity problems from patients responsive to murine-sourced Ab.  Chimeric or 
humanized mAb product emerged nearly a decade later to reduce the side effects 
associated with the potential immunogenicity [10].  Most mAb products on market now 
are humanized and their therapeutic effect is usually achieved through various 
mechanisms including neutralization (bind to the ligand or receptor expressed on the cell 
surface and block the target signaling pathway), ADCC, CDC or even antibody-mediated 
toxin delivery [11].  When the body is in a diseased or dysfunctional condition, there is 
typically an upregulation or downregulation of immune cell activation level and cytokine 
secretion level.  Exogenous therapeutic mAb could thus be administered to counteract 
this irregular condition through immune response augmentation or suppression.  In cancer 
therapy, a need for cytotoxic T cell stimulation is usually favorable.  For example, mAb 
product Ipilimumab, which binds to the negative regulator of T cell activation CTLA-4, 
could be used to block its interaction with its ligands CD80/CD86.  The blockade of 
CTLA-4 has been shown to augment T-cell activation and proliferation, thus enhancing 
the treatment to melanoma.  In a similar way, PD-L1, which blocks T-cell function and 
activation through interaction with PD-1 and CD80, could serve as another anti-cancer 
target.  Delivering mAb binding to PD-L1 (e.g. Durvalumab) could release the inhibition 
 9 
of immune responses, increase T-cell activation in vitro and decrease tumor size in vivo.  
In contrast, immune system sometimes needs to be suppressed through mAb intervention 
in transplantation management to reduce the incidence of rejection or prolong the graft 
survival time.  For example, Basiliximab, which binds to IL-2Rα expressed on the surface 
of activated T cells, competitively inhibits IL-2 mediated activation of lymphocytes, a 
critical pathway in the cellular immune response involved in allograft rejection.  
Therefore, Basiliximab is used to prevent rejection in organ transplantation, especially in 
kidney transplant.  In summary, the immune regulation exerted by mAb therapeutics 
could be two-ways: either in cancer therapy to boost effector T cell function against 
tumor cells or as immunosuppressive agent in transplantation scenario or autoimmune 
diseases to aid in induction of tolerance.  
Unmet needs in therapeutic antibody delivery 
Most mAb products on market are formulated for intravenous infusion or 
injection, usually at high doses because of their stoichiometric rather than catalytic 
pharmacodynamics.  More recently there have been products approved for subcutaneous 
administration.  These are often packaged in pre-filled syringes designed for self-
administration by patients, which can improve compliance.  Because of incomplete 
absorption of subcutaneous administered mAbs into the systemic circulation, very high 
doses are required (up to 100 mg/kg), making the costs of mAb therapies for patients who 
need regular repeated dosing comparatively unaffordable [4].  Another important aspect 
associated with systemic delivery of immune modulatory mAbs is the induction of 
potential immune-related adverse events (irAEs).  These effects could be significant 
because the impacts could remain after cessation of the therapy, due to loss of T cell 
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tolerance.  Such effects have been documented in checkpoint inhibitors in anti-CTLA-4 
and anti-PD-1 mAbs in cancer patients, in some cases resulting in drug-induced 
rheumatoid arthritis [12].  Based on these reasons, direct administration of therapeutic 
mAbs into diseased tissues is justified.  The technical challenge is that the mAb must be 
retained at the site of intended action for extended durations.  Therefore, localized 
delivery vehicle for sustained release of mAbs at diseased site is essential to provide 
opportunities to modulate the immune pathogenesis and at the same time reduce the risk 
of irAEs.   
Sustained-release strategies for therapeutic antibodies 
Delivering active pharmaceutical ingredient (API) locally using matrix based 
vehicles such as hydrogels or particles is a common strategy exploited to control the 
release of the drug from delivery system.  Drug loaded vehicle administered topically can 
serve as a local drug depot to provide stable supply of the drug over a prolonged time 
duration compared to drug delivered in aqueous formulation.  The matrix geometry 
including pore size, material architecture and interaction of the matrix with loaded drugs 
would affect the release profile of the API from the vehicle [13].  
Compared to conventional small molecular drugs, mAb drugs possess the 
advantage of high intrinsic specificity and affinity to numerous targets and molecules of 
various size and chemistry (binding constant at sub-nanomolar concentrations) [14].  
However, due to its protein nature, it is easy to denature and aggregate under harsh 
conditions.  Their functions, which are linked to their 3D conformation, would be 
compromised if they are subject to chemical and physical degradation including 
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proteolytic and chemical degradation, physical unfolding and aggregation.  Therefore, 
mAb products are usually limited to parenteral formulations to avoid proteolytic 
degradation in GI tract.  While particle-based system does improve the injectability of 
these formulations and achieve prolonged release, most of them suffer from low 
encapsulation efficiency or incomplete release [15].  Also, organic solvent and high 
mechanical energy introduced during the preparation of the polymer-based particles 
could be detrimental to mAb stability.  In addition, environmental changes such as pH 
within the particle matrix throughout the release process could destabilize the 
encapsulated protein molecule [16].   
Alternatively, hydrogels, which are made of crosslinked polymers, can serve as 
vehicles for mAb loading and release.  The gel formation process usually proceeds at 
ambient temperature and organic solvents are rarely required in the process due to the 
hydrophilic nature of gel forming polymers [17].  The mild preparation condition of 
hydrogels can help to preserve protein stability.  The resulting porous structure of the 
hydrogels, along with their high water content, are suitable properties to accommodate 
high loads of water soluble molecules like mAbs.  The nanostructure of the hydrogel 
network, especially the mesh size, determines the mobility of encapsulated molecules and 
controls their release rate from the network.  Upon injection, hydrogels can also adapt to 
the tissue contour in vivo.  In addition, ‘smart’ hydrogels, or stimuli-responsive hydrogels 
can be constructed.  With varying chemical compositions and ionic moieties designed to 
monomer comprising the polymer, the gelation of polymer solution can be triggered upon 
environment changes such as temperature, pH or ionic strength.  When the solution-gel 
transition occurs at physiological conditions, in-situ forming hydrogels could be obtained, 
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which is favorable in their biomedical applications including drug delivery.  With the 
exhibition of all the advantageous physicochemical properties, hydrogels can serve as an 
excellent platform for local mAb delivery to preserve its stability while slow down its 
release from the gel matrix [18]. 
Drug delivery hydrogel formed by β-sheet fibrillizing peptide  
β-sheet fibrillizing peptide (βFP) is one type of self-assembling peptides (SAPs) 
emerging as a novel material in the field of drug delivery and tissue engineering due to 
their excellent biocompatibility and ease for manipulation [19-22].  The first discovered 
βFP sequence EAK16-II (AEAEAKAKAEAEAKAK with A as alanine, E as glutamic 
acid and K as lysine) self-assembles into cross-linking fibrils upon exposure to electrolyte 
solutions [23].  EAK16-II can be used to formulate depots of small molecule drugs, 
proteins, and even cells [24-27].  The in-situ gel forming feature of EAK16-II allows it to 
be administered through conventional needled syringes.  In gels made with the FP 
sequence RADA, the molecular size of the encapsulated protein governs release kinetics; 
IgG, the largest molecule tested, reaches maximum release by 24 hours [28].  
Koutsopoulos et al. subsequently demonstrated that burst release can be suppressed by 
encapsulating IgG in double-layer nanofibers using two amphiphilic building blocks, 
RADA and KLDL [29].  These studies demonstrate the versatility of FP in controlling 
the release of protein drugs. 
The release rate of loaded protein from FP hydrogel is mainly controlled by the 
relative size of the protein and the pore size of the hydrogel matrix because simple 
diffusion is the only mechanism controlling the release and the diffusion coefficient is 
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affected by mesh size and protein size according to obstruction-based theories [17].  In 
general, the smaller the drug molecule and the larger the pore size of the hydrogel matrix, 
the faster the drug would release from the hydrogel.  Therefore, large protein like IgG 
would have the slowest release rate compared to other smaller molecules when the mesh 
size of the gel, temperature and viscosity of the fluid are fixed and the protein gel non-
specific interaction is the key factor determining the release rate.  Although Ab is 
released slower in hydrogel than in simple aqueous solution, a burst release effect still 
takes place within the first few hours [30].  Therefore, an improvement on the design of 
the βFP based hydrogel is required to achieve the desired sustained release of Ab from 
the gel. 
Bioaffinity hydrogel for sustained release of antibodies 
  To further extend the release duration, an affinity mechanism controlling the 
drug release from hydrogel could be introduced to the hydrogel design.  This mechanism 
is chemically-controlled release where the release of loaded protein drug is determined by 
reactions that occurs within the hydrogel matrix.  Reversible binding occurring between 
the polymer network and protein falls into this category of reaction where the binding 
equilibrium reflected by binding constant (Kd) and association rate (kon) or dissociation 
rate (koff) would determine the drug release rate [17].  Biomolecules can provide affinity 
interactions for tuning protein release from hydrogel matrices.  The Sakiyama-Elbert 
group has engineered heparin-embedded hydrogels as protein delivery systems.  As 
highly sulfated glycosaminoglycans, heparins bind growth factors through ionic 
reversible interactions.  These systems mimic reservoirs of endogenous growth factors in 
extracellular matrix [31-36] in which secreted proteins are protected from denaturation 
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and aggregation.  Hydrogels functionalized with aptamers have been used to control 
protein release [37-40].  The Shoichet group has used Src homology domain 3 (SH3) to 
tune the release of growth factors fused with SH3 ligands [41-44].  In these designs, rapid 
diffusion is suppressed; instead, drug release is a function of the affinity of the binding 
interactions (Kd), the relative ratio of binding sites (ligands) to proteins, and the 
dissociation rate constant (koff) of the protein-binding site complexes [43].  Thus affinity-
based hydrogels afford the ability to tune release kinetics by adjusting classical 
biochemical parameters.  Based on this mechanism theory, through appropriate 
functionalization of βFP, the retention or release of drug cargo could be extended by 
introducing an affinity module onto the βFP sequence, allowing elongated therapeutic 
effect.  Hydrogels formed by the coassembly of EAK16-II and its functionalized analog 
provide affinity mechanisms for tuning Ab release from hydrogel matrix.   
The design of EAK16-II based bioaffinity hydrogel in our lab hinges on the 
design of bifunctional constructs where IgG binding module is linked to gel forming 
sequence EAK directly through recombinant technology or indirectly through a 
functional domain attached to EAK to provide additional imaging advantage.  
The IgG binding modules we employed in our design are essentially based on 
protein A, protein G, or the recombinant protein A/G (pA/G).  Protein A and protein G 
are Ig-binding proteins found on the surface of cell wall of bacteria staphylococcus 
aureus and streptococcal respectively [45, 46].  They are extensively used as antibody 
purification tools because of their specific affinity to the Fc domain of Ab.  Protein A 
consists of five IgG binding domains and protein G consists of three IgG binding 
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domains [46, 47].  The interaction of protein A with Igs is pH dependent with the binding 
capacity for protein A optimal at pH 8-9 whereas the binding capacity of protein G is 
high over a broader pH range [48].  Protein G also has a wider reactivity profile than 
protein A and it binds to all human IgG subclasses as well as rabbit, mouse and goat IgGs 
but does not binds to IgM, IgA, and IgD [45].  Its binding to Igs is often stronger than 
protein A [49].  pA/G is a recombinant protein comprising of four Ig binding sites from 
protein A and two Ig binding sites from protein G and is ideal for binding the broadest 
range of IgG subclasses from different species.  
pA/G was used as the antibody binding moiety in the first generation of the 
bioaffinity hydrogel design in my dissertation.  In this design, protein A/G was 
immobilized to the hydrogel matrix through a fluorescence-based module: a fluorogen-
activating protein (FAP) dL5 and its fluorogenic partner malachite green (MG).  FAP 
dL5 is a single chain variable antibody fragment light chain homodimer that has a 
specific affinity for MG.  The fluorescence of MG (λex = 653 nm, λem = 684 nm) is 
enhanced 20,000-fold upon binding to dL5 due to the constraint of single bond rotation 
within MG molecule.  Functional dL5 was recombinantly attached to EAK to generate a 
bifunctional construct dL5_EAK.  dL5 can thus be embedded in the hydrogel by 
coassembly of dL5_EAK with excess EAK16-II [50].  Both the immobilization and 
detection of pA/G in the hydrogel could be achieved by conjugating MG to pA/G.  With 
the help of the conjugation, the resulting conjugate pAGMG helps to link the binding sites 
pA/G to the hydrogel matrix through the binding between MG and embedded dL5.  The 
generated fluorescence upon binding provides signal for antibody binding sites detection 
(Figure 1-2). 
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Figure 1-2 schematic representation of the FAP dL5 embedded bioaffinity hydrogel 
design 
 
The benefits of this design are three-fold: first, it provides affinity driven capture 
and release; second, specific binding of IgG molecules to pA/G facilitates oriented IgG, 
rendering reduced denaturation; third, the intrinsic fluorescence generated within the 
fluorescence based module (dL5 and MG) allows easy monitoring of the IgG binding 
sites. 
The second generation of the bioaffinity hydrogel design (Figure 1-3) is based on 
a novel bifunctional construct pG_EAK where a truncated Fc-binding domain pG was 
directly attached to gel forming βFP in order to simplify the first generation design and 
promote the translational prospect.  With less components involved in the design, 
therapeutic antibodies could be directly anchored to the bioaffinity hydrogel formed by 
pG_EAK and EAK16-II coassemblies and the release rate of antibodies from the 
hydrogel is directly controlled by their binding affinity with pG. 
 17 
 
Figure 1-3 schematic representation of pG embedded bioaffinity hydrogel 
 
Projects overview 
My dissertation work centers on the design of biomaterials for therapeutic Ab 
delivery.  The biomaterial delivery platform is based on self-assembling βFP EAK16-II. 
EAK 16-II and its functionalized analogs (dL5_EAK or pG_EAK) are formulated into 
injectables to establish hydrogels in which antibodies could be stably localized.  The 
central hypothesis of this project is that the release of subcutaneously injected antibodies 
could be extended using bioaffinity hydrogels made of βFP EAK16-II and its 
functionalized analogs.  To test this hypothesis, two designs of the bioaffinity hydrogel 
were proposed and characterized.  
In the first generation design (chapter 3), fluorogen activating protein dL5 was 
attached to EAK sequence to form the functional analog dL5_EAK.  The coassembly of 
EAK16-II and dL5_EAK was optimized in molar ratio.  The colocalization of dye labeled 
IgG molecules with MG fluorescence after loading of the conjugate pAGMG and model 
IgG within the bioaffinity hydrogels, have been experimentally verified.  Prolonged 
release and delivery of IgG were demonstrated in vitro and in vivo.  A sustained release 
profile was observed for our pAGMG-decorated dL5 hydrogels for at least two months.  
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For in vivo study, after subcutaneous foot pad injection of IgG loaded bioaffinity 
hydrogels, local retention of the antibody showed higher signal intensity for 3 days 
compared with hydrogels without pAGMG. 
In the second generation design (chapter 4), Fc binding domain protein G (pG) 
was directly attached to EAK sequence to form the functional construct pG_EAK.  The 
coassembly of pG_EAK with EAK16-II was verified using gel electrophoresis and 
Congo Red absorbance change after binding.  A superior IgG loading on pG hydrogel 
and a sustained release profile of IgG from the gel for at least three months were 
observed.  The prolonged retention of IgG loaded on the bioaffinity pG hydrogels was 
monitored in normal subcutaneous tissue for 2 days and murine skin allo-transplantation 
model for 6 days after local injection compared to control system with free IgG or IgG 
loaded in nonspecific EAK gel.  Less systemic exposure of IgG displayed by pG 
bioaffinity gel was reflected in the constrained organ distribution compared to the control 
groups. 
The continuous miniaturization of the Fc binding domain attached to EAK was 
pursued to reduce the potential immunogenicity of the bioaffinity hydrogel.  Z34c, a B 
domain mimetic of native protein A, is a disulfide-linked cyclic peptide has a much 
smaller molecular weight (4.18 kDa).  It was fused to EAK to construct the bioaffinity 
hydrogel with fewer potential MHC-II ligands in the Fc binding domain which indicates 
a lower predicted immunogenicity compared to other Fc binding domains.  Preliminary 
studies have been performed to study the anti-neutrophil IgGs (anti-Ly6G and anti-
CD11b IgGs) loaded Z34c gel in inhibiting neutrophil trafficking in skin transplant model 
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(Appendix I).  The infiltration of neutrophils at the graft site were verified both ex vivo 
and in situ by detecting neutrophil elastase activity as the indicator.  Reduced neutrophil 
accumulation at transplantation site was observed in treated mouse by tracking the 
neutrophils after tail vein injection of neutrophil specific, NIR fluorescent imaging agent.  
The concept of combinational use of bioaffinity hydrogel and gel trapped particles 
was proposed.  Anti-neutrophil IgGs loaded bioaffinity hydrogel, coupled with anti-
neutrophil elastase particles (load with elastase inhibitor), could potentially work 
synergistically to effectively impede continuous neutrophil infiltration as well as counter 
tissue-destructive mechanism elicited by neutrophil elastase. 
Another valuable application for bioaffinity hydrogel is cellular therapeutics 
which is exemplified in the construction of mini thymic unit by 3D aggregation of TECs 
with anti-EpCAM antibody displayed bioaffinity hydrogels (Appendix II). The formation 
of 3D clusters of TECs facilitated by the bioaffinity hydrogel was observed in in vitro 
culture and the cell viability was verified. The artificial mini thymus units were 
transplanted into athymic nude mice and their support to T-lymphopoiesis in vivo was 
confirmed [51].  
Significance 
Each year more than 1.1 million patients suffer from thermal and chemical burns 
(Center for Disease Control and Prevention), with close to 30,000 hospitalizations in 
specialized burn centers.  Patients with extensive partial and full-thickness burns benefit 
from intact epidermis and dermis which together serve as a protective barrier to minimize 
desiccation of the underlying tissues, limit water evaporation, reduce bacterial 
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contamination, relieve pain, and promote wound healing by accelerating re-
epithelialization [52].  Despite the use of immunosuppressants, a significant fraction of 
organ allografts undergoes acute rejection, resulting in substantial parenchyma loss 
within weeks [53].  While multiple leukocytes are involved in the rejection mechanisms, 
neutrophils are one of the early cell types infiltrating graft tissues and induce necrosis 
[54].  Neutrophils rapidly infiltrate into wounds, constituting for more than 50% of all 
cells on day one.  These early arriving neutrophils can shape subsequent adaptive 
immune responses [55, 56].  Currently there are no therapies approved for selective 
suppression of neutrophil infiltration in transplant settings.  Survival of skin allografts 
can be prolonged by systemic depletion of neutrophils [57].  Wound healing is 
accelerated in neutrophil-depleted mice [58].   
One potential application of our bioaffinity hydrogel platform is to create a local 
anti-neutrophil Ab depot at the transplant site to reduce graft damage by arresting local 
neutrophil infiltration in the first 48 hours.  Blunting the intensity of this early event is 
expected to bend the overall trajectory of the rejection by limiting the production of 
proteases, the flow of alloantigens to draining lymph nodes [59, 60], suppressing T cell 
proliferation [61, 62], and subverting the migration of T cells to inflamed tissues [63].  
Localized delivery of immunomodulatory mAb can increase drug concentration at the 
inflamed graft while reducing non-specific toxicities in off-target tissues. 
Another target for mAb therapeutics is tumor.  mAbs could be locally 
administered to the tumor site to reprogram the immune system more efficiently [64, 65].  
The tumor site delivery can serve as a vaccination site to locally amplify the immune 
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system by redirecting the lymphocytes to the activated form instead of tolerant form, 
thereby impeding the metastasis of the tumor.  Delivery of Ab against the checkpoint 
proteins such as PD-1 and CTLA-4 is an effective way to unleash T cell suppression in 
cancer immunity [66].  Local delivery of Ab therapeutics by our bioaffinity hydrogels 
could concentrate the IgGs to their antigen rich region, thus augmenting the immune 
response toward tumor in a more efficient way. 
The broader Impact of the research is that the bioaffinity hydrogels may lead to 
development of new strategies in formulating mAb for subcutaneous (SC) administration 
in attaining systemic absorption.  While the majority of marketed mAbs are formulated 
for intravenous (IV) administration, SC administration of mAb has the advantage of 
allowing patients to self-administer in ambulatory settings.  However, a key challenge in 
SC administration of recombinant proteins is incomplete bioavailability, in particular at 
high doses [67].  For macromolecules such as IgG (Mr >145 kDa), lymphatic uptake is 
the main route of absorption from the SC space into the systemic circulation.  Preclinical 
studies indicate that movement of IgG through the extracellular matrix (ECM) is the rate-
limiting step.  The slow diffusion of IgG through the ECM exposes the drug to pre-
systemic, intracellular catabolism [68].  The reduction of bioavailability via this 
elimination pathway is compensated in part by binding of IgG to local tissue neonatal Fc 
receptors (FcRn) and endosomal recycling, in which a fraction of the administered mAb 
is protected from proteolytic degradation in cells.  High doses of IgG (e.g. 40 mg/kg), 
however, can saturate FcRn in local tissues, thereby increasing the fraction vulnerable to 
proteolysis [69].  Reducing the rate of mAb release from SC depot constructed by our 
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bioaffinity hydrogels has the opportunity to increase bioavailability by keeping drug 
concentrations in ECM below FcRn saturation. 
Summary 
In summary, embedding bioaffinity domain into fibrillar hydrogels can help 
extend the retention of incorporated IgGs at injection sites and prolong the release of IgG 
from local depot. 
The first generation of EAK based functionalized gel described in this dissertation 
incorporated a fluorescence based module to introduce an imaging feature in the design.  
The fluorescence generated upon the binding of embedded functional domain dL5 to its 
fluorogenic partner MG provide a convenient way to detect the IgG binding sites after 
conjugating MG to protein A/G.  The loading of IgG to the hydrogel was found to be 
colocalized with MG fluorescence where protein A/G is located which indicates the 
specific binding of IgG to protein A/G. The near to 700nm fluorescence peak wavelength 
allows the imaging of binding sites in superficial tissue after subcutaneous injection of 
the system locally.  This facilitates the in vivo optimization of the antibody delivery 
vehicle. 
The second generation of EAK based bioaffinity hydrogel entails a simplified 
design where the IgG binding domain protein G was directly attached to the self-
assembling domain EAK.  With a wider and stronger reactivity profile towards Ab 
compared to protein A, protein G embedded hydrogel provide a valid affinity mechanism 
for efficient IgG loading and sustained release for IgGs of all human subtypes.  The 
improvement of IgG retention enabled by the bioaffinity hydrogels and restrained 
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systemic exposure was both verified in normal and inflamed tissues after subcutaneous 
injection.  
For both dL5 and pG gel designs, the ratio of the IgG dose and IgG binding sites 
embedded in the hydrogel will determine the release profile for a specific formulation. 
Higher dose of the IgG will render higher portion of IgG to be release through simple 
diffusion with less percentage of IgG being sustained by the bioaffinity mechanism. 
Therefore, by modulating the comparative amount of the two, locally administered IgG 
aimed for systemic exposure and local effect could be manipulated to achieve the optimal 
therapeutic outcome for a specific disease condition. 
In addition, the bioaffinity hydrogel system could be exploited for cell 
therapeutics in tissue engineering by enabling 3D organization and proper cell to cell 
interaction in the cell culture.  The formation of mini thymus unit by generation of 3D 
aggregation of thymus epithelial cells (TECs) could be realized by mixing the cells with 
anti-EpCAM (TECs surface marker) antibodies loaded bioaffnity hydrogels.  The 
successful support of T cell development by these mini thymus unit after transplanted to 
athymic mouse suggests this bioaffinity gel platform could serve as a promising tool in 
modulating immunity through cell therapeutics.  
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Chapter 2  
Literature Review: Self-assembling Peptides as Hydrogel Forming 
Materials  
Self-assembly amphiphilic peptides have gained substantial interests among 
biomaterials scientists in the past twenty years.  The reasons being that peptides are 
generally biodegradable and that novel peptides can be generated through amino acid 
substitutions.  They can form noninvasive and injectable supramolecular scaffolds upon 
exposure to environmental stimuli such as temperature, pH, ionic strength.  Although 
initially present as soluble solutions, the self-assembled three-dimensional structures can 
serve as a versatile platform for tissue regeneration and drug delivery.  They are also 
capable of displaying bioactive epitopes and/or proteins, as well as resembling 
hierarchical structures of extracellular matrix (ECM) component.  Extensive research has 
been conducted on various self-assembly systems in recent years, from synthetic 
molecules to naturally occurring biomaterials.  This chapter will focus on the three most 
widely studied self-assembling peptide amphiphiles: ionic-complementary self-
assembling peptides, self-assembling β-hairpins and alkylated peptide amphiphiles.  The 
first category is the design basis for our bioaffinity hydrogel.  Common analytical 
techniques used to characterize the micro- or macro-structure of the assemblies or to 
investigate the self-assembling mechanisms will be summarized.  The characteristics of 
assemblies and their corresponding biomedical applications will be elaborated.  The 
limitations and challenges facing the development of peptide-based self-assembly 
systems and the future directions will be discussed in this chapter as well. 
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Introduction 
Molecular self-assembly is a very prevalent phenomenon in nature.  For example, 
phospholipid molecules can self-assemble into a bilayer and is the basis of cell membrane 
composition.  Detergent surfactant molecules can self-assemble into micelles when its 
concentration exceeds critical micelle concentration (CMC) and help to clean poorly 
soluble lipophilic species.  Silk fibroin proteins can be fabricated into silk materials over 
2km in length and have sufficient stiffness and toughness to be used in textile 
manufacture [70].  By definition, molecular self-assembly is considered as the process by 
which molecules spontaneously organize themselves into well-defined and stable 
structures through non-covalent interactions under near thermodynamic equilibrium 
conditions [71].  Essentially, it is a reversible formation of large molecular aggregates. 
The effects of self-assembly can be both beneficial and deleterious.  For instance, it can 
serve as an essential mechanism for organism composition formation, such as cell 
membranes.  However, it can also be the cause of harmful diseases such as Alzheimer’s, 
Parkinson’s, Huntington’s diseases as well as type II diabetes.  For example, amyloid 
fibril formation resulting from protein assembly is extensively considered as the cause for 
the listed neurodegenerative diseases [72].  Amyloid β-protein (Aβ), a well-known self-
assembling biomolecule, has been considered as an important factor in the cause of 
Alzheimer’s disease [73].  These protein assemblies are rich in cross β-sheet structures.  
The macroscopic membranes or plaques formed by these assemblies are speculated to 
interfere with and/or prevent cell-to-cell communications, thus leading to neurological 
disorders [74].  
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There are numerous molecular systems that can self-assemble, such as collagen 
mimetic peptides, peptide amphiphiles, protein polymer hybrids and DNA-based 
materials.  Among these different types of materials, self-assembling peptide amphiphiles 
have been extensively designed to form well-ordered structures for biomedical 
applications since 1990s.  They were brought to the attention of scientists mainly because 
of their noticeable advantages in biodegradability and low toxicity to the biological 
entities.  The self-assembly process can lead to the formation of different nanostructural 
architectures such as nanotubes and ribbons.  It can also further develop into fibers or 
hydrogels [75].  The unique properties of the formed structure can provide different 
applications in diverse fields especially in tissue engineering and drug delivery.  
Meanwhile, due to their similarity in the resulting self-assembly structures to amyloid 
proteins, some of them were studied as a simpler substitute for amyloid protein (40-42 
amino acids) as a way to find inhibitors to prevent fibrillogenesis in neurological 
disorders [76, 77].  
These self-assembling peptide amphiphiles can serve as novel materials for tissue 
engineering mostly due to the hierarchical supra-molecular structures they generate can 
resemble biological ECM and interact with cells at the molecular level.  They are 
exploited to create scaffolds for drug delivery basically owing to the unique 
characteristics of the matrix geometry formed after self-assembly and their non-covalent 
interactions with the drug payload.  In addition, the triggered self-assembly feature of 
these peptide amphiphiles can provide a ‘switch’ function which means the formation of 
insoluble structures (typically fibrous networks) can be induced by the changes in their 
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external environment.  This makes it possible for self-assembly to take place in response 
to physiologically relevant changes through rational design of the peptide composition. 
Considerable studies have been done on three types of self-assembling peptide 
amphiphiles, namely, ionic-complementary self-assembling peptides, self-assembling β-
hairpins and alkylated peptide amphiphiles.  Each type possesses distinct peptide 
sequence composition and/or structural organization.  The ionic-complementary self-
assembling peptide consists of regular repeats of alternating hydrophobic and hydrophilic 
amino acid residues.  The hydrophilic residues contain both positively charged and 
negatively charged amino acids.  These charged residues exhibit a self-complementary 
pattern of charge when the peptides are aligned in a β-sheet conformation.  By 
comparison, self-assembling β-hairpins are peptide amphiphiles comprising a central 
tetrapeptide flanked by two extended strands.  The central tetrapeptide has high β-turn 
propensity, while the two strands are composed of alternating hydrophilic and 
hydrophobic residues, primarily lysine and valine respectively.  In contrast, alkylated 
peptide amphiphiles are made of a long linear hydrophobic alkyl tail attached to a 
polypeptide block that includes β-sheet-forming segments, charged residues, and 
biological epitopes, etc.  Although displaying distinct molecular organization and 
adopting slightly different mechanisms during self-assembly, these peptide materials do 
share common features in terms of self-assembled macrostructures and functional 
applications.  To facilitate a comprehensive understanding of peptide amphiphiles and 
meanwhile identify their similarities and differences, the characteristics, self-assembling 
mechanisms and applications for each peptide amphiphile will be summarized and 
compared in this chapter. 
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Analytical techniques in characterizing the assemblies 
In order to prepare a detailed discussion about the properties of each peptide 
amphiphile, it is necessary to summarize the analytical methods commonly used to 
characterize structures and properties of peptide-based materials.  These techniques 
usually offer insight into the secondary structures of the peptide in the self-assembled 
state, the nanoscale morphology of the assembled structures and the bulk mechanical 
properties of the resulting biomaterials. 
Fluorescent spectroscopy 
Fluorescence is the property of some substances to emit light at a longer 
wavelength shortly after they absorb light at a certain wavelength [78].  Fluorescent 
spectroscopy has been one of the most powerful methods to study protein folding, 
dynamics, assembly and interactions due to its high signal-to-noise ratio and small 
sample amount required for analysis.  Extrinsic fluorescent dyes such as Thioflavin T, 
ANS, Bis-ANS, and Nile Red are widely used as tools for protein characterization 
because of their versatility, sensitivity and suitability for high-throughput screening [79].  
The fluorescence emission of these dyes will change after interacting with protein 
structures.  This interaction will induce a change on the preferred relaxation pathway of 
the dye molecule, therefore exhibiting a distinct fluorescent spectroscopy profile as 
compared to the unbound dye molecule.  This detected change in fluorescent 
spectroscopy profile can be indicative of the presence of certain protein structures. 
Among those dyes, Thioflavin T is commonly used in the field of fibrillation and 
amyloid fibril characterization [80].  For Thioflavin T, its fluorescence properties can be 
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affected by the solvent viscosity and the rigidity of its microenvironment.  In solvent of 
low viscosity, Thioflavin T has low fluorescence.  In the presence of amyloid aggregates, 
Thioflavin T exhibits an additional absorption peak at 450 nm and a highly fluorescent 
emission maximum at 480 nm [72].  The mechanism for the change in emission spectra 
of Thioflavin T is still not very clear. Some propose that Thioflavin T interacts with β-
sheet structures [81] while others attribute the fluorescence increase to the formation of 
Thioflavin T micelles which bind to the grooves of the twisted protofibrils or fibrils [82].  
Researchers have been using the unique feature of thioflavin T to semi-quantify the 
formed β-sheet fibril structures [83].  Given that peptide amphiphiles have been expected 
to form similar fibrillar structures to amyloids, thioflavin T could be utilized to 
characterize and quantify the self-assembled structures formed by these peptide 
amphiphiles. 
It is worth mentioning that Congo red is a dye frequently used in combination 
with Thioflavin T for fibril analysis.  When Congo red interacts with fibrils, the changes 
lie in the shifts of UV absorbance (from 490 nm to 540 nm) and other optical effects such 
as birefringence under plane polarized light, instead of the increase in fluorescent 
intensity.  Moreover, with the help of Congo Red, the invisible and insoluble fibrillar 
structures could be visualized under bright field microscopy, which facilitates the 
recognition of amyloid proteins and study of the macrostructure formed by self-
assembling peptides [84].  
Atomic force microscopy (AFM) 
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AFM is a type of scanning probe microscopy with relatively high resolution.  It 
can serve as an important tool to study the local nanostructure or morphology of the self-
assembled materials because it can gather information by probing the surface of the 
sample with a mechanical cantilever.  In contrast to other popular microscopic 
techniques, the outstanding signal-to-noise ratio of the AFM topograph and 3D AFM 
images allows the observation of structural details of these assemblies [85-89].  
Compared to scanning electron microscope (SEM), AFM provides superior topographic 
contrast as well as the direct measurement of surface features such as quantitative height 
information [90].  In addition, the AFM samples could be imaged in their hydrated state 
and no dehydration of the sample is necessary.  This renders it a non-destructive 
technique.  However, its capability to accurately measure the XY dimension which 
defines the width of the fiber is limited [75]. 
Circular dichroism (CD) 
Circular dichroism (CD) is defined as the phenomenon of the unequal absorption 
of left-handed and right-handed circularly polarized light by some materials [91].  It is 
known that any linearly polarized light wave can be obtained as a superposition of a left 
circularly polarized and a right circularly polarized light waves (with electric fields 
rotating clockwise ER and counterclockwise EL respectively) when their amplitude is 
identical.  Therefore, if linearly polarized light traverses a substance exhibiting circular 
dichroism, its properties will change since the substance could absorb the two circularly 
polarized components to different extents.  CD is either reported in units of ∆E (the 
difference in absorbance of ER and EL by an asymmetric molecule) or in degree ellipticity 
(the angle whose tangent is the ratio of the minor to the major axis of the ellipse).  CD is 
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considered as an excellent tool to rapidly determine the secondary structure or folding 
properties of proteins or peptides [92-94].  Different structures of proteins or peptides 
possess characteristic CD signature spectra due to the varying aligned patterns of the 
chromophores from the amides of the polypeptide backbone of the proteins.  For 
instance, α-helix has negative bands at 222 nm and 208 nm and a positive peak at 193 
nm.  Well-defined β sheet has a negative band at 218 nm and positive peak at 195 nm.  
Disordered proteins have very negative bands near 195 nm and very low ellipticity above 
210 nm.  Figure 2-1 shows the CD spectra for some representative secondary structures 
in polypeptides and proteins.  One of the biggest advantages of CD is that the data can be 
collected and analyzed within a few hours.  Samples containing only 20 ug or less of 
protein in aqueous buffers under physiological conditions can be analyzed.  This makes 
CD the most frequently used method for studying secondary structures of peptides and 
proteins.  
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Figure 2-1 CD spectra for polypeptides and proteins with representative secondary 
structures (reprinted from reference [91]). 
 
Fourier transform infrared (FTIR) spectroscopy 
FTIR spectroscopy is another commonly used technique to study the secondary 
structure of peptides in the self-assembled state.  IR is a vibrational spectroscopy with 
spectra observed in the wavelength range between 1 and 100 µm (102-104 cm-1).  
Infrared absorption comes from a changing dipole moment in the molecules during the 
vibration of interest.  Therefore, it is sensitive to the changes in inter-nuclear distances 
and bond angles which are decided by the conformations and configurations adopted by 
the particular molecular groupings [95].  Fourier transform is a mathematical process 
required to convert the raw absorption data into the actual spectrum.  A major advantage 
of FTIR spectroscopy is that its structural characterization does not rely on the physical 
state of the sample.  Samples could be easily examined in the form of aqueous or organic 
solutions, hydrated gels, in homogeneous dispersions or solids.  Also, it is not limited by 
protein size (can be very big) or the nature of the environment.  It is especially valuable 
when a peptide or protein is existing in a rapidly inter-converting dynamic equilibrium 
[96].  There is an empirical correlation between the frequency on FTIR spectroscopy of 
the amide I and amide II absorptions of a protein and the predominant secondary 
structural motif within the protein.  The amide I absorption contains mainly the 
contributions from the C=O stretching vibration of the amide group while amide II arises 
from N-H bending and C-N stretching vibrations.  Comparatively, amide I absorption is 
considered to be more useful since it is purer in its composition.  This empirical 
correlation in amide I frequencies and various secondary structure can be explained by 
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dihedral angles, hydrogen bond strengths and C=O group electron density.  Briefly, the 
dihedral angles of a polypeptide chain determine the chain geometry, thereby dictating 
the length and direction of the hydrogen bonds.  Different resulting hydrogen bond 
strengths further contribute to the different characteristic electron densities in the amide 
C=O groups.  The stronger the hydrogen bond, the lower the electron density in the C=O 
group thus the lower the amide I absorption appears.  As a result, while CD is sensitive to 
the backbone information, FTIR is more sensitive to the degree and strength of hydrogen 
bonding to the amide C=O groups.  The following table (Table 2-1) provides the most 
common correlations between protein secondary structure and the amide I frequency. 
Table 2-1 The correlations between common protein structures and amide I frequencies 
(adapted with permission from reference [97]. Copyright (1992) American Chemical 
Society) 
Structure Amide I frequency (cm-1) 
Antiparallel β-sheet 1675-1695 
α-helix 1648-1660 
Unordered 1640-1648 
β-sheet 1625-1640 
Aggregated strands 1610-1628 
 
Oscillatory rheology 
Oscillatory rheology is a technique used to measure the viscoelastic behavior of 
soft materials such as emulsions, foams, colloidal suspensions or polymer systems which 
have mechanical properties that lie between a purely elastic solid and a viscous liquid 
[98].   Many researchers use it to study the mechanical properties of hydrogels made of 
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self-assembling peptides [87, 93, 99].  An oscillatory rheometer is the instrument 
designed to make measurement of these viscoelastic properties.  The principle of the 
instrument is to measure the resultant stress response of the material after a sinusoidal 
shear deformation is applied to the sample.  The viscoelastic behavior of the sample at 
certain frequency of oscillation (ω) is characterized by the storage modulus G’(ω), and 
the loss modulus G’’(ω).  These two moduli characterize the solid-like and fluid-like 
contribution to the measured stress response respectively [98].  Knowledge of the 
mechanical properties of these self-assembled peptide materials through oscillatory 
rheology measurement allows rational design of the peptides with appropriate mechanical 
strength for specific applications in biomedical engineering or nanotechnology. 
Surface tension measurement 
Surface tension measurement is commonly employed to study the solution 
properties of molecules with an amphiphilic structure.  Axisymmetric drop shape 
analysis-profile (ADSA-P) is a powerful and reliable technique to acquire surface tension 
at the interface between water and air [100].  Technically, in order to get surface tension 
information for a peptide amphiphile solution, a pendant drop of the solution can be 
formed at the tip of a vertical Teflon needle which is connected to a motor-driven 
microsyringe.  The sample should be placed in a temperature-controlled environmental 
chamber which is saturated with water vapor.  The image of the pendant drop can be 
acquired by an optical microscope and a CCD camera and then transferred to a computer 
for software analysis.  The surface tension value is finally generated by fitting a 
theoretical curve governed by the Laplace equation of capillarity to the profile of the 
pendant drop [76].  Hydrophobicity, surface activity of the peptide and kinetics of peptide 
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adsorption can be quantified by applying ADSA-P measurement.  The conformation of 
the peptide assemblies or the aggregation status can be related accordingly [101].  By 
monitoring the surface tension change under various conditions or over time, we can get 
a better understanding about the self-assembly process and thus speculating the self-
assembly mechanism. 
Other analytical techniques 
In addition to the frequently employed methods listed above, there are still a lot of 
other techniques which are less commonly used due to inconvenient sample preparation, 
high cost or inaccurate information.  These techniques include solid-state nuclear 
magnetic resonance (ssNMR) [102-104], X-ray diffraction (XRD) [104], molecular 
dynamics (MD) simulations [92], scanning electron microscopy (SEM)[87] and 
transmission electron microscopy (TEM) [99, 105] et al.  Some of them, especially 
ssNMR and XRD, can provide us with even higher resolution and more precise 
information down to molecular or atomic level.  They are increasingly recognized as 
more useful and accurate tools to study fibril structure although high cost and limited 
availability may constrain their wide application.  It should be noted that, when studying 
these peptide amphiphiles, multi-technique approach is required to generate a more 
comprehensive and accurate picture of the self-assembly structure.  
Self-assembling peptide amphiphiles and their corresponding properties 
I. Ionic-complementary self-assembling peptide 
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Zhang et al. from Massachusetts Institute of Technology discovered the ionic-
complementary self-assembling oligopeptides [106].  These peptides are composed of 
alternating hydrophilic and hydrophobic amino acid residues and tend to adopt β-sheet 
conformation in solution.  The hydrophilic amino acids contain both positively charged 
and negatively charged residues.  They are able to form complementary ionic pairs in 
secondary or higher order of structures.  This class of self-complementary oligopeptides 
can spontaneously assemble to form large macroscopic structures/matrices when exposed 
to environmental stimuli such as temperature, pH, and monovalent inorganic salts. 
The first discovered self-assembling peptide of this type is EAK16-II (sequence: 
Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys-Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys) (structure see 
Figure 2-2).  It was originally found in a region of zuotin, a putative left-handed Z-DNA 
binding protein in yeast [107].  Because of the adoption of β-sheet conformation in 
solution, this oligopeptide molecule can present hydrophobic alanine side chains on one 
side while orienting self-complementary pairs of positively charged lysine and negatively 
charged glutamic acid side chains on the other surface.  It can form membrane-like 
structures upon addition of monovalent metal ions.  The assembly is considered to be 
facilitated by side chain ionic bond interactions between glutamic acids and lysines as 
well as the hydrophobic interactions among alanines in addition to the conventional β-
sheet backbone hydrogen bonding (Figure 2-3).  The formed membrane has high 
stability.  It is resistant to protease digestion, high temperature and a wide range of pH 
values (1.5-11).  It is also mechanically stable and can be stained by Congo red, a dye 
that preferentially stains β-pleated sheet structures.  SEM observation revealed that the 
membrane was composed of a fibrous structure consisting of interwoven individual 
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filaments (Figure 2-4) [23].  It was later found that those interwoven filaments have 
diameters of 10-20nm and porous enclosures of about 50-100nm in diameter [24]. 
 
Figure 2-2 Schematic three-dimensional molecular model of EAK16-II (carbon atoms are 
cyan, oxygen atoms are red, nitrogen atoms are blue and hydrogen atoms are white, A, E 
and K are single letter codes for amino acids alanine, glutamic acid and lysine 
respectively, reprinted from reference [108]) 
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Figure 2-3 Initially proposed model of the membrane by Zhang et al. (a) view 
perpendicular to the β-sheet; (b) stacking of β-sheets (reprinted from reference [23], 
Copyright (1993) National Academy of Sciences, U.S.A.)  
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Figure 2-4 SEM images of membranes formed by EAK16-II with serial magnification. 
The diameter of the filaments are about 10-20 nm and the distance between fibers are 
about 50-80 nm. (a, 300X, b, 1200X, c, 4500X, d, 15,000X, arrows mark the same 
location. Reprinted from reference [23], Copyright (1993) National Academy of 
Sciences, U.S.A.) 
 
Later, EAK16-II was systematically altered to generate other ionic 
complementary peptides, such as RAD16, EFK16, KLD12 and EAR8 etc, which could 
also self-assemble through similar mechanisms.  Presumably, any hydrophobic amino 
acid residue, such as valine (V), leucine (L), isoleucine (I) and phenylalanine (F) can be 
used to substitute alanine (A).  Likewise, on the hydrophilic side, arginine (R), histidine 
(H) as well as lysine (K) can be included as positively charged residues while aspartic 
acid (D) and glutamic acid (E) are commonly used negatively charged residues in the 
alternating sequence.  There are usually 8-32 amino acids in the short peptides.  For 
easier reference, the hydrophilic sides have been classified into several moduli according 
to their varied charge distribution patterns: modulus I (-+-+-+-+); modulus II (--++--++); 
modulus III (---+++); modulus IV (----++++) [109].  Here, the roman numerals indicate 
the number of the same kind of charges grouped together.  The total number of amino 
acid residues in the peptide is indicated in the name as well.  For example, EAK16-II has 
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16 amino acid residues and a charge distribution pattern of modulus II (--++--++).  
Notably, these oligopeptides all consist of L-amino acids.  Therefore, their degradation 
will only yield normal amino acids which will not arouse any biocompatibility problem 
in vivo [110]. 
This class of ionic-complementary self-assembling peptides has also attracted 
significant interest from P. Chen group from Waterloo University in Canada.  His group 
set forth to investigate various factors that influence the self-assembling process of these 
oligopeptides.  Those factors include peptide concentration, pH, salt concentration, 
charge distribution, etc.  Their findings, together with data collected by Zhang’s group, 
accelerated our knowledge about these peptides and provided us with critical information 
to speculate the self-assembling mechanisms.  
Self-assembling mechanisms and factors affecting the self-assembling 
It was initially postulated by Zhang et al. that the β-sheet system formed by 
EAK16-II may exist in two possible forms [111].  One is a single β-pleated sheet 
containing many EAK16 molecules.  In the middle of the single sheet, each amino acid 
residue is held to its neighboring peptides by two hydrogen bonds.  Meanwhile, on one 
side of the sheet there is a collection of alanine side chains forming a hydrophobic 
domain while on the other side of the sheet there are a number of ionic bonds between 
lysine side chains on one peptide strand and glutamic acid side chains on another.  The 
other existing form could be two or more sheets assembled together.  Specifically, there 
would be layered structure in which the sheets are held together alternatively by 
hydrophobic interactions and ionic interactions between the sheets (Figure 2-3b).  
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Without doubt, the hydrogen bonds, hydrophobic interactions and ionic interactions 
stabilizing the single sheet still exist in this form. 
It was experimentally proven that different conditions such as amino acid 
sequence, peptide concentration, salt concentration, pH, etc. can influence the peptide 
aggregation process and further development of macrostructures.  Therefore, it is of 
importance to investigate the influential factors in order to understand the self-assembling 
mechanisms for the amphiphilic oligopeptides.  
The amino acid sequence of these peptides is critical to the self-assembling 
mechanism.  Various sequences of the EAK family repeats such as KFE12, KIE12, 
KVE12, KFE8/16 KFQ12 were designed by Caplan et al. to study the sequence influence 
[112] (sequences see Table 2-2).  Three aspects were taken into consideration: 1) the 
hydrophobic side chains; 2) the number of repeats; and 3) the charged side chains.  The 
results of this study showed that increasing the hydrophobicity of the nonpolar resides 
would facilitate the self-assembling which is reflected in the decrease of the critical 
coagulation concentration (CCC) after increasing the hydrophobicity of the nonpolar 
residues.  CCC is defined as the salt concentration below which the oligopeptide does not 
form a gel and above which it does form a gel.  Therefore, lower salt concentration is 
required to drive the gel formation if the nonpolar residues are more hydrophobic.  The 
phenomenon that increasing the hydrophobicity of the nonpolar residues contributes to 
matrix formation was also supported by another study.  It has been reported that alanine-
containing amphiphilic peptides (such as EAK) require at least sixteen-mer peptides for 
salt-induced stable matrix formation.  By contrast, leucine-containing amphiphilic 
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peptides (such as ELK) form salt-induced stable matrices from eight-mer peptides [113].  
Wang et al.  found that, for aliphatic residues, not only the hydrophobicity, but also the 
size of these residues could introduce different steric topologies to the non-polar side of 
the β-strand, thus affecting the matrix morphology of self-assembled structure [114].  
Specifically, if different non-polar residues are incorporated into one peptide sequence, 
diverse topologies of the β-strand non-polar side can be formed by modulating the 
hydrophobic residue combinations of glycine, alanine, valine, leucine, isoleucine, and 
phenylalanine.  It was proven that steric size differences of non-polar residues can cause 
variations in peptide secondary structures and complementary non-polar topologies 
encourage cooperative binding between amphiphilic peptides which would further 
facilitate matrix formation. 
Table 2-2 amino acid sequences studies by Caplan et al. (reprinted from [112]) 
 
 
As to the number of repeats, it was found that increasing the length of the 
oligopeptide will increase the intermolecular attraction as well as the entropy of the 
backbone.  Since self-assembly is a process facilitating intermolecular attraction while 
also decreasing peptide backbone entropy, the competition of these two opposite effects 
to the thermodynamic process would make the final CCC have a biphasic trend (i.e. 
minimum CCC exists at intermediate length).  
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In addition, the charged residues in the sequence can decide the charge 
distribution and overall charge carrying in the peptide molecules.  Charge distribution can 
make a difference to the self-assembling process even when the same amino acid 
composition is concerned.  In particular, different types of EAK16 (EAK16-I, EAK16-II 
and EAK16-IV) with the same amino acid composition but varying charge distributions 
were studied [108].  The difference in charge distributions can lead to distinct favored 
conformations for each molecule.  This will further affect the final self-assembly 
structure observed by AFM.  It was demonstrated that EAK16-I and -II favors relatively 
stretched conformation and forms a fibrillar self-assembly structure while EAK16-IV 
favors a β-turn conformation and forms globular self-assembly structure.  On the other 
hand, the overall charge carried by the peptide can be manipulated by substituting the 
charged residues with other uncharged residues.  This allows the control of the conditions 
(especially pH) under which the oligopeptides can gel.  Peptides have a higher propensity 
to self-assemble when there are no repulsive charge forces between peptide molecules.  
Therefore, pH can take effect by changing the charge distribution/status of the peptide 
sequence [115].  For peptides having a positive overall charge at neutral pH, increasing 
the environmental pH can initiate the self-assembling whereas for negatively charged 
peptides at neutral pH, decreasing pH helps to protonate the negative charge, bringing the 
overall charge to zero.  Hence, different sequences may display totally opposite trends in 
conformational change and self-assembly process when exposed to a pH change in the 
solution as evidenced by M. Altman et al. [116]. 
Concentration is also a key factor controlling the self-assembling process.  It was 
proposed by Fung et al. [101] that oligopeptides like EAK16-II aggregate into 
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protofibrils through seeding and/or a nucleation process depending on its critical 
aggregation concentration (CAC).  Below CAC (~0.1 mg/ml), two forms of nanostructure 
of protofibrils can be adopted, i.e. the thin filament and globular aggregates which were 
postulated to consist of monolayers of β-sheets and at least 2 layers of β-sheets 
respectively.  Over time these protofibrils can further aggregate into fibrils at 
concentration above CAC and these fibrils are composed of many globular aggregates 
lining up and stacking together.  It is worth noting that incubation time is another 
important factor to consider in order to understand the kinetics of aggregation.  
Oligopeptides at low concentration may start to aggregate at prolonged incubation time 
under the condition in which it will not normally self-assemble. 
The effect of salt is of particular importance because salt concentration is 
physiologically relevant and is a most frequently utilized trigger to initiate the self-
assembling.  They can affect the aggregation process and resulting aggregation 
morphologies by electronically screening ionic interactions during the molecular self-
assembling.  However, it was also found by Hong et al. [117] that the self-assembling 
process of EAK16-II to form nanostructures does not strongly depend on the presence of 
NaCl (i.e. electrostatic interactions) when the peptide concentration is high (>0.3 mg/ml).  
On the other hand, the dimensions of the resulting self-assembled nanofibers at low 
peptide concentrations (<0.1 mg/ml) appear to be dependent on NaCl concentration.  The 
size of the nanofibers increases until the NaCl concentration reaches about 20 mM.  The 
radius of the peptide fibrils decreases with further increase in salt concentration.  Besides, 
globular assemblies were observed in the absence of NaCl at low peptide concentration 
but not observed when the electrolyte is present.  This indicates that NaCl promotes 
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formation of fibril at low peptide concentration.  It was thus speculated that the charge 
screening effect of the salt promotes non-electrostatic interactions between the peptide 
molecules. 
In summary, consensus has been reached on the theory that these peptides 
assemble in water due to the hydrophobic effect and the charged polar side chains also 
play important roles in determining what conditions promote assembly and what 
conformation the aggregates will preferentially adopt [118].  Specifically, the 
hydrophobic effect facilitates self-assembling through the entropy increase of water 
molecules in the system.  On the other hand, like-charge repulsion from the charged 
residuals prevent self-assembling from happening.  The superposition of hydrophobic 
interactions and electrostatic repulsion decide the existence state of the peptide in a 
certain media.  However, most of current mechanism studies are still limited to these 
qualitative conclusions summarized from phenomenon observed under varying 
conditions.  Few publications look deep into the assembled structures down to the 
molecular level and explain the process from the physicochemical or thermodynamic 
perspective.  Systematic research is still lacking for the big ionic self-complimentary 
peptide family since most studies are concentrated on EAK16 and RAD16.  More efforts 
need to be invested to obtain a broad understanding about this type of peptide, thereby 
generating more reliable self-assembling mechanisms. 
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Characteristics and applications 
Having explored the self-assembling mechanisms for ionic complementary 
oligopeptides, the features of the resulting self-assembly structures and their potential 
applications will be discussed.  
Mechanical strength of the hydrogel scaffolds is a critical property in deciding 
their potential to have a satisfactory manner within the biological environment in which 
they are applied [119].  It was found that higher concentration of peptide usually leads to 
higher density of the fiber network which further contributes to the increase in gel 
stiffness.  Also, crosslinking can be an effective strategy to increase the stiffness of self-
assembling oligopeptide gels.  It can be achieved, for example, by introducing cysteine 
into the sequence to allow disulfide bond formation or adding glutaraldehyde to crosslink 
amine groups in the residue side chains [120].  With a thorough understanding of 
fundamental mechanisms governing the mechanical properties of these gels, we can 
custom-design a gel scaffold with desirable stiffness for a specific biomedical 
application. 
It is worth noting that the well-defined nanofiber scaffold formed by ionic self-
complementary peptides could reassemble after undergoing certain types of mechanical 
breakage.  This is evidenced by the dynamic reassembly of RAD16-I [(RADARADA)2] 
after disrupted by sonication.  The smaller fragments resulting from sonication are able to 
quickly reassemble into nanofibers which were indistinguishable from the original self-
assembly [120, 121].  This feature is of great value because the self-assembly scaffold 
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will be subject to certain mechanical strength when applied to an in vitro or in vivo 
environment.  
Chirality of the amino acids could also play some role for the final properties of 
the self-assembly structure.  It is already known that natural proteins are made of only L-
amino acids.  Using the chiral counterpart –D-amino acids to generate a chiral mirror 
image peptide (such as d-EAK16-II) can make the self-assembled structure more stable 
and better resistant to natural enzyme degradation since the chiral peptide cannot be 
recognized by natural proteases and is thus more durable [84, 122].  
With so many superior features being displayed, these self-assembling 
oligopeptides have been demonstrated to have the potential for diverse biomedical 
applications including scaffolds for tissue repair, tissue regeneration, instant stopping of 
bleeding, wound healing, drug delivery and biological surface engineering, etc.  These 
applications arise from their capability to self-assemble into a three-dimensional matrix 
scaffold in situ under physiological conditions as well as their potential to resorb into 
biocompatible degradation products.  
With regard to tissue engineering, self-assembling peptide scaffolds have been 
proven to support cell attachment and differentiation of plenty of mammalian primary 
and transformed cells [24, 123-125].  For example, it was noted that scaffold generated 
by RAD16-II peptides provided cells with a soft three-dimensional support which can 
facilitate angiogenesis and allow them to form capillary-like structures [126].  This 
capillary morphogenesis and endothelial cell adhesion can be affected by primary 
sequence of the self-assembling peptide considering the fact that KFE8 and KLD12 
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cannot produce this effect while RAD16-I and RAD16-II can [127].  Moreover, the self-
assembled structure can serve as substrates for extensive neurite outgrowth and active 
synapse formation in addition to supporting neuronal cell attachment and differentiation.  
It did not elicit any measurable immune response or tissue inflammation when introduced 
to animals [128].  It was also reported that hydrogel scaffold made from RAD16-I could 
be used for instant stopping of bleeding when applied on top of multiple tissues and a 
variety of wounds [115].  The results showed that the complete hemostasis can be 
achieved in less than 20 seconds.  The hemostatic process is directly proportional to the 
length of the self-assembled nanofibers: the longer the nanofiber, the shorter the duration 
of bleeding [129].  Furthermore, the nanofiber scaffolds with favorable designed 
properties could be used in in-vitro 3-dimensional cell culture which mimics the 
extracellular matrix (ECM) in providing support and allowing the natural flow of oxygen, 
nutrients and growth factors.  
In addition, functional motifs such as RGD (Arg-Gly-Asp, for cell adhesion), 
BMHP (bone marrow homing peptide) [130],  YIGSR and RYVVLPR (two sequences 
present in laminin-1 to promote cell adhesion, migration and endothelial cell tubular 
formation), and TAGSCLRKFSTM (sequence from collagen IV to bind to heparin and 
promote adhesion and spreading of bovine aortic endothelial cells) [131], can be 
incorporated in the peptide sequence by direct solid phase synthesis extension at peptide 
termini in order to be displayed in the gel matrix for biologically active applications.  In 
fact, sequences with desired biological functions can be incorporated into the self-
assembling peptide with varied insertion patterns, not necessarily on the two termini.  For 
example, a metalloproteinase (MMP-2)-sensitive substrate can be inserted centrically 
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within RADA blocks with 3 RADA units flanking on each side.  The hydrogel matrix 
formed by this novel peptide has comparable mechanical properties and nanofiber 
morphology to material built with RAD16-I alone.  Exposure of the new gel to MMP-2 
can lead to peptide cleavage, mimicking the remolding of natural ECM during tissue 
engineering [132].  Notably, both regular and D-form (chiral counterpart) self-assembling 
peptide systems could be employed to form the matrix and promote cell viability and 
functionality through rational design [133].  It is encouraging that the oligopeptide 
RAD16-I has already been developed as a product under the brand name PuraMatrixTM 
for multiple biomedical applications [134, 135], mainly as 3D cell culture matrix. 
Ionic-complementary self-assembling peptides have also drawn a lot of attention 
in controlled drug delivery field due to their desirable properties.  For example, they can 
be easily engineered to form a variety of stable nanostructures such as fibers, rods, tubes, 
nanovesicles and globules and these structures have great potential to be used as delivery 
vehicles [136].  Since there are two sides on the β-sheets formed through backbone 
hydrogen bonding: hydrophobic side and hydrophilic side, this class of peptide 
amphiphile possesses a superior capability to incorporate both polar and nonpolar drugs 
in the matrix as a drug delivery platform.  A wealth of successful examples especially for 
hydrogels made of EAK16-II or RAD16-I have been found for the delivery of 
hydrophobic drugs [26, 136] as well as functional proteins [30], cytokines [137], growth 
factors [138] and antibodies [139].  The release profiles of these molecules are usually 
controlled by the self-assembling peptide concentration (nanofiber density) as well as the 
electrostatic interaction between the fiber surface and diffusant molecules [140].  The 
release will decrease with increasing peptide concentration (physical hindrances) and 
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stronger charge-induced interactions.  Thus, the release kinetics can be tailored 
accordingly by changing the peptide composition and concentration.  It was also 
demonstrated that the conformation and functionality of the proteins or antibodies will 
not be affected by the peptide matrix encapsulation and the loading efficiency can reach 
as high as 100% since the peptide hydrogel consists of water up to 99.5% [139].  
Moreover, the self-assembling peptides may have the potential to form complexations 
with some hydrophobic drugs in aqueous solution (e.g. EAR8-II with anticancer drug 
pirarubicin) [141] or allow the drugs to present as different molecular states in the carrier: 
protonated and crystalline (such as EAK16-II with drug ellipticine), resulting in different 
therapeutic activities [27, 136].  It is also worth noting that hydrogels composed of more 
than one species of peptide have been designed for programmable sustained release of 
cargo.  For example, RAD16-I and KLD12-I were paired to make a two-layered hydrogel 
structure for human IgG release with a concentric sphere of RAD16-I as the core and 
KLD12-I as the shell [139].  Controlled release of the antibody can be fine-tuned by this 
system. 
In the Meng lab, we have been working on EAK16-II and EAK16-II with 
appended functional groups such as EAKIIH6 [19, 20] (with six consecutive histidines at 
the C-terminus) and dL5_EAK (with a fluorogen activating protein dL5 attached to the 
N-terminus) [50].  All of them can co-assemble with EAK16-II to form an insoluble 
bioaffinity hydrogel, thus presenting the functional groups at local site of injection for an 
extended period of time.  For EAKIIH6, with the help of intermediate protein adaptors 
(anti-H6 antibody and protein A/G), any antibody of interest could be displayed locally 
by the co-assembly structure for immune modulation purposes.  Its effectiveness has been 
 51 
proven in vivo using two epithelial tumor cells.  As to dL5_EAK, due to the fluorescence 
enhancement function of the dL5 domain upon specific binding to the dye malachite 
green (MG), it has a potential to be used as an in situ forming local biosensor.  In both 
cases, EAK16-II functions to immobilize and concentrate the functional group in situ. 
Other than applications in tissue engineering and drug delivery scaffold, the self-
assembling peptides have also been used in electronics field as template for metallic 
nanowire and electronic device fabrication.  For example, functional Cu2+ binding group 
GGH (G, glycine; H, histidine) was attached to the C-terminus of EAK16-II by H. Yang 
et al. to create a bi-functional material which can form stable nanofibers and at the same 
time incorporate copper into the structure via a metal binding site in the self-assembling 
peptide [142]. 
Additionally, these peptides may serve as a good model system for studying the 
mechanism of many neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
diseases considering that the fibrillar nanostructures resulting from these peptide 
assemblies are similar to the amyloid fibrils found in those diseases.  Therefore, the 
mechanism or theoretical studies for this self-assembling system will give us insight into 
the driving forces for the assembly of more complex endogenous proteins such as β-
amyloid and prion proteins, thereby facilitating the research trying to find the treatment 
that will prevent plaque formation in vivo. 
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II. Self-assembling β-hairpins 
Pochan, Schneider and coworkers in Delaware developed a type of peptide that 
can have an intramolecular folding event before undergoing intermolecular self-assembly 
into hydrogel scaffolds.  This intramolecular folding can be triggered by different kinds 
of stimuli such as changes in pH [143], temperature [144], ionic strength [145], light 
[146] or the introduction of cell culture media [147].  This class of peptide amphiphile is 
composed of a central tetrapeptide (VDPPT) which has high β-turn propensity flanked by 
two extended strands containing high β-sheet propensity residues.  The first peptide 
designed by this group is named MAX1 (structure see Figure 2-5).  The strands contain 
alternating hydrophilic and hydrophobic residues, mainly lysine (K) and valine (V) 
respectively.  Interestingly, these strands have a similar pattern to the ionic-
complementary self-assembling peptides discussed above in terms of amino acid 
organization.  The biggest difference lies in the charge state of the sequence.  Here, 
mainly positively charged lysine is incorporated as the hydrophilic residue while 
positively charged and negatively charged amino acids were alternated in the previous 
case.  Therefore, the overall net charge for β-hairpins at neutral pH is positive compared 
to zero for the ionic-complementary peptides.  This difference can affect their 
corresponding self-assembling trigger conditions.  Later, derivatives of MAX1 containing 
other amino acid substitutes at different positions and/or with different numbers were also 
created to achieve tunable stimuli functions. 
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Figure 2-5 proposed β-hairpin structure and amino acid sequence of MAX 1, a typical 
peptide of this category (20 residues). (reprinted with permission from reference [145]. 
Copyright (2004) American Chemical Society) 
 
Self-assembling mechanisms 
It is not surprising that the self-assembling of β-hairpins can also be initiated by 
the previously mentioned environmental cues (temperature, salt, pH, etc.) to form the 
hydrogel scaffold.  Many researchers have shown interest in studying the underlying 
mechanisms as well. Work on different stimuli will be discussed separately. 
For pH responsive hydrogels, the charge state of the hydrophilic residues plays an 
important role in intramolecular folding.  Since lysine is basically the hydrophilic amino 
acid incorporated in the sequence of β-hairpins, increasing the pH above the intrinsic pKa 
(10.8) of the lysine side chains can reduce the intrastrand charge repulsion from 
neighboring lysines, thus initiating the intramolecular folding and subsequent self-
assembly to hydrogel structure.  The final self-assembled structure is supported both 
laterally through hydrogen bonds between adjacent hairpins and facially by hydrophobic 
association of the valine-rich faces [143]. 
For ionic strength responsive hydrogels, the addition of salts is able to trigger the 
intramolecular folding due to the formation of salt-bridge physical cross-links or charge 
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screening effects for the electrostatic interactions between the charged amino acids [145].  
In the folded state, the single peptide molecule is facially amphiphilic, displaying all 
hydrophobic residues on one face of the hairpin and hydrophilic residues on the other.  
Once it is folded into a β-hairpin conformation, self-assembly can be driven by both 
intra- and inter-molecular hydrogen bonding laterally and hydrophobic interactions 
facially.  Well-defined, bilayered fibrils can thus be formed and further developed into a 
β-sheet rich hydrogel network.  The final elastic property of the hydrogel can be tuned by 
salt concentration.  The higher the salt concentration added, the more rigid the hydrogel 
formed.  The network of the hydrogel is composed of dense fibrillar assemblies that are 
cross-linked to each other by physical junction points.  The proposed self-assembling 
pathway and fibril structure for MAX1 β-hairpin molecule are shown in Figure 2-6. 
 
 
Figure 2-6 (a) proposed self-assembly pathway for MAX1, (b) the structure of self-
assembled MAX1 β-hairpin molecules in a fibril and (c) TEM micrographs of MAX1 
hydrogels showing the nanostructure of 0.5% wt% network, scale bar: 100 nm; insets: 
magnification of MAX1 fibrils that are ≈ 3 nm in width, scale bar: 20 nm. (adapted with 
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permission from reference [145] and [148]. Copyright (2004) American Chemical 
Society and Copyright (2007) National Academy of Sciences, U.S.A.) 
 
For thermally responsive hydrogels, the hydrogel forms upon temperature 
increase.  The increase in temperature serves to dehydrate the nonpolar residues of the 
unfolded peptide and the folding is hence triggered via hydrophobic collapse [144].  
As to light-activated hydrogel formation, it is achieved through covalently 
incorporating a photocleavable moiety into the peptide sequence.  The photocleavable 
moiety possesses an electrostatic feature which inhibits peptide folding.  Therefore, after 
exposed to light at a certain wavelength, the photocage can be released to initiate 
intramolecular folding, self-assembly and finally the formation of a mechanically rigid 
hydrogel [146]. 
It was proposed by Yucel et al. [149] that after the bilayered β-sheets are formed 
through folding, the possible cross-linking mechanisms for the final hydrogelation 
include (1) self-assembly defect-induced branching (i.e. kinetically trapped, imperfect 
hydrophobic face collapse may lead to nucleation of a branch, see Figure 2-7) and (2) 
entanglement of self-assembled fibrils. Both can lead to permanent physical cross-links. 
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Figure 2-7  Schematic representations for two different self-assembled cross-links: (a) a 
defect-induced branch and (b) an entanglement (adapted with permission from reference 
[149]. Copyright (2008) American Chemical Society) 
 
 It is worth mentioning that more than one environmental stimuli can take place 
simultaneously.  For example, the folding and self-assembly of the parent MAX1 peptide 
can be induced by changing the solution pH to reduce the point charge of the lysine 
residues, increasing the ionic strength to screen the electrostatic repulsions, or increasing 
the temperature to enhance the attraction between hydrophobic residues.  These changes 
can work collectively to facilitate the hydrogelation process. 
Since most peptides developed by this research group possess a high β-turn 
propensity tetrapeptide flanked with two extended strands, predominantly an alternating 
sequence of valine and lysine residues or some point substitutions with other amino acids, 
the charge state of the whole strands was proven to affect the gelation kinetics of the 
peptides because the electrostatic repulsion between positively charged lysine is an 
important force preventing the folding and self-assembly.  Therefore, the rate of the gel 
formation becomes faster for point substitutions with less total charge.  As a result, the 
careful design of the peptide sequence can be employed to modulate the charge state and 
finally the gelation kinetics of the peptides to obtain a desired profile under certain 
environmental condition [150]. 
Characteristics and applications 
Stimuli-responsive hydrogels generated from β-hairpin peptides have the potential 
to be used as biomaterials due to their superior morphological and physicochemical 
features.  At early-time hydrogelation, peptides undergo intramolecular folding into β-
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hairpins and concurrently self-assemble into branched clusters of well-defined, β-sheet 
rich nanofibrils.  These fibers are very uniform with monodisperse dimensions (3nm 
cross section).  It was postulated that the hydrogel network rigidity is boosted by the 
finite interpenetration of percolating cluster with smaller clusters as well as permanent 
intercluster entanglements [149].  
One of the most distinguished advantages of β-hairpin hydrogels is that they can 
be injected as pre-formed solids.  The pre-formed solid gel can shear-thin under a proper 
shear stress and consequently flow during injection; but upon removal of the stress, it 
recovers back into a solid immediately.  This feature allows the hydrogel system, together 
with the payloads that are encapsulated during the original hydrogelation, to be delivered 
via simple syringe to a targeted in vivo site and stay localized at the site of injection to 
achieve the required therapeutic effect.  The unwanted leakage and flow of the injected 
liquid to neighboring tissue or the blood stream can be minimized by the design of higher 
viscosity precursors or fast in situ gelation kinetics.  The duration of shear, the shear rate 
as well as the pre-shear gel rigidity all affect the gel stiffness immediately recovered after 
flow and the ultimate stiffness after complete rehealing of the gel [151].  It was also 
demonstrated that the shear-thin delivery process of syringe injection had little or no 
effect on cell viability and three dimensional cell distribution which indicates that these 
peptidic hydrogels can serve as excellent candidates for injectable therapeutic delivery 
vehicles for cells [147, 151, 152]. 
Interestingly, the chirality of the β-hairpin peptides (MAX 1) was found to affect 
the mechanical rigidity of the self-assembled hydrogels.  Specifically, hydrogels 
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generated from enantiomeric mixtures of self-assembling β-hairpins exhibit non-additive, 
synergistic enhancement in mechanical rigidity compared to gels made from either pure 
enantiomer.  The racemic hydrogel shows the greatest mechanical rigidity [105].  The 
underlying molecular mechanism for this phenomenon is still not clear, but spectroscopy, 
rheology and microscopy data suggest that it might be due to energetically favorable 
interactions between the enantiomers either occurring at molecular level or hydrogel 
network level or both.  Therefore, biomolecular chirality has a potential to be utilized as a 
tool for material design and controllably modulating the mechanical properties to the 
desired level by adjusting the molar ratio of β-hairpin enantiomers. 
When it comes to applications, β-hairpin self-assembling peptides are mainly used 
to prepare hydrogels as injectable therapeutic delivery vehicles.  Similarly to ionic 
complementary peptides, a large range of drug molecules, from hydrophobic small 
molecules such as curcumin [153] to hydrophilic macromolecules such as proteins [154], 
could be encapsulated into the self-assembling peptide hydrogels to make an injectable 
localized drug delivery system for sustained and controlled release.  This is achieved by 
initiating the self-assembly in the presence of drug of interest.  The drug molecule 
mobility within and release out of the hydrogels can be adjusted by the mesh size of the 
gel, which can be modulated by altering the peptide sequence or simply varying the 
concentration of the peptide.  Furthermore, the electrostatic interactions between the drug 
molecules and the peptides constructing the gel can affect the mobility and release of the 
drug.  For example, for electropositive fibrillar hydrogels, release of positively charged 
and neutral molecules is controlled by the steric effect imposed by the gel network.  In 
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contrast, negatively charged drugs interact strongly with the positively charged network, 
leading to significantly slower release [155]. 
β-hairpin peptides self-assembly and hydrogelation can also be employed to 
deliver cells through triggering the self-assembly in cell culture medium containing cells 
of interest.  The resulting well-controlled, homogeneous, three-dimensional encapsulation 
of desired cells and the maintenance of high cell viability after the shear-thinning process 
render these gels promising tools to deliver cells at target biological sites for tissue 
engineering or other purposes [148].  
Moreover, the electrostatic character of the gels can affect cell behavior 
incorporated within.  Although hydrogel networks can afford similar rheological behavior 
and local network morphologies, different network electrostatic status can influence the 
cell viability after encapsulation and delivery, extracellular matrix deposition, and gene 
expression.  For example, by comparing hydrogels made of different charge state 
monomers MAX8 and HLT2 (+7 and +5 per monomer, respectively), less electropositive 
HLT2 gel was found to provide a microenvironment more favorable to chondrocyte 
encapsulation, delivery and phenotype maintenance.  Besides, a higher cell viability was 
observed for HLT2 gels compared to MAX8 gel [156]. 
 
III. Alkylated peptide amphiphiles 
The Stupp research group from Northwestern University in Chicago has 
developed a type of peptide amphiphile (PAs) which consist of a long linear hydrophobic 
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alkyl tail coupled to a polypeptide block [157].  This polypeptide block usually includes 
β-sheet-forming segments, charged residues for solubility and biological epitopes, etc.  
There are a large variety of possible combinations for the peptide block components.  
Some only contain a β-sheet-forming segment and a charged head group while others 
also include different kinds of sequences for biological signaling and functionality.  In 
addition, consecutive cysteine residues can be incorporated to introduce intermolecular 
cross-linking for higher robustness of the supramolecular fibers and photo-cleavable 
group can be employed to introduce photo-responsive property.  This type of alkylated 
peptide amphiphile has the potential to self-assemble into cylindrical nanofibers with 
diameters on the order of a few nanometers and lengths in the micrometer scale [158].  
The hydrophobic alkyl tails pack on the inside of the fiber while the peptide portions are 
displayed on the surface of the fiber which makes a cylindrical micelle with an overall 
conical shape from intersection [159] (see Figure 2-8).  The amino acid selection and 
alkyl tail modification confer nanofibers with varying morphology, surface chemistry, 
and potential bioactivity [157].  The alkyl tail is usually attached to the N-terminus of the 
peptide and the epitope segment is placed at the C-terminus which will be displayed on 
the periphery for cell interaction after self-assembly.  There are also PAs with reverse 
polarity which means the alkyl tail is attached to the C-terminus and free N-terminus is 
exposed to the periphery.  They co-assemble with PAs with free C-terminus leading to 
assemblies with unusual thermal stability when compared to assemblies composed of 
only one type of PA molecules [160].  There are three main modes of induction for the 
alkylated peptide amphiphiles to self-assemble into nanofibers: pH control, divalent ion 
induction, and concentration induction [161]. 
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Figure 2-8 (a) Chemical structure of one alkylated peptide amphiphile with 5 key 
structure regions. Region 1: alkyl tail; region 2: four consecutive cysteine residues; 
region 3: three glycine residues serving as a flexible linker; region 4: phosphorylated 
charged residue; region 5: cell adhesion ligand RGD (b) Molecular model of the PA 
showing the overall conical shape of the molecule going from the narrow hydrophobic 
tail to the bulkier peptide region; (c) Schematic showing the self-assembly of peptide 
amphiphile molecules into a cylindrical micelle; (d) Vitreous ice cryo-TEM image of the 
fibers reveals the diameter of the fibers to be 7.6 ± 1 nm (adapted from reference [159]) 
 
Self-assembling mechanisms 
Since there are usually more than three distinct components in one PA molecule 
(such as alkyl tail, β-sheet-forming segment, tetra-cysteine region, charged residues and 
biological epitopes), studying the effect of each portion to the self-assembling 
phenomenon is essential for the comprehensive understanding of the self-assembling 
mechanism.  In order to know what components of the peptide amphiphile are 
responsible for their self-assembly, different derivatives of the PAs were designed by 
Hartgerink et al. [157] and three main regions of the molecules were modified: the length 
of the alkyl tail (from 22 carbons to no carbon), the tetra-cysteine region (cross-linking 
effect of thiol groups) and the head group region (the C-terminal end which can interact 
 62 
with the environment and incorporate different cell adhesion ligands or crystal nucleation 
centers).  It was found that hydrophobic interactions between the alkyl tails play a key 
role in self-assembly in water given the fact that the PAs without an alkyl tail cannot self-
assemble and PAs with sufficiently long alkyl tails can self-assemble more easily.  
Moreover, the presence of cysteine residues is not required for self-assembly although it 
can provide covalent capture of the fibers by the formation of intermolecular disulfide 
bonds upon oxidation.  Also, the head group of PAs, which would be exposed on the 
surface of self-assembled fibers, allows a large flexibility on the sequence.  In other 
words, different bioactive motifs or even sequences without bioactivity can be 
incorporated in this region without hurting the self-assembling propensity of the general 
design.  Paramonov et al. demonstrated that hydrogen bonding close to the hydrophobic 
core was necessary for the nanofiber formation and had the biggest impact on the gel 
properties [162]. 
The mechanism of peptide amphiphile self-assembly was also studied by 
molecular simulation technique with a model that incorporated molecular structure and 
inter- and intra-molecular interactions [163, 164].  Different morphology could be formed 
due to different molecular structures or at different phases of self-assembly.  These 
morphologies include single β-sheet connected laterally by hydrogen bonds, stacks of 
parallel β-sheets, spherical micelles, micelles with β-sheets in the corona and long 
cylindrical fibers (Figure 2-9).  It was found that the self-assembly of PA molecules is 
driven mostly by the interplay of hydrophobic interactions between alkyl tails and 
hydrogen bonds between peptide blocks.  Molecular length and thermodynamic 
parameters such as temperature and concentration all play important roles in self-
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assembly.  However, this study did not consider electrostatic interactions between epitope 
head groups or with salt ions as well as the effect of the solvent which may hydrogen 
bond with the peptide units.  The thorough consideration of all influencing factors 
requires significant computational resources and efforts. 
 
Figure 2-9 The simulated morphologies that could exist during PA molecule self-
assembly process. A) free molecules, b) spherical micelles, c) micelles with β-sheets on 
the outside forming the corona, d) long cylindrical fibers, e) stacks of parallel β-sheets, 
and f) single β-sheet. (Adapted with permission from reference [163]. Copyright (2008) 
American Chemical Society) 
 
In regard to different modes of alkylated PA self-assembly, pH is one of the major 
triggers.  When the pH is neutral, peptides containing acidic amino acids have a net 
negative charge which keeps the PAs from self-assembly due to electrostatic repulsion.  
This negative charge can be eliminated upon acidification so that hydrophobic tails can 
start to aggregate after pH is reduced.  In addition to pH, polyvalent metal ions such as 
Ca2+, Mg2+, and Cu2+ can also induce self-assembly which could be explained by the 
ionic interactions between the acidic groups in PAs and positively charged counterions 
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(could be the formation of ion-peptide complex).  However, monovalent ions are not able 
to induce the formation of self-supporting gels for most PAs.  Thus, it appears that 
polyvalent ions are significantly more effective initiators of self-assembly than 
monovalent species.  Gels produced by addition of polyvalent metal ions to PA solutions 
are very stable under a broad pH range (from 4-11 for some PAs) and high temperature 
up to 100 °C.  In contrast, gels formed by pH-triggered mechanism are only stable at pH 
below 3.5.  The high stability of cation-mediated PA gels is postulated to be determined 
by the diversity of intermolecular interactions including hydrophobic, ionic and hydrogen 
bonds [165].  In addition, concentration is important simply because sufficient fibers are 
needed to form the three-dimensional networks which will further allow the gelation to 
occur. 
Characteristics and applications 
This type of alkylated PA molecules consists of a fatty acid chain containing 10-
22 carbon atoms in length connected via an amide bond to a peptide block which includes 
6-12 amino acid residues for different functions.  They can self-assemble into self-
supporting gels at concentration as low as 0.25% by weight [165].  The gels are 
composed of a network of cylindrical nanofibers, and these fibers formed by alkylated 
PAs all possess a diameter between 5-10 nm and a length on the order of microns.  As we 
already discussed, the hydrophobic alkyl tails are located at the core of the fiber while the 
hydrophilic peptide segments comprise the outer surface.  Although all the PAs form 
fibers with comparable diameter, the length and stiffness of the fibers vary significantly 
depending on the sequence of these PAs [166].  It was demonstrated by FTIR studies that 
the hydrogen bonding of β-sheets tends to be aligned along the long axis of fibers but 
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with some amount of twisting or disruptions [167] (see Figure 2-10).  Since the alkyl tails 
are attached to the same terminus of the peptide segment for a certain kind of PA 
molecule, every peptide would have the same C-N direction in the formed nanofibers. 
Therefore, it is very likely that the fibers contain only parallel β-sheets. 
 
Figure 2-10 Schematic representation of a single β-sheet in (a) linear and (b) twisted 
geometry in a peptide amphiphile nanofiber; (c) schematic of two β-sheets in the fiber 
with arrows indicating the hydrogen bonds. (adapted with permission from reference 
[167]. Copyright (2010) American Chemical Society) 
 
Aside from the cylindrical shaped fibers, giant flat nanobelts could also be formed 
by certain alkylated peptide amphiphiles which contain an alternating sequence with 
hydrophobic and hydrophilic side chains in its peptide block [158].  The nanobelts 
possess fairly mono-disperse widths on the order of 150nm and lengths of up to 0.1mm, 
eliminating all curvature from the nanostructure.  With variations in monomer 
concentration, these PAs can generate morphology with twisted ribbons.  After 
appropriate functionalization, these nanostructures could offer a novel architecture to 
display epitopes to cells for therapeutic applications. 
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It was also demonstrated that oppositely charged PA molecules with different 
bioactive sequences can co-assemble into nanofibers with the simultaneous display of all 
epitopes on the surface [160].  The electrostatic attractions between the oppositely 
charged head groups can facilitate self-assembly by forming salt-bridged pairs at neutral 
pH [168].  In this case, pH serves as a trigger to introduce the opposite charge state to the 
PA molecules, thus promoting the self-assembly.  In addition, since different PA 
molecules are capable of co-assembly, optimized cell signaling can be achieved by 
mixing a specific bioactive molecule with a different bioactive molecule or a non-
bioactive diluents molecule to vary the epitope density on the assembled nanostructure. 
The stiffness of the gels formed by PAs is an important feature when the matrix is 
used for regenerative medicine scaffold since cells respond to the mechanical properties 
of their environment and the mechanical properties could influence cell behavior [169-
171].  The matrix stiffness can be affected by the amino acid sequence in the PAs.  A 
study was performed to investigate the number and position of valines and alanines in the 
peptide sequence to the mechanical properties of the nanofiber gels that the PAs form 
[167].  It turned out that increasing both the number and fraction of valine, which has the 
highest propensity to from β-sheets, is especially effective at raising mechanical stiffness 
of the gels.  Moreover, the high gel stiffness is also facilitated by alignment of hydrogen 
bonds along the fiber axis as well as the placement of β-sheet-forming residues near the 
hydrophobic core of nanofibers. 
The alkylated self-assembling PA molecules studied by the Stupp’s group were 
initially designed for tissue engineering purposes and have been used for a host of 
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biological applications.  For example, a phosphorylated residue was introduced into the 
peptide segment to induce the mineralization of hydroxyapatite in order to recreate the 
nanoscale structure of bone [159].  Also, with proper functionalization in the peptide 
terminus, the self-assembled nanostructures offer architecture to present epitopes to cells 
for varying therapeutic applications.  Commonly incorporated epitopes include RGD 
[172], IKVAV [173] and YIGSR[174], etc.  Some bioactive epitopes can promote rapid 
and selective differentiation of neural progenitor cells into neurons [175].  A heparin-
binding peptide amphiphile (HBPA) was designed by Ghanaati et al. with a heparin-
binding domain to specifically bind and self-assemble at the presence of heparin sulfate-
like glycosaminoglycans (HSGAG), allowing for the capture of angiogenic growth 
factors such as VEGF and EGF-2 in a biomimetic fashion.  The formed gels were 
demonstrated to have good biocompatibility and be able to promote angiogenesis in vivo 
which was reflected by extensive blood vessel formation in a rat cornea [176].  It can also 
improve cell viability and function in the interior islets as an artificial ECM after 
delivered to pancreatic islet at a very low concentration together with angiogenic growth 
factor.  This contributes to the treatment of  type 1 diabetes through islet transplantation 
[177].  Moreover, the heparin-presenting nanofiber networks were demonstrated to 
capture and deliver paracrine factors therapeutically for cardiovascular diseases to elicit a 
paracrine effect [178].  Another example includes bioactive, cylindrical nanofibers 
bearing a cationic α-helical cytotoxic peptide (KLAKLAK)2.  This novel amphiphilic 
molecule is generated by attaching the peptide to a PA molecule.  These (KLAKLAK)2 
nanostructures formed after self-assembly, but not the peptide alone, could be readily 
internalized by breast cancer cells and induce cancer cell death by membrane disruption 
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[179].  The cytotoxic peptide amphiphiles bearing (KLAKLAK)2 have been applied  for 
cancer therapy since it can self-assemble into supramolecular membranes acting either as 
reservoirs for sustained release of cytotoxicity upon enzymatic degradation or just as 
membranes with surface-bound cytotoxicity [180]. 
As we already know, the nanostructure matrix formed in the presence of 
suspended cells before self-assembly can entrap cells in the matrix.  This entrapment 
should not arrest cell proliferation and motility and is presumably expected to improve 
cell viability and promote retention after targeted application if we use PA-based 
nanostructure scaffold for cell delivery.  This has been demonstrated with bone-marrow 
mononuclear cells (BMNCs) for ischemic tissue therapies [181].  In addition, the 
entrapped cells were proven to be able to internalize the nanofibers and probably utilize 
PA molecules for metabolic pathways which solves the toxicity problem and at the same 
time provide nutrients for the cells [165]. 
Since the cylindrical nanofibers formed by these PAs containing hydrophobic 
cores, hydrophobic small molecules or drug moieties have the potential to be 
encapsulated within the core for desirable delivery.  The encapsulation has been tested in 
multiple substances such as pyrene [182], prodan [183] etc. 
In addition to therapeutic applications, magnetic resonance imaging (MRI) 
contrast agents could also be designed into some PA molecules to combine high-
resolution three-dimensional MR fate mapping of the scaffolds with targeting of specific 
cellular receptors [184, 185]. 
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Common features of these self-assembling peptide amphiphiles 
Although the self-assembling mechanisms and peptide orientations in the fibers 
are slightly different for each type of peptide amphiphiles discussed in this chapter, the 
intrinsic forces contributing to the self-assembly are the same in nature.  They include 
hydrogen bonding, hydrophobic forces, electrostatic interactions, repulsive steric forces, 
nonspecific van der Waals interactions, π-π stacking and chiral dipole-dipole interactions 
[157].  All systems involve a combination of these forces which could counterbalance the 
entropic cost caused by peptide aggregation. 
These self-assembling peptide amphiphiles are all designed to go through sol-gel 
transition after exposure to external environmental changes and they share a lot of 
common features in regard to the physical structure of resultant material after self-
assembly.  The interwoven fibrillar networks formed by all of these peptide amphiphiles 
possess diameter and length on the same order of magnitude although their specific 
values may vary due to their different lengths, compositions and external cues 
(comparison see Table 2-3).  These peptide-based networks can serve as novel materials 
for tissue engineering simply because the hierarchical supramolecular structures and 
mechanical strength those peptides generate resemble biological ECM and they can 
interact with cells at the molecular level [165].  Their applications as drug delivery 
scaffolds can be attributed to the restriction effect of gel matrix to the drug molecules 
incorporated.  The release of the drug payload is dependent on the mesh size of the 
matrix as well as the electrostatic interaction between the drug molecule and peptide 
scaffold.  In addition, these peptide-based structures are biologically benign toward 
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various cell lines and will not incite immune responses in macrophages since they could 
be eventually degraded to naturally occurring amino acid residues. 
Table 2-3 Comparison for properties of representative peptide amphiphiles from each 
category 
Peptide 
category 
Representative  
sequence  
Concentration 
threshold 
Hydrogel 
geometry 
Reassembly 
property 
Mechanical 
rigidity 
Ionic- 
complementary 
self-assembling 
peptide 
EAK16-II CAC: 0.1 
mg/ml (6*10-5 
M) 
[101] 
Fiber 
diameter: 
10-80 nm;  
pore size: 
20-500 nm 
[24, 84, 101] 
 
N/A G’< 20 Pa 
even at 10 
mg/ml 
[133] 
RAD16-I 
(PuraMatrixTM) 
N/A Fibers 
width: 10-20 
nm; 
length:100-
1000 nm 
[115];  
pore size: 5-
200 nm 
[130, 131] 
 
Dynamic 
reassembly 
completes 
within time 
scale for 
hours [120, 
121] 
G’= 36.81 
Pa [130] / 
1541.7 Pa 
[132] / 4.7 
kPa [120] for 
10 mg/ml 
RAD16-I  
(not 
consistent) 
β-hairpins (VK)4VDPPT(VK)4 
(MAX 1) 
N/A Fiber width: 
3 nm 
Fiber height: 
2 nm [145] 
Fiber length: 
10-200 nm 
[148] 
Pore size 
18-50 
nm[155]  
 
Gel 
recovers 
immediately 
after 
cessation of 
shear [151] 
mechanically 
rigid gel 
G’>2500Pa 
(2 hours 
after 
initiating 
self-
assembly for 
2% MAX1) 
[147] 
 
Alkylated 
peptide 
amphiphiles 
C16H31O-NH-
CCCCGGGS(P)RGD 
(Generally: 10-22 
carbon chain 
attached to 6-12 
amino acids) 
Gelation 
threshold: 
0.25% (wt%) 
[157]  
Fiber 
diameter: 
7.6nm  
(5-10nm in 
general)   
Fiber length: 
several 
micrometers 
[157, 167]  
 
N/A stiffness 
varies 
considerably 
depending 
on sequence 
(G’: from 
<100 Pa to > 
10 kPa) 
[165, 167] 
CAC: critical aggregation concentration; N/A: not available 
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Moreover, most of the peptides can be easily chemically synthesized through 
solid-state phase peptide synthesis technology and this technology can produce peptide 
amphiphiles in relatively large quantities within short time.  One exception is alkylated 
PAs which need an additional manual coupling reaction to attach the peptide portion 
generated from solid phase synthesis to long-chain aliphatic acid via the formation of an 
amide bond.  Alternatively, with the help of genetic engineering, epitopes with different 
functionalities can be incorporated into the peptide sequence to introduce adhesion, 
differentiation or other specific biological effects [186].  Supramolecular self-assembling 
biomaterials could thus be easily controlled in terms of architecture, shape and 
dimensions as well as density of bioactive signals.  
Owing to the easy manipulation of both peptide composition as well as external 
conditions, the properties (including gelation kinetics, gel stiffness, network mesh size) of 
the self-assembled structure (usually cross-linked fibrils) can be readily controlled and 
modified by the adjustment of amino acid sequence, peptide concentration or external 
environmental conditions such as solution ionic strength, pH or temperature etc. in order 
to achieve desired cell encapsulation or controlled release of therapeutics [152]. 
Altogether, common features shared by these peptide amphiphiles such as low 
toxicity and high biocompatibility, easy production and manipulation, and wide 
biomedical applications have made the study of these self-assembling peptides the focus 
interest of multiple research groups.  So far, great strides have been made in the study of 
multifaceted aspects of these peptides, from underlying self-assembly mechanism to 
macrostructure characteristics favoring their practical use in diverse fields.  Continuing 
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effort is still needed to design novel materials and explore their applications in different 
aspects. 
Conclusions and future prospects 
Extensive research has been done on the self-assembling peptides in the last three 
decades due to their favorable features and extensive potential applications in biomedical 
engineering and nanotechnology.  These peptide-based molecules are present in different 
forms as single molecules as discussed above, however, they all tend to form similar 
fibrillar-entangled macrostructures after self-assembly.  This self-assembling process 
usually needs to be initiated by exterior environmental stimuli and the final resulting 
structure has a semi-solid gel-like behavior with a certain mechanical strength.  Those 
unique characteristics of the materials make them ideal material candidates as tissue 
engineering scaffolds or drug delivery vehicles.  Despite high levels of similarity in 
macrostructures, the differences in self-assembling mechanisms and material 
microstructures still exist.  Therefore, it is challenging but beneficial to distinguish the 
differences among them and find the optimal application for each category. 
Comparison and property predictions 
Although considerable effort has been invested in the study for each type of self-
assembling peptide amphiphile as well as their corresponding biomedical applications, 
little comparison has been made to find their relative suitability at a given condition.  For 
example, if three-dimensional culture for a particular cell line is desired, little information 
is available for us to target the best fit material for this situation.  Therefore, a systematic 
prediction system for the performance of each peptide amphiphile under certain condition 
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is expected to be created to take the most advantage of the existing resources.  In order to 
accomplish this, a structure-property correlation for these self-assembling peptides needs 
to be established.  With the knowledge of this relationship, more rational molecular 
design for these peptides is made possible by simply modifying their 
sequences/compositions or stimulus conditions.  Hence, not only comparison within each 
type of peptide is valuable, inter-category comparison would further facilitate the 
selection of the best possible material for each specific situation.  A more thorough 
understanding of relationship between peptide molecular structure and network 
biomedical properties can ultimately lead to a better bio-molecular network behavior in 
general.  This could be one of the most compelling directions for future research. 
Standardization of analytical techniques 
To get a better comprehension of the self-assembling systems, the analytical 
techniques employed to determine their structures and speculate their self-assembling 
mechanisms are of critical importance.  So far, CD and FTIR are the most frequently 
used methods to determine the secondary structures of these peptides in self-assembling 
process while AFM and SEM are the most popular microscopic methods to observe the 
dimensions and morphologies for the self-assembled structure.  However, most 
researchers use only two or three techniques for each peptide studied.  This may lead us 
to less accurate conclusion since each technique has its own limitations.  Another 
drawback is that the results obtained by one group lack consistency to the results 
observed from other groups who use different techniques [187].  For example, the fiber 
diameter measured by one group was 10-20nm [23] but 40-80nm [117] by another group 
for the same peptide.  Therefore, the speculation for its organization in the self-assembled 
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structure could be significantly different.  That explains why controversy still exists in 
terms of peptide molecules orientation in the self-assembled fiber structures for ion-
complementary self-assembly peptides.  Some proposed that these oliogopeptides are 
either staggered or organized in registry to form intermolecular interactions (i.e. 
hydrophobic and ionic interaction between the polar and nonpolar side chains) and fiber 
is formed by the extension of these interactions where the direction of these 
intermolecular interactions is parallel to the fiber axis [23].  Others speculated that fibers 
are developed in length through the extension of intermolecular backbone hydrogen 
bonding where hydrophobic interactions only help to form the β-sheet bi-layer which 
determines the height of the filament [112].  Since the fiber dimensions are usually used 
to speculate molecular organization in the structure and the self-assembling mechanisms 
are derived accordingly, different values obtained from different groups may lead to 
contradictory conclusions with regard to self-assembling mechanisms.  Therefore, 
multiple other technologies with higher resolutions such as X-ray crystallography, solid 
state nucleic magnetic resonance (ssNMR) and even computer simulation could be 
employed together with CD, FTIR, and microscopy to generate a more comprehensive 
picture.  More detailed information on the molecular level of these peptides can be 
provided by X-ray fiber diffraction [188] and ssNMR [189] to confirm those speculations 
and facilitate the development of more accurate mechanisms.  For example, ssNMR 
studies (together with 13C isotopic labeling) performed on RAD16-I recently [189] 
confirmed that the nanofibers are composed of two stacked β-sheets stabilized by a 
hydrophobic core formed by alanine side chains.  More detailed studies should be 
conducted in future work to derive more convincing and precise mechanisms/theories for 
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peptide self-assemblies.  This will promote the fundamental understanding of self-
assembling principles and practically avoid unnecessary contradictory conclusions drawn 
by different groups, thereby facilitating rational design of peptide-based self-assembling 
materials for specific applications. 
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Chapter 3   
Genetic Engineering of a Fluorogenic Module in Bioaffinity 
Hydrogels for Antibody Delivery 
A biomaterial design in which a fluorogen-activating protein (FAP) is used to 
mediate loading and release of antibodies is described in this chapter.  The system 
consists of the FAP dL5, a dimerized single-chain variable fragment (scFv), appended 
with three repeats of the amphiphilic sequence AEAEAKAK via a glycine-serine peptide 
linker.  This fusion generates a polypeptide called dL5_EAK.  Intermixing dL5_EAK 
with the -fibrillizing peptide AEAEAKAKAEAEAKAK (commonly known as EAK16-
II) results in a functionalized composite referred herein as dL5 hydrogel.  The bioaffinity 
hydrogel illuminates fluorescence upon addition of malachite green (MG), the 
fluorogenic partner of dL5.  MG was conjugated with protein A/G (pAGMG) as an adaptor 
that can capture IgG to the dL5.  Using confocal microscopy and dose-response titration, 
we demonstrate that loading of IgG into the hydrogel was mediated by binding of pAGMG 
to dL5.  In in vitro experiments, it was observed that only 26% of the IgG were released 
from hydrogel embedded with pAGMG after five days, compared to close to 90% in 
hydrogel without pAGMG.  Close to 60 % of the antibody recovered over time remained 
bioactive.  Denaturation may be further reduced by modulating the ratio of IgG to the 
multivalent pAGMG, identified in the computational simulations as a principal parameter.  
In mouse footpads, dL5 hydrogel delivered IgG were retained locally, with distribution 
through the lymphatics impeded.  The ability to monitor bioaffinity sites in vitro and in 
vivo, orthogonal to IgG release, will aid the development and optimization of local 
antibody delivery systems. 
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Background and Rationale 
Drug discovery efforts are increasingly turning toward immunomodulatory 
monoclonal antibodies aimed for chronic ailments [190].  While most antibodies are 
formulated for systemic infusion, opportunities exist in developing delivery systems to 
concentrate drugs in affected tissues and to target regional lymph nodes in order to affect 
local immune milieu [191].  Outcomes of inflammation are governed in part by the 
phenotypes of granulocytes, myeloid cells, and lymphocytes trafficking between injured 
tissues and draining lymph nodes.  As such, there are opportunities for developing novel 
systems for local delivery of biologics.  In situ-forming hydrogels can create depots of 
antibody drugs in subcutaneous space.  Local administration of immune modulators can 
enhance efficacy and reduce adverse events.  In situ-forming hydrogels or coacervates 
formed by cross-linked polymer chains that remain physically intact with high water 
intake are particularly attractive because of their ability to adapt to tissue space [192].  
Drug loading can be accomplished by introducing the biologic during polymer cross-
linking.  The pore sizes (5-100 nm) and the resulting high permeability of such depots 
[193], however, preclude the ability to concentrate antibodies at injection sites and 
accumulate in draining lymph nodes.  Rapid diffusion of drugs out of the network (“burst 
release”) can be limited by increasing cross-linking density [194] or through bioaffinity 
retardation [17].  A less explored challenge is that the location of the depot cannot be 
ascertained in vivo, making it difficult to determine the rate-limiting mechanism of drug 
localization. 
The EAK16 series of low molecular weight, -sheet fibrillizing peptides (FP) 
can be formulated into hydrogels for delivering small molecule drugs, proteins, and cells 
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[195-197].  The FP EAK16-II, comprised of AEAEAKAKAEAEAKAK (with A as 
alanine, E as glutamic acid, and K as lysine), self-assembles into cross-linking fibrils in 
high ionic strength aqueous environment [195].  When administered through 
conventional needled syringes, EAK16-II forms stable networks in vivo, adapting and 
adhering to the local tissue contours [198].  Due to the high water content (~99.5% w/v) 
[195], IgG can be loaded into the gel matrices with high efficiency.  The amphiphilic 
EAK16-II, carrying no net charge at pH 7.4, presumably interacts with IgG via weak 
non-specific interactions, resulting in a large fraction of the protein molecules remained 
unbound [199].                 
We have used a coassembly strategy to engineer biochemical functionalities into 
EAK16-II fibrillar matrices [198, 200-203].  Using the analogue EAKIIH6, His-tags are 
incorporated into EAK16-II fibrils, driven by the FP domain for -sheets.  The two 
peptides co-assemble efficiently, with greater than 90% of EAKIIH6 incorporated into 
the composite [198] generated from excess EAK16-II.  By embedding recombinant 
protein A/G (pA/G) via anti-His-tag antibodies, IgG can be loaded and release over time 
[201-203].  Because Protein A and Protein G bind to IgG with relative high affinities 
(with apparent binding constants reported at 2.9 x 107 and 1.13 x 108 M-1 [204], 
respectively), pA/G provides a stable and extended affinity mechanism [205].  In vivo, 
diffusion of IgG from the material is driven by concentration gradient between the depot 
and the surrounding tissues, including the lymphatics.  The system renders retention of 
IgG molecules in subcutaneous injection sites for up to ten days [201].  The EAK16-
II/EAKIIH6 system, when adapted with pAG and anti-His-tag antibodies, was designed 
as antibody-functionalized scaffolds for cytokines and cells [201, 202]. The ability to 
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monitor binding sites in vivo would enhance correlation with in vitro or in vivo 
optimization.   
In this chapter, we describe an in situ-forming hydrogel platform on which the 
binding sites for IgG, pA/G, can be monitored using an activation-dependent fluorescent 
module.  The hydrogel are generated by intermixing EAK16-II with its analogue 
dL5_EAK, a polypeptide consisting of a FAP with two light chains, called dL5, fused to 
three repeats of AEAEAKAK via a glycine-serine spacer, (GGGGS)3 [200] (Figure 3-1a).  
In high ionic strength environment, EAK16-II and dL5_EAK undergo solution-gel phase 
transition and coassembly, apparently simultaneously.  The resultant materials are 
illuminated in the presence of malachite green (MG), the fluorogen that can be activated 
by dL5 [206].  Relative to free MG, the fluorescence of dL5-bound MG is enhanced by 
up to 20,000 folds, due to constraining of the rotatable bonds in MG by two L5 proteins.  
Crystallographic studies have shown that MG mediates dimerization of two L5 proteins 
to form a fluorescent ternary complex [207].  We hypothesized that the system of MG-
conjugated pAG (pAGMG), dL5_EAK and EAK16-II, when deployed together (called 
dL5 hydrogel, see Figure 3-1b), serves as a self-illuminating, injectable formulation for 
local deposition of IgG.  The tight binding of dL5 to MG ensures a stable intermediate 
[207].  The exceptionally low fluorescence background renders the fluorogenic module 
an efficient reporter of binding sites, independent of model IgG drugs [206].  We 
characterized and modeled the release kinetics in vitro, and found that the dL5 hydrogel 
retained IgG at the injection site and draining lymph node in vivo. 
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Figure 3-1 Diagrams showing (a): the construct of dL5_EAK and (b) pAGMG embedded 
dL5 gel displaying IgG molecules. 
 
Materials and Methods 
EAK16-II and expression of dL5_EAK 
EAK16-II was custom synthesized by American Peptide Company (Sunnyvale, 
CA) at greater than 95% purity with the N-terminus acetylated and C-terminus amidated. 
The sequence was confirmed by mass spectrometry.  The peptide, received lyophilized, 
was reconstituted in sterile deionized water (18.2 M at 25C) as needed and stored at -
80°C until use.  Construction of plasmids encoding dL5_EAK was described previously 
[200].  Specifically, the plasmid pET21 GST HRV dL5 was constructed by PCR 
amplification of L5 (E52D L91S, referred to as L5 in this work) monomer and ligation 
into the bacterial expression vector pET21 GST HRV.  An annealed DNA insert 
encoding the amino acid repeat (G4S)4 was ligated downstream from the L5 subunit, 
followed by the ligation of PCR amplified DNA encoding an additional L5 subunit. The 
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plasmid pET21 GST HRV dL5_EAK was constructed by ligation of double stranded 
DNA encoding 3 additional repeats of (G4S) followed by 3 repeats of the amino acids 
AEAEAKAK downstream of the dL5 sequence of pET21 GST HRV dL5.  Plasmid 
sequences were verified by DNA sequencing.  Expression and purification of dL5_EAK 
was carried out by transforming pET21 GST-HRV-dL5_EAK into calcium competent 
Rosetta-Gami 2(DE3) E. coli. (Novagen, Madison, WI).  The transformed bacteria were 
grown in 500 ml volumes and induced using 500 µM IPTG and 0.4% glucose overnight 
at 20ºC.  Proteins in cell lysates were captured using Ni-NTA agarose columns (Qiagen, 
Valencia, CA) and eluted by HRV3C protease.  Fractions containing the protein were 
combined and dialyzed against PBS, with the resultant concentrate quantified using UV-
Vis ( = 280 nm).  Details of plasmid construction, protein expression and purification, 
can be found in Saunders et al. [200].   
Conjugation of protein A/G 
Protein A/G (pA/G) and malachite green isothiocyanate (MG-ITC) were 
purchased from Life Technologies (Carlsbad, CA).  Conjugation of pA/G to MG-ITC 
was carried out in alkaline aqueous buffers (pH = 8.5 to 9.5), with the resultant conjugate 
separated from unreacted MG-ITC using PD-10 columns (Sephadex G-25 M, GE 
Healthcare, Aurora, OH).  The degree of labeling of the eluent was calculated based on 
the molar ratio of dye concentration to protein concentration. Each mole of pA/G was 
conjugated with 0.67 mole of MG, as determined by bicinchoninic acid assay for the 
former and UV-Vis absorbance at 633 nm of the latter.     
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Gel electrophoresis  
Different amounts of EAK16-II (10 L, 20 L, 40 L, 80 L or 160 L, at 5 
mg/ml) were added to 8.3 L of dL5_EAK (72 M) to prepare mixtures containing 
EAK16_II to dL5_EAK at 50:1, 100:1, 200:1, 400:1, and 800:1 molar ratios.  Each 
sample was suspended in a total volume of 500 l, followed by incubation at 37°C 
overnight.  The samples were centrifuged at 16,000 RFC for 6 minutes with the 
supernatants analyzed using denaturing Novex NuPAGE 4-12% Bis-Tris gels.  To each 
sample, the supernatant (5 µL) was added with 5 µL of NuPAGE SDS buffer and 10 µL 
of PBS, with the resulting solution heated at 70 °C for 10 minutes before loading.  All 
samples were run at 200 V for 35 min in NuPAGE MES SDS running buffer.  Proteins 
were visualized using the SilverQuestTM staining kit for which a detection limit of 0.3 ng 
has been reported.  All electrophoretic reagents were purchased from Life Technologies 
(Carlsbad, CA).  Images were captured using the Kodak 440 Image Station (Kodak, 
Rochester, NY), and band intensities were quantified using the NIH Image J software.  
Percent dL5_EAK incorporated into the insoluble fraction was quantified by subtracting 
the intensity of the protein band in samples containing EAK16-II from the intensity of the 
samples without EAK16-II.  
Viscosity measurement 
Stock solutions of EAK16-II and dL5_EAK were prepared in distilled water at the 
level of 10 mg/mL and 12.2 M respectively.  Samples of EAK16-II with or without 
dL5_EAK were prepared in PBS (pH = 7.4) and drew into positive displacement pipettes 
(RheoSense Inc., San Ramon, CA).  EAK16-II was prepared in different concentrations 
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(0.01–2 mg/ml) in two solvents (PBS and distilled water).  The EAK16-II with dL5_EAK 
in PBS was prepared at the ratio 400:1 and the final concentrations were 1.5 mg/ml and 
2.3 µM, respectively.  Measurements were performed using the VISC unit (RheoSense 
Inc.) equipped with a temperature control module, which was set at 25C.  Samples were 
subjected to different shear rates by changing the flow rate through the capillaries (depth 
= 50 m) in the sensor cartridge (HA01-01).  The instrument is capable of measuring 
viscosity between 0.2 to 100 mPa·s from shear rates 6.5 to 5,850 s-1 at within 2% 
accuracy according to the manufacturer.   
Titration of pAGMG to dL5_EAK gel 
Hydrogels composed of EAK16-II and dL5_EAK (400:1) were established in 
Corning FluoroBlok 96-well plate (Thermo Scientific, Inc.).  Different amounts of 
pAGMG were added to the hydrogel to generate samples containing dL5_EAK to pAGMG 
molar ratios of 1:8, 1:4, 1:2, 1:1, 2:1, 4:1, 8:1, or 16:1.  Sufficient PBS was added to each 
well to attain a final total volume of 200 l.  The solvated hydrogels were incubated 
overnight at 37 °C before measuring MG/dL5 fluorescence using a Tecan Infinite M1000 
microplate reader, with excitation set at 635 nm and emission at 670 nm.  EAK16-II 
with pAGMG, or EAK with a PEGylated form of MG [206] were used as the controls 
(n=3). 
Laser-scanning confocal microscopy 
Samples were prepared for confocal imaging as described below.  To 20 L of 5 
mg/ml EAK16-II, 40 L of 10 M dL5_EAK were added and mixed to produce a gel 
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with a molar ratio of 150:1.  To this mixture, 12.2 µL of 11 M pAGMG, 4 µL of 0.05 
mg/mL FITC-labeled rat anti-mouse CD23 IgG antibody were added in a confocal dish 
(MatTek Corp., Ashland, MA).  The sample was brought up to 100 µL with PBS and 
incubated overnight.  The hydrogel was collected by centrifugation and washed with 200 
µL of fresh PBS five times before transferring to a glass bottom microwell dish.  Imaging 
was performed using a Zeiss Axioplan 2 imaging microscope equipped with a mercury 
lamp.  Fluorescein fluorescence was collected a 470/530 nm filter, and Cy5 fluorescence 
was obtained using a 710/75 nm filter (Chroma, Lititz, PA).  Control samples without 
dL5_EAK, without pAGMG, or containing only EAK16-II and fluorescein-labeled IgG, 
were also imaged.   
In vitro IgG release 
The kinetics of release of a fluorescein-labeled antibody (Pierce goat anti-human 
IgG) from pAGMG-embedded dL5 hydrogel were determined by monitoring fluorescence 
over time.  The IgG-loaded materials were established in MicroSert (inner diameter = 
4.15 mm, maximum volume = 500 µL) by instilling a mixture of EAK16-II (60 nmol), 
dL5_EAK (150 pmol), pAGMG (150 pmol), and IgGFITC (75 pmol).  The 50 l mixture 
was incubated overnight at 37°C before adding 400 l of PBS (0.1% BSA, 0.025% 
NaN3) as the release medium.  The insert was placed in its receptacle vial and capped 
before incubation at 37°C at the start of the release.  At various time points, 200 l of the 
release medium was collected for measurement (excitation = 485 nm; emission = 535 
nm) using the Tecan Infinite M1000.  Aliquots of fresh release medium were added to 
restore the system to its initial volume.   
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Modeling Methodology 
To delineate the parameters driving IgG release, a mathematical model is 
described and implemented here.  The data for this comparison is taken directly from the 
in vitro case described in Figure 3-10, in which diffusion of the antibody IgG from a 
tailored hydrogel with and without pAGMG binding sites is compared.  Six components in 
the system with four possible interactions were considered:   
     k1 
pAGMG  +  dL5  ⇌  pAGMG·dL5        
      k2  
 
            k3 
IgG  +  pAGMG·dL5  ⇌ IgG·pAGMG·dL5      (1) 
           k4 
 
    k5 
IgG  +  pAGMG  ⇌  IgG·pAGMG 
   k6 
 
   k7 
IgG. pAGMG  +  dL5   ⇌  IgG·pAGMG·dL5   
   k8 
 
To understand the affinity interactions on the overall release dynamics, we 
considered the systems of equations previously described for other affinity systems 
designed for sustained release of proteins and drugs [17, 32, 42, 208].  These models 
contain parameters analogous to those describe the current system in which two sets of 
reversible interactions operate: binding of pAGMG to dL5_EAK, and binding of IgG to 
pAGMG.   Free pAGMG would bind IgG, generating IgG-pAGMG complexes that bind to 
dL5 associated with EAK16-II fibrils. All dL5_EAK are assumed remained in the main 
EAK16-II fibrils throughout.  The relative fractions of these components are governed by 
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the rate constants associated with identifiable processes: with k1 > k2, and k7 > k8.  
Because pAGMG was found to be relatively immobile compared to the IgG (Figure 3-8b), 
the concentration of pAGMG in the sample was held constant.  This allows for the isolated 
study of IgG diffusion for describing the behavior of the system, focusing on the third 
reaction in Equation set (1). 
The diffusion of unbound IgG from the hydrogel is first modeled through Fick’s 
law in a heterogeneous medium as shown in Equation (2), where  IgG  is the molar 
concentration of unbound IgG, and D is the variable diffusion coefficient.  Diffusion is 
assumed to be one-dimensional, and the hydrogel and aqueous regions are assumed to be 
divided neatly into two cylindrical volumes as depicted in Figure 3-10a. 
   2
2
diff
IgG IgG
D
t x
 

 
     (2) 
The diffusion equation is solved using central-order finite-difference methods.  
The hydrogel and release medium are discretized with respect to x with even grid spacing 
(100 points evenly distributed across the length of the vial).  The change in IgG 
concentration at each node is then estimated and integrated through finite difference 
approximations (Equation (3)) [209]. Zero-flux boundary conditions are enforced at 
either end of the vial.  Since the diffusion coefficient is assumed to vary with location, the 
averaged value between the neighboring nodes is used. 
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The binding-release behavior of IgG from the pAGMG sites is assumed to follow 
Hill’s law [210], commonly used for ligand binding with multiple sites.  This equation 
was selected due to uncertainty of the exact nature of the binding sites, by combining 
them into a single association constant with a variable describing their interactions.  Each 
pAGMG possesses six binding sites for IgG (4 on protein A, 2 on protein G), which may 
exhibit cooperative or competitive effects between the sites as binding progresses.  Here 
n is Hill’s coefficient, where n > 1 corresponds to positive cooperativity and n < 1 
corresponds to negative cooperativity.  Y  is the ratio of bound sites to total sites, and K is 
the association constant.   
 
 1
n
n
K IgG
Y
K IgG


         (4) 
As the unbound IgG diffuses away from the hydrogel and into the surrounding 
medium, the equilibrium value for the bound pAGMG complexed with IgG shifts as well, 
releasing a portion of the IgG to replace some of the diffused components.  Therefore, the 
total change in IgG concentration may be modeled as a combination of diffusion and 
release.  The diffusion component is captured through Equations (2, 3), and the release 
component may be calculated by taking the derivative of Equation (4) with respect to the 
concentration of unbound IgG and multiplying by the total change in concentration [211, 
212].  This produces the final system of equations summarized as Equation (5). 
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Zero-flux boundary conditions are enforced, and the total concentration of IgG within the 
vial is integrated and tracked throughout the simulation to estimate and control the error.  
The resulting model calculates the concentrations of both bound and unbound IgG with 
respect to time for various conditions and association constants and cooperativities. The 
apparent association constant K is estimated by assuming that the concentration of bound 
and unbound IgG within the hydrogel at t = ∞ are equal, and K is recalculated for each 
value of the Hill coefficient n from Equation (6). 
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                                     (6) 
 
Mice and in vivo studies  
Six to eight week old female (certified-virus-free) BALB/c mice were purchased 
from Charles River Laboratories (Wilmington, MA) and housed in the Duquesne 
University Animal Care Facility certified by the USDA.  Animals were handled in 
accordance with protocols approved by Institutional Animal Care and Use Committee.  
The injection mixtures contained 60 nmol (in 20 µL) of EAK16-II together with 0.15 
 89 
nmol of dL5_EAK, 0.15 nmol of pAGMG, and 75 pmol of Dylight-800 4X PEG 
conjugated IgG (Thermo Scientific).  Mixtures, some without pAGMG, were drawn into 
25 G’ needled syringes and injected subcutaneously into the footpads of mice while 
anesthetized with isoflurane (induction 5%, maintenance 3%).  For retention studies 
(Figure 3-11), each mouse was injected with the system and control, but on different 
footpads.  Four replicates were performed.  For distribution studies (Figure 3-12), each 
mouse received either solutions containing the intact system or control, in both footpads.  
Three replicates were performed for these experiments.  In both studies, footpads and/or 
lymphatic organs were excised 72 hours after injection and imaged using an Odyssey 
imager (Li-Cor, Inc., Lincoln, Nebraska).  All images were captured at low intensity (2.0) 
and the same focus offset (3.2 mm), and quantified using the software Image Studio (Li-
Cor, Inc.).  Table 3-1 shows the formulations used in the in vivo experiments.  
Table 3-1 Formulations used in in vivo experiments 
 Intact systema 
Control: retentionb 
(g) 
Control: 
distributionc 
EAK16-II (µg) 100 100 - 
dL5_EAK (µg) 4.3 4.3 - 
pAGMG (µg) 7.7 - - 
IgG (µg) 11.3 
Fluorescein 
11.3 
Fluorescein 
11.3 
Fluorescein Total volume 
(l) 
49.4 49.4 49.4 
a“System” formulation used in experiments shown in Figure 3-11 and Figure 3-12.  
b“Control” formulation used in experiments shown in Figure 3-11. 
c“Control” formulation used in experiments shown in Figure 3-12. 
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Results 
In this chapter, we aimed to develop a bioaffinity-driven system in which the 
release of IgG from a fibrillar matrix was retarded in order to concentrate therapeutic 
antibodies locally at injection sites and in regional lymph nodes.  By concentrating 
antibodies in lymph nodes to which inflamed tissues drained toward, dosage of the 
injection can be reduced.  Techniques of parenteral injections targeting selected lymph 
nodes are established [213].  The design hinges on engineering a fluorogenic module into 
the network of FP within which binding sites for IgG can be monitored optically.  Two 
dye-labeled IgG molecules, IgGFITC and IgG800, were used as model payloads in in vitro 
and in vivo studies, respectively.  Expression and purification of dL5_EAK were 
enhanced by that the polypeptide does not self-assemble.  The identity of dL5_EAK was 
verified using SDS-PAGE and mass spectrometry [200].  Building upon the prototype 
described in Saunders et al. where the coassembly of dL5_EAK and EAK16-II were 
visualized by the dye Congo red and probed with SEM (Figure 3-2), we determined here 
that intermixing EAK16-II with dL5_EAK at 400:1 molar ratio resulted in 94% of the 
latter being incorporated into the final composite (Figure 3-3b).  Unless noted otherwise, 
the experiments described herein were conducted at the same molar ratio.   
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Figure 3-2 Morphological features of EAK16-II and dL5_EAK/EAK16-II hydrogels as 
revealed in (a) Optical images (40X; scale bar=50 µm) captured using a cooled CCD 
camera immediately after solutions containing 5 µL of EAK16-II (left panel), 5 µL of a 
1:100 ratio of dL5_EAK to EAK16-II (middle panel) and 5 µL of 58 µM dL5_EAK 
alone (right panel) were pipetted into an equal volume of PBS with 0.01% Congo red and 
spotted on glass slides. β sheet structures formed by self-assembly of EAK16-II domains 
are visible by Congo red incorporation. (b) SEM images (5000X magnification) of fixed 
and lyophilized membrane samples. The particles (circles and pointed by a red arrow in 
the image) formed on the membrane is indicative of dL5 domain.  
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Figure 3-3 Co-assembly and association of dL5 gel system components. (a) Schematic 
depiction of the affinity hydrogel for release of IgG.  (b) Analysis of incorporation of 
dL5_EAK into EAK16-II fibrils using SDS-PAGE. Increasing amounts of EAK16_II 
were added to the same amount of dL5_EAK to make the ratio of the two from 50:1-
800:1. The bands represent unincorporated, soluble fraction in the mixture after 
centrifugation.  (c) Viscosity of EAK16-II mixed with dL5_EAK at different shear rates 
(n = 3).  Measurements were made at 25°C using a µVISC unit equipped with a 
temperature control module. 
 
To characterize the mixing effect of adding dL5_EAK to EAK16-II fibrillar 
networks, viscosity of solutions containing both was measured using capillary rheometry 
by which pressure gradient of the sample is measured across microfluidic channels [214].  
Consistent with results reported by the Chen group [215], viscosity of diluted EAK16-II 
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peaked at approximately 25% of PBS (Figure 3-4), indicating that the method is sensitive 
to the same material behavior of the FP.  Mixtures containing EAK16-II and dL5_EAK 
were tested in a range of shear rates at 25C in PBS.  Solutions dissolved with only 
dL5_EAK exhibited baseline viscosity, at near 1 mPa·s (Figure 3-3c), confirming our 
previous observation that the polypeptide does not self-assemble at the concentrations 
tested.  At shear rate 4,000 s-1, the viscosity values of EAK16-II and EAK16-II mixed 
with dL5_EAK both fell between 1 to 1.5 mPa·s, indicating that the materials lack shear 
resistance.  Scanning EAK16-II in PBS at lower shear rates (1,000-3,000 s-1) revealed a 
sharp transition at 1,800 s-1 for EAK16-II (Figure 3-3c); the downward trend from 2.1 
mPa·s to 1.5 mPa·s suggests a pseudo-elastic material.  The transition was attenuated in 
the presence of dL5_EAK, with viscosity measured between 1.3 to 1.5 mPa·s within the 
range of shear rates tested.  Intermixing the two peptides does not diminish staining by 
Congo red [200].  These results show that the microscopic organization in EAK16-II 
appeared sensitive to perturbation by dL5_EAK, but the macroscopic structure appeared 
intact.  The lack of mechanical strength of the materials is not unexpected because the 
low-molecular weight and the low concentration of the FP used.  The mixture can be 
injected without clogging, for the shear rate applied in 25 gauged syringe needles is 
estimated approximately 8000 s-1.  The deformable hydrogels can adapt to tissue space 
when injected subcutaneously.   
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Figure 3-4 Viscosity of EAK16-II at different salt concentrations. Measurements were 
made using VISC with shear rate set at 1,600 s-1 at 25°C.  Symbols represent 
independent experiments conducted. 
 
pAGMG conjugate  
Malachite green (MG) was conjugated to pA/G by using an amine reactive form 
of MG –MG isothiocyanate (ITC). Under slightly alkaline pH, the lone pair electron on 
the amine group of amino acid residues of pA/G is attacking the electron deficient carbon 
in the ITC group and forms the thiourea product pAGMG.  SDS-PAGE verified the slight 
increase in molecular weight of pA/G after the conjugation (Figure 3-5). 
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Figure 3-5 Electrophoretic analysis of native pAG and pAGMG using SDS-PAGE. 
 
Localization of IgG in pAGMG-embedded dL5 hydrogel 
The conjugate pAGMG was tested for binding to composites of dL5_EAK mixed 
with molar excess of EAK16-II (referred to as “dL5 hydrogel” hereafter) pre-formed on 
plastic surface.  KD between pAG
MG and dL5 gel was determined to be 90.9 nM, 
calculated based on titration experiments using MG fluorescence as the readout (Figure 
3-6a).  Saturation was observed at molar ratio of 1:1 between pAGMG and dL5.  No 
fluorescence was observed in PBS containing pAGMG, or in water dissolved with 
EAK16-II without dL5_EAK (Figure 3-7a), all indicating specific binding of pAGMG to 
dL5.   
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Figure 3-6 Binding and localization of pAGMG in dL5 hydrogel.  (a) Titration of pAGMG 
to established hydrogel (n = 3).  KD was determined using the one site-specific binding 
model (y axis title: FI, fluorescent intensity; a.u., arbitrary unit). No washing steps were 
needed because no background fluorescence was generated from unbound MG.  (b) Top 
view of IgGFITC-loaded pAGMG-dL5 gels, the intact system, showing fluorescence 
associated with IgG (green), MG-dL5 (red), and the two combined. Scale bar represents 
20 μm. (c) Side view of the intact systems, showing fluorescent components along the 
vertical axis of the gel.  Gels were deposited into glass bottom microwells immediately 
prior to imaging. Controls examined included gels made with components used for 
making the intact system without pAGMG or dL5_EAK (Figure 3-7b).  
       
We next determined if pAGMG can indeed mediate IgG loading in dL5 hydrogel.  
As the EAK16-II fibrillar network contains large aqueous void volume (99.5% w/v), we 
did not attempt to saturate the system, but determined that at least 70 g of IgG could be 
loaded per mg of the peptides.  Even this sub-saturating dose may suffice for delivering 
Merged
Side view
IgG-FITC MG
Top view(b)
(c)
(a)
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antibodies for local effects, for example with an anti-tumor necrosis factor antibody 
[216].  Using laser scanning confocal microscopy, we observed scattered non-specific 
IgG adsorption (green) on the surface, but the extensive co-localization (yellow) 
underneath suggests dL5-bound pAGMG captured the majority of the antibodies in the 
matrix (Figure 3-6).  Without pAGMG, IgGFITC in the matrix was significantly reduced, as 
evidenced by the relatively low fluorescence (Figure 3-7b).  These data support the 
fluorescence-generating loading mechanism.  
                       
Figure 3-7 Loading and co-localization of IgGFITC in dL5 hydrogels.  Images were 
obtained from the same experiment described in Figure 3-6 (b and c).  (a) MG 
fluorescence in solutions containing different components.  (b) Images obtained using 
(a)
(b)
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confocal microscopy of control samples, including the intact system (EAK16-II, 
d_5_EAK, pAGMG, and IgGFITC) without dL5_EAK (top panel), without pAGMG (second 
panel) and without IgGFITC (third panel).  The last panel shows image of a sample made 
with EAK16-II and IgGFITC without the other components. 
     
In vitro IgG release from pAGMG-embedded dL5 hydrogel 
Release of IgGFITC from pAGMG-embedded dL5 hydrogel was monitored in vitro 
over two months.  The experiment was initiated by mixing the antibody with the hydrogel 
components in a small cylindrical vessel with defined dimensions.  In the control 
experiment in which hydrogel were made without pAGMG, almost 90% (mean value, 
n=3) of the antibody loaded were released in the first five days (Figure 3-8a).  In contrast, 
a biphasic pattern was seen with hydrogel embedded with pAGMG; a slow initial phase, 
during which only 26% were released by day 5, was followed by a second phase during 
which approximately 50% were released over 2 months.  At the end of the eight-week 
period, 22.7% of the IgG still remained, suggesting that the release would continue.  The 
cumulative amount released might suffice the dosage needed for local antibody drug 
delivery [216].  The IgGFITC, an anti-human IgG antibody, released from the hydrogel at 
the end of the 2-month period were shown to bind its cognate antigen (human IgG) at 
58% capacity: 1.7 g/ml of the 2.9 g/ml anti-human IgG released recognized plastic-
adsorbed human IgG (Figure 3-9).  Dissociation of pAGMG from dL5 appeared slow, as 
evidenced by that more than 60% of the initial MG fluorescence remained in the gels at 
the end (Figure 3-8b).  These results demonstrate that the affinity binding delayed the 
release of IgG from the matrix, and that pAGMG-bound dL5 is a relatively stable 
component.    
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Figure 3-8 Monitoring in vitro IgG release and pAGMG – dL5 interaction.  (a) Cumulative 
release of IgGFITC from dL5 gels with (n = 3) or without pAGMG (n = 3).  Each time point 
represents measurement from triplicate samples in gels setup in parallel.  (b) Images and 
quantification showing MG fluorescence in release vessels at the start and the amount 
remained at the end of the period (n = 3 for all groups).  “Start” refers to day 0, “End” 
refers to day 60, “Control” was the same in (a), and “Blank medium” refers to vials 
containing PBS with no other components added.    
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Figure 3-9 Biological activity of released anti-human IgGFITC tested by binding to 
immobilized human IgG (y axis title: FI, fluorescent intensity; a.u. arbitrary unit).  (a) 
Standard curve established for quantifying the anti-human IgGFITC (b) Titration of the 
anti-human IgGFITC to plate-bound human IgG as target antigen with concentrations 
determined using the standard curve. (c) Fluorescence measurements of fresh anti-human 
IgGFITC and the same antibody incubated at 37°C for 60 days to validate the stability of 
FITC fluorescence as the readout for IgG release amount quantification.   
 
Modeling and simulation of release  
We sought to understand the parameters governing the kinetics of IgG release 
from the hydrogel.  The initial phase of the in vitro release was fit to the non-steady state 
Fickian model (Figure 3-10a and Table 3-2).  Apparent diffusion coefficients (Dapp) were 
(a)
(b)
(c)
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determined by relating Mt/M as a function of t
0.5.  Dapp of IgG in hydrogel without 
pAGMG was an order of magnitude higher than Dapp of IgG in hydrogel embedded with 
pAGMG.  Release of IgG was impeded in both systems, as Dapp of IgG in aqueous solution 
is estimated much higher [29].  While the analysis does not encapsulate the entire release 
profile, the results show that without pAGMG, a large fraction of loaded IgG would escape 
by rapid diffusion shortly after the components coalesce.  
 
Figure 3-10 Modeling and simulation of IgG release in vitro.  (a) Short time 
approximation of release of IgGFITC in vitro (see Figure 3-8) using Fick’s second law.  
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Because the small vial diameter relative to the vial length, the release is assumed 1-D 
along the vial length into the saline medium.  No IgG escapes the sides and bottom of 
from the gel placed in the cylindrical glass vials.  The volume of the gels was assumed 
constant, as FP matrices do not swell.  IgG was assumed distributed in the matrices 
homogenously and released in one-dimensionally, with IgG concentration at boundary 
assumed zero at the start. The height of the gel is 3.7 mm, with the base inner diameter 
equals to 4.15 mm (per manufacturer specification). (b) The evolution of unbound IgG 
with respect to time for non-cooperative binding (n = 1.0).  Initially the IgG is contained 
exclusively within the fibrillar matrix. Upon exposure to the release media, the IgG 
begins to diffuse into the simulated vial, accompanied by a gradual release of the bound 
IgG from the gel.  (c) The percentage of IgG released into the vial is plotted with respect 
to time with varied binding characteristics through the Hill equation.  The release profiles 
show the effect of the binding characteristics, and an increase in sustained release 
achievable through cooperative hexavalent binding. 
 
Table 3-2 Apparent diffusivities (Dapp) determined using approximation of early release
a   
 Dapp (10-10 m2s-1) R2 IgG remained in gel (%) 
Control 0.075 0.92 1.4 
System 0.0086 0.82 22.7 
IgG in aq. 0.40b N/A N/A 
aFick’s second law was used in the approximation, with Dapp being apparent diffusion 
coefficient, t as time in hours, H is one-dimensional height of matrix (3.7 mm), Mt being 
the amount of IgG released at time = t, and M∞ being the theoretical maximal amount 
released at time infinity.  Dapp were determined by regression of the data to the question:  
𝑀𝑡
𝑀∞
=(
16 𝐷𝑎𝑝𝑝. 𝑡
𝜋 𝐻2
)
0.5
 
 
bCalculated based on the Stokes-Einstein approximation of IgG in water at 37°C [29].  
 
The numerical model outlined in modeling methodology section was used to 
further examine the experimental results, expanding on this observed decrease in 
apparent diffusion with the bioaffinity hydrogel.  Figure 3-10b shows the predicted 
evolution of the unbound IgG along the length of the vial, assuming 1-D diffusion.  
Initially all IgG is assumed to exist only in the gel, and the concentration along the length 
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of the vial is approximated through a sharp sigmoidal function at the boundary of the 
fibrillar matrix.  The diffusion coefficient is assumed to vary in a similar fashion between 
the Control value and the IgG in aqueous values in Table 3-2, and the difference between 
the measured Control and system values is accounted for by the binding behavior within 
the model.  The concentration is calculated by dividing the initial IgG concentration by 
the volume of the matrix, assuming an even distribution.  Equation (4) is then used to 
divide the concentration into bound and unbound concentrations.  As the model IgG 
diffuses out of the hydrogel into the release media, additional IgG is dissociated from 
pAGMG, thereby replenishing in the matrix the IgG lost to diffusion.  
The concentration of unbound IgG outside of the matrix region was integrated 
with respect to time and divided by the saturation concentration.  This is calculated as the 
original number of moles of IgG within the vial divided by the total volume of the vial (
 
n
final
IgG ), and remains constant between each case.  Four cases are recreated; one 
without pAGMG, and three with varying levels of cooperativity between the binding sites 
on pAGMG, n=0.5 (negative cooperative binding), 1.0, and 2.0 (positive cooperative 
binding) as defined in Equation (4) and (6).  The apparent association constant K is 
estimated by assuming that the concentration of bound and unbound IgG within the gel at 
t = are equivalent, and K is recalculated for each value of the Hill coefficient n from 
Equation (4).  The values for the association constant K are calculated as 1.08, 62.54, and 
2.08 * 105 for n = 0.5, 1.0, and 2.0 respectively. 
The molar concentration of IgG outside of the gel is integrated across the length 
of the vial and divided by the equilibrium concentration, where the moles of IgG are 
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evenly distributed across the vial volume.  The total fluid volume considered is 250 L to 
better approximate the original fluid left in the vial between measurements.  This 
methodology does not take into account the experimental removal and replenishment of 
the buffer solution, as this removal of IgG concentrations introduced undesirable 
instability in the finite difference method.  Consequently, the model under predicts the 
diffusion rate for the Control case, likely due to a combination of the 
removal/replenishment behavior combined with the potential convective flow introduced 
as a result.  However, the complete system simulations in which IgG is bound to the 
fibrillar matrix provides a favorable result, indicating that the binding between IgG and 
pAGMG is responsible for the controlled rate of diffusion, and suggesting that the nature 
of the binding is cooperative.  If the diffusion for the complete system is enhanced 
experimentally by the removal/replenishment of the buffer solution, then the binding is 
likely to further favor the cooperative case. 
Simulated cases containing a positive cooperativity show a more sustained 
release.  Comparing the results to Figure 3-8a, it is demonstrated that the improved and 
controlled release offered by the bioaffinity gel may be predicted through a numerical 
model, and this model predicts that the IgG-pAGMG binding is cooperative.  The profile 
of the release is intrinsically tied to the hexavalent binding between IgG and pAGMG, and 
this binding is crucial for the controlled and sustained release observed in experiments. 
From the plots given, the estimated values for the pAGMG-IgG binding are an association 
constant of K 2.08 * 105, and a Hill coefficient of n 2.0.   
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Deposition of dL5 gel formulated IgG in vivo  
To test the notion that dL5 hydrogel serves to retain IgG in vivo, dL5_EAK and 
EAK16-II mixed with pAGMG and IgG800 were injected subcutaneously into footpads of 
mice and imaged ex vivo (Figure 3-11a).  The results indicate that gelation occurred 
beneath the skin (Figure 3-11b).  Compared to IgG800 formulated without pAGMG, the 
intact hydrogel system rendered superior retention at the injection site, as reflected by the 
relatively strong fluorescence emitted in the 800 nm channel (green).  The concentrated 
fluorescence sustained for at least 72 h, after which the signals in both sets of mice 
dissipated to background level.  Movement of animals would no doubt perturb the 
materials located in the subcutaneous space.  To this end, we probed the localization of 
the pAGMG-dL5 hydrogels in footpads of living mice.  In a separate experiment, it was 
detected at the injection site (after 48 h) that IgG800 (green) co-localized with pAGMG-
bound dL5 (red; 700 nm) (Figure 3-11c).  No MG fluorescence was detected in the 
control footpad administered with free IgG800.  Note that in footpads injected with the 
intact system, IgG was also detected in the draining lymph node (indicated by arrow).  
No MG fluorescence was detected in the same lymph node, consistent with the in vitro 
observation that the pAGMG/dL5 complex is a stable component in the matrix.  These 
results demonstrate the consistent coalescence of IgG800, pAGMG, dL5_EAK, and 
EAK16-II in vivo.   
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Figure 3-11 Retention of IgG and binding sites in footpad.  Retention of IgG delivered 
with dL5 gel at injection site. (a) Diagram depicting the in vivo experiments.  Each 
mouse was injected subcutaneously with solutions containing all hydrogel components 
(system) in one footpad and the same except without pAGMG (control) in the other. The 
mixture was drawn into a 25’ G needled syringe as a low viscosity liquid by keeping in 
low ionic strength buffer.  The mice were sacrified at 72 hours after the injection. (b) 
Images of four replicates showing fluorescence associated with IgG800 in footpads of each 
mouse three days after injection.  (c) Images taken from a separate experiment 48 hours 
after injection, showing fluorescence in mouse injected with IgG800 injected in saline (left 
panel) and the same antibody injected in the same mouse with all components in the 
system (right panel).  
(a)
(b)
(c)
control system control system
control system
mouse #1
control system
mouse #2
control system
mouse #3
control system
mouse #4
NIR800 MG
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In a separate set of mice, distribution of IgG800 was traced by fluorescence in 
regional and distant lymphoid organs (Figure 3-12).  Mice injected with the antibody in 
plain PBS (into both footpads) resulted in detectable fluorescence in sciatic, inguinal, 
brachial lymph nodes, and to a lesser extent, the spleen.  Distribution of IgG800 delivered 
with the system (i.e. pAGMG, dL5_EAK and EAK16-II) was mostly sequestered to sciatic 
lymph nodes, draining from the footpads; inguinal and brachial nodes showed lower 
fluorescence, with spleen at near background level of intensity.  In mice receiving the 
intact system, the low fluorescence in distant lymph nodes is congruent with the strong 
fluorescence remained at the injection site.  These results indicate the dL5 hydrogel 
impeded the distribution of IgG deposited at the injection site.     
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Figure 3-12 Distribution of IgG800 injected in footpads 72 h after injection. (a) Mice were 
injected with either control or system mixtures in both footpads.  Unlike the experiments 
described in Figure 3-11, here each mouse was injected with the same formulation.  (b) 
The images show fluorescence associated with IgG800 in (1 and 1’) sciatic, (2 and 2’) 
inguinal, (3 and 3’) brachial lymph nodes, the spleen, and footpads from mice 
administered with the intact gel system mixed with IgG800, or IgG800 in PBS (control).  
1
2
3 spleen
footpads
control mouse #1system mouse #1
control mouse #2system mouse #2
control mouse #3system mouse #3
1’
2’
3’
same injection (system or 
control) in both footpads
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Discussion 
This bioaffinity hydrogel design was motivated by the need for a tractable 
injectable system by which antibodies could be concentrated and monitored in vivo.  
Potential applications include intratumoral antibody injection [20], and topical delivery of 
anti-cytokine antibodies [217].  The inflammatory mediator TNF driving non-healing 
cutaneous wound is a case in point.  In addition to releasing soluble TNF, macrophages 
infiltrated into the wound tissues express transmembrane TNF [218].  Together with 
neutrophils and adipocytes, macrophages impose local inflammation via autocrine and 
paracrine actions of both forms of TNF.  To maximize effectiveness, topically delivered 
anti-TNF antibody must penetrate into tissues underneath the wound bed.  Macrophages 
and neutrophils transverse on and below the wound surface, trafficking through the 
dermis and draining lymph nodes, and cluster around adipocytes underneath.  Thus, 
design of topical formulations should aim at rendering sustained anti-cytokine antibodies 
releasing into local-regional tissues, yet without excessive drug partitioning into the 
blood circulation.    
The results presented herein demonstrate that the dL5 hydrogel system can 
accumulate IgG at the site of injection and in draining lymph nodes.  The study is a step 
towards modular engineering of local antibody delivery.  The binding of pAGMG to dL5 
serves two purposes, in rendering IgG binding sites, and generating fluorescence that can 
be detected in subcutaneous tissues.  We presented data demonstrating that the system 
delayed release of IgG.  In vitro, approximately 50% of IgGFITC were released in the last 
55 days of the two-month period with dL5 hydrogel embedded with pAGMG, without 
which near 90% of the antibody were released in the first five days (Figure 3-8). The 
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adaptor pAGMG mediated IgG loading (Figure 3-6) and was found to be a relatively 
immobile component in the system (Figure 3-8b).  In vivo, distribution of IgG was 
impeded by the dL5 hydrogel, restricting a large fraction of the dose at the injection site 
and in the immediate draining lymph node (Figure 3-11 and Figure 3-12).  The prototype 
delivered a limited dose over 24 hours, but such formulation may be suffice for local 
immune modulation [216].  The computational simulations suggest cooperative binding 
of IgG to pAGMG (Figure 3-10).           
The hydrogel is generated through coassembly for functionalized FP [210, 219-
222].  We have shown that the EAK16-II/EAKIIH6 composite prolongs in vivo retention 
of IgG in inflammatory tissues, in mammary tumors implanted in syngeneic mice [201], 
and in tissues underneath skin allografts [202].  By separating affinity binding and 
gelation, the former can be adjusted independently of the latter.  The ability to vary the 
density of dL5 through intermixing the polypeptides allows mutual optimization of bulk 
physical properties and IgG loading and release kinetics.  Because the pore size and 
tortuosity of the hydrogel matrix can be tuned by changing EAK16-II concentration, 
other agents, including small molecule drugs, or clusters of cells [223], may be 
encapsulated without impeding the ability to regulate IgG loading and release.  In the 
presence of excess EAK16-II, dL5_EAK incorporates efficiently into the network, 
without disrupting the integrity of the fibrils [200].  But excess dL5_EAK in vivo may 
self-aggregate (similar to EAKH6 [198]), creating ectopic clusters of pAGMG outside the 
hydrogel matrix, diverting IgG from the main depot.  This can be mitigated by 
formulating the molar fractions of the two polypeptides such that greater than 90% of 
dL5_EAK is incorporated (Figure 3-3).  Thus the ratio of the two polypeptides is an 
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important parameter in engineering functionalities within the EAK16-II fibrillar matrix 
[21].    
After incubation for two months in vitro, IgG released from dL5 gels retained 
58% of antigen-binding capacity (Figure 3-9).  The high water content of EAK16-II 
hydrogels should preserve protein native conformations [224], but the long incubation 
period in vitro (Figure 3-8) may have promoted denaturation of the IgG.  Through Fc 
binding to pAGMG, IgG in dL5 hydrogel are oriented [225-227] and patterned such that 
random adsorption and denaturation can be reduced.  This is supported by scanning 
electronic microscopic images of EAK16-II/EAKIIH6, which show what appear as 
individual islands of IgG/pAG complexes [201].  The templated antibodies are active 
against soluble [201] and cell-bound antigens [203].  Denaturation can be minimized by 
optimizing key parameters; the simulations (Figure 3-10) show cooperativity of IgG 
binding in the system driven by the hexavalent pAGMG on which two or more IgG may 
be captured.  Altering the density of pAGMG in the hydrogel, guided by MG fluorescence, 
could minimize the loss of protein activity.   
Potential systemic toxicities are mitigated by the fact that the gel is largely 
retained locally at the injection site.  Because pAGMG remained largely with the hydrogel, 
the amount released into the systemic lymphatic and blood circulation should be low.  
Phagocytes will likely opsonize the fluorogen-protein conjugate. We have evidences 
showing that EAK16-II appears non-inflammatory; neither EAK16-II nor pAGMG elicited 
IL-6 production from freshly isolated splenocytes cultured in vitro (data not shown).  As 
with other synthetic biomaterials, the hydrogel is likely be degraded by the foreign body 
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reaction (FBR) [228].  The process is triggered by adsorption of endogenous proteins, 
followed by adhesion of macrophages, which may fuse into foreign body giant cells 
(FBGC).  This pathway, which may take weeks to consummate, serves to sequestrate 
foreign substances.       
The system described herein is unique in that the bioaffinity module has a built-in 
imaging feature.  In dL5-pAGMG, the hydrogel can be imaged in superficial tissues.  
Compared to conventional fluorescent reporters, MG-dL5 has enhanced photo-stability.  
The FAP protects the fluorogen from oxidative damage as crystallographic studies show 
that a single MG molecule is flanked by two L5 domains [207].  This feature was 
exploited here to monitor the stability of the IgG binding sites, as pAGMG would escape 
from the gel matrix to become non-fluorescent.  Degradation of dL5, either through 
extracellular or intracellular means, would diminish the signal, as unbound MG has low 
intrinsic fluorescence.  The fluorescence generated by MG and dL5 interaction could 
serve as a surrogate for the extent of in vivo degradation, such as phagocytosis by 
macrophages [229].   
While the present study used dL5-MG as the fluorogenic module, other FAPs 
have been synthesized for additional fluorogens.  FAP-fluorogen pairs can be selected 
based on binding affinities and fluorescent spectra suited for specific applications.   
Fluorescence generated from dL5-MG can be detected optically in superficial tissues, but 
other FAP systems, such as far-red fluorogenic dyes currently being explored, may be 
used for internal imaging [230].  There are also promiscuous FAPs that can bind more 
than one fluorogen [231], with alternate excitation and emission wavelengths and varying 
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affinity constants for fluorogen binding.  There may be biological scenarios in which 
higher or lower binding affinities are called for, such as using a low affinity FAP-
fluorogen combination as a more rapid but controlled release mechanism, through 
disassociation of the pA/G-dye conjugate from the FAP itself.  Additionally, other dyes 
which generate higher quantum yields and signal such as cyanine-tagged MG [232] could 
be used to improve signal-to-noise ratio for hydrogel with low FAP incorporation 
efficiency.  These other FAPs can be genetically fused with FP domains such as 
AEAEAKAK as functional modules in excess EAK16-II, as demonstrated here. 
Conclusions 
We demonstrated herein that biochemical and imaging functionalizing of a βFP-
based injectable platform.  This depot platform can be used to deliver IgG locally of a 
variety of specificities.  The delayed release demonstrated in vitro may be translated into 
in vivo prototypes through iterative optimization, guided by in situ detection of MG-dL5 
fluorescence.  This design could be used to deliver antibodies for suppressing cutaneous 
inflammation and targeted immune modulation in draining lymph nodes.  
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Chapter 4  
A Facile Fc-binding Composite in Bioaffinity Hydrogel for Antibody 
Delivery 
The ability to congregate high concentrations of multiple antibodies in diseased 
tissues for prolong durations renders a method to engage diverse molecular targets in a 
sustained manner.  In this chapter we sought to determine the extent to which IgG 
molecules could be concentrated in subcutaneous tissues and allogeneic skin transplants 
while limiting systemic exposure using a facile Fc-binding composite.  This biomaterial 
design centers on the novel polypeptide pG_EAK, consisting of a truncated protein G 
fused with repeats of the amphiphilic sequence AEAEAKAK (“EAK”).  The direct 
attachment of Fc binding domain protein G to EAK reduced the number of noncovalent 
interactions involved in the bioaffinity hydrogel compared to the pAGMG-dL5 gel 
described in the previous chapter, rendering a design with a better translational prospect.  
Intermixing pG_EAK with molar excess of EAK generated fibrillar gels with multivalent 
Fc-binding sites.  Capture of IgG was verified in gels prepared from admixing pG_EAK 
and EAK16-II (pG gel).  Injection of a dye-conjugated IgG formulated with pG gel into 
skin allografts resulted in detectable fluorescence at the site in mice for at least six days, 
at which time only background signal was observed in grafts injected with the same 
antibody delivered in saline or non-Fc binding EAK gels.  The advantage coincided with 
weaker fluorescence in the liver, spleen and lymph nodes, relative to those in graft-
bearing mice injected with the antibody formulated in saline or non-Fc binding EAK gels.  
In conclusion, pG gel was shown to display IgG locally, thus a potential platform for 
modulating the cellular and molecular mechanisms in target tissues. 
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Background and rationale 
Described in the preceding chapter was a system in which IgG capture was made 
possible by two non-covalent interactions and one conjugation reaction.  The complexity 
of the design complicates the effort to optimize performance of such system.  To reduce 
the complexity and improve the translational prospect, a second generation bioaffinity 
hydrogel was constructed by incorporating the IgG capture domain directly in the EAK 
gel matrix, without the need for conjugating pA/G with MG [233].  This simplified 
system consists of only one interaction between IgG and Fc-binding domain, in this case 
a truncated Streptococcal protein G appended with EAK repeats, hereafter referred as 
“pG_EAK”.  Functionalized gels can be prepared by intermixing excess EAK with 
pG_EAK, thereby encasing the latter.  
Protein G (along with protein A) is widely used in lab-scale and commercial 
purification of antibodies.  Staphylococcal Protein A (SpA) has been developed into a 
systemic therapeutic agent (PRTX-100) approved for use in humans [234].  Native 
protein G variants are cell wall components isolated from Streptococcal strains (e.g. 
G148) [45].  The optimal binding of protein G spans over a broad pH range, from 4 to 9 
for human IgG [48].  Compared with SpA, protein G reacts with IgG from broader range 
of species, and in particular binds to all four subclasses of human IgG [47, 235].  The 
equilibrium binding and kinetic constants of protein G for IgG have been determined 
(Table 4-1), and the binding was found to be more stable than protein A-IgG [48].  Since 
the affinity interaction between protein G and IgG is not as pH and salt-dependent as it 
between protein A and IgG and protein G has a wider and stronger reactivity profile 
compared to protein A [236], protein G was selected to be directly attached to 
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amphiphilic self-assembling peptide EAK for the bioaffinity gel construction.  Through 
coassembly of the novel construct pG_EAK with excess parent polypeptide EAK16-II, 
protein G could be directly embedded in the hydrogel for IgG loading, thereby 
independently replacing dL5 bound pAGMG in the gel design described in the previous 
chapter. 
Table 4-1 Equilibrium constants comparison between protein G and protein A with IgG 
from various species  (Determined by Scatchard plots using immobilized IgG and 
radioiodinated protein G or protein A. Republished with permission from reference [48], 
permission conveyed through Copyright Clearance Center, Inc.) 
IgG Protein G Protein A 
 M-1 (X 10-9) 
Human 67.4 44.1 
Rabbit 69.8 52.3 
Goat 14.3 Not detected 
Mouse 41.5 25.7 
Rat 1.4 0.018 
Human IgG1 2.0 1.3 
Human IgG2 3.1 2.1 
Human IgG3 6.1 Not detected 
Human IgG4 4.7 3.4 
 
 
Native protein G contains multiple domains, including three homologous regions 
to the amino-terminus that have affinity for albumin [237, 238].  Toward the C-terminal 
end of protein G are three Fc-binding domains (C1, C2 and C3) followed by a cell 
membrane anchoring domain [47, 237].  In constructing the pG_EAK polypeptide, only 
the Fc-binding track of sequence (C1-D1-C2-D2-C3) was included, with three GS linkers 
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connecting to three repeats of AEAEAKAK at the C-terminal (Figure 4-1 (a)).  The 
rationale for the order is that the Fc-binding and amphiphilic domains are physically 
connected yet operate independently.  Removal of the albumin binding sites reduces the 
extent of cellular internalization via opsonization [239].  The pG_EAK polypeptide was 
expressed in E. Coli transformed with a plasmid encoding the amino acid sequence of the 
truncated pG domains, the GS linker, and the EAK tract, as well as GST and His-tag for 
purification.  Composites of pG_EAK and EAK were characterized in vitro and in vivo 
for stability and kinetics of association with IgG molecules.  As with the dL5 gel system, 
the purpose is to construct an antibody-delivery system for local or topical applications in 
models of inflammatory diseases.  The diagram for the proposed design is shown in 
Figure 4-1 (b). 
 
Figure 4-1 Diagrams showing (a): the construct of pG_EAK and (b) coassembled pG gel 
displaying IgG molecules. 
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Materials and Methods 
Peptides and reagents  
EAK16-II was custom synthesized by American Peptide Company (Sunnyvale, 
CA) at greater than 95% purity with the N-terminus acetylated and C-terminus amidated. 
The sequence was confirmed by mass spectrometry by the manufacturer.  The peptide, 
received lyophilized, was reconstituted in sterile deionized water (18.2 M at 25°C) as 
needed and stored at -80°C until use. 
Expression and purification of pG_EAK 
Expression and purification of pG_EAK was performed after transforming 
plasmid (pET21) engineered with the nucleotide sequences encoding both protein G and 
EAK, together with 10X His GST HRV cleavage site into BL21(DE3) competent 
Escherichia Coli (Invitrogen One Shot®).  The diagram showing the complete procedure 
is depicted in Figure 4-2.  Full protein sequence of pG_EAK after HRV protease 
cleavage is as follows: 
GPSKLTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDAT
KTFTVTEKPEVIDASELTPAVTTYKLVINGKTLKGETTTEAVDAATAEKVFKQYA
NDNGVDGEWTYDDATKTFTVTEKPEVIDASELTPAVTTYKLVINGKTLKGETTT
KAVDAETAEKAFKQYANDNGVDGVWTYDDATKTFTVTEGGRGGGGSGGGGS
GGGGSAEAEAKAKAEAEAKAKAEAEAKAK.  
Specifically, the starter culture of transformed bacteria was grown in 5 ml of LB 
media with 100 μg/ml ampicillin, then transferred to 500 mL of LB+ media (LB media 
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with 100 mM phosphate, 20 mM succinic acid and 0.4% gylcerol) and grown until its 
optical density at 600 nm reached 0.6.  The temperature was then changed to 20°C and 
the culture was grown for another 1h before adding 500 μM IPTG and 0.4% glucose 
(final concentration) to start induction for expression of pG_EAK.  After overnight 
culture at 20°C, cells were pelleted at 4°C, 6000 rcf for 20 min, resuspended in 30 ml of 
buffer (50 mM Tris HCl, 750 mM NaCl, 50 mM imidazole, 0.1% TritonX-100 and 
0.025% Tween 20) and frozen at -20ºC for at least 4 hours.  Thawed cell pellet was lysed 
by sonicating on ice for 15 min (level 3, 10s on, 5s off).  Lysate was clarified by 
centrifugation at 13000 rpm, 4°C for 30 min.  Lysate was then added to 0.6 ml of Ni-
NTA agarose (washed with 1X Ni-NTA bind buffer: 300 mM NaCl, 50 mM NaH2PO4, 
10 mM imidazole, pH 8.0) and incubated on shaker in cold room for 2 hours.  Bound 
agarose was washed with 21 mL of 1X Ni-NTA wash buffer (300 mM NaCl, 50 mM 
NaH2PO4, 20 mM imidazole, pH 8.0) and 14 ml of 1X HRV 3C cleavage buffer (150 
mM NaCl, 50 mM Tris-HCl, pH7.5).  The column was capped on bottom after which 120 
µL of 2U/µL HRV 3C protease and 1.2 ml of 1X HRV 3C cleavage buffer were added to 
the Ni-NTA agarose.  The column was capped on top as well and incubated overnight on 
shaker in cold room.  Eluted proteins were collected the following day by adding 50 µL 
of Ni-NTA agarose to bind potential excess HRV 3C protease, followed by incubation in 
cold room for another 2 hours.  Column was then uncapped and eluent was collected.  
Additional 0.8 ml of 1X HRV 3C protease cleavage buffer was passed over the column 
twice to collect any additional digested protein.  Purified pG_EAK was quantified by 280 
nm absorption measurements. 
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Figure 4-2 Diagram showing the procedure flow for pG_EAK plasmid construction, 
transformation, expression and purification. 
 
MALDI-TOF mass spectrometry 
Purified pG_EAK obtained from above procedure was diluted 10 times with a final 
concentration of 5.46 µM.  Combine 40 ul of this diluted solution with 10 µL of 0.5% 
TFA in MilliQ-water and apply the protein directly to target of Applied Biosystems 
Voyager DE-STR MALDI-TOF mass spectrometer. 
Coassembly experiments 
Coassembly of pG_EAK into EAK16-II fibrils was studied using gel 
electrophoretic (SDS-PAGE), Congo red binding, and viscosity measurement which were 
described separately below. 
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Gel electrophoresis 
Different amounts of EAK16-II (10 µL, 20 µL, 40 µL or 80 µL, at 5 mg/ml) were 
added to 7.34 ul of pG_EAK (82.2 μM) to prepare mixtures of EAK16-II and pG_EAK at 
different molar ratios (50:1, 100:1, 200:1 and 400:1) of the two components.  Each 
mixture was q.s to a total volume of 500 µL and incubated overnight at 37°C.  The 
samples were centrifuged at 16000 rfc for 6 min with 5 µL of the supernatant analyzed 
using denaturing Novex SDS-PAGE gel electrophoresis (NuPAGE 4-12% Bis-Tris 
Electrophoresis system).  For sample preparation, 5 µL of the supernatant was mixed 
with 5 µL of NuPAGE sample buffer and 10 µL of PBS.  The mixtures were heated at 
70°C for 10 min before loading while 5 µL of the molecule maker was mixed with 10 µL 
of sample buffer and 25 µL of PBS without heating before loading.  All samples were run 
at 200 V for 35 min in NuPAGE MES SDS running buffer.  Fast silver staining 
procedure (SilverQuestTM staining kit) was used to visualize the protein bands.  Gel 
images was captured using Kodak 440 image station and band intensities were quantified 
by Image J software.  Percentage of pG_EAK incorporated into EAK coassemblies was 
calculated by subtracting the intensity of the protein band in samples containing EAK16-
II from the control sample with only pG_EAK in solution. 
Congo red binding 
The stock solution of 0.005% Congo red was prepared by diluting 30 µL of 0.1% 
of its aqueous solution using 570 µL of PBS.  The absorbance spectra of Congo red were 
scanned from 400 nm to 700nm with Tecan Infinite M1000 microplate reader after 
adding 40 µL of the stock solution to each of the samples either containing 20 µL of 
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EAK alone at the concentration of 5 mg/ml, 20.8 µL of pG_EAK alone at the 
concentration of 7.2 μM or the mixture of the two components.  For the sample 
containing only one component before adding Congo red, either water was added to 
substitute EAK or PBS was added to substitute pG_EAK.  The molar ratio of EAK and 
pG_EAK was at 400:1. Incubation was performed for 1 hour after adding Congo red and 
before the absorbance scan.  The absorption peak of each sample was registered for 
comparison as an indication for fibril formation confirmation. 
Viscosity measurement 
Stock solutions of EAK and pG_EAK were prepared at 10 mg/ml in water and 
9.26 μM in PBS respectively.  Samples of EAK with or without pG_EAK were prepared 
in PBS and drew into positive displacement pipettes (RheoSense Inc., San Ramon, CA). 
The ratio of EAK to pG_EAK was prepared at 400:1 and the final concentrations were 
1.5 mg/ml and 2.3 μM, respectively.  Measurements were conducted using the μVISC 
unit (RheoSense Inc) equipped with a temperature control module, which was set at 
25°C.  Samples were subjected to different shear rates (1200-4000 s-1) by changing the 
flow rate through the capillaries (depth = 50 μm) in the sensor cartridge (HA01-01).  
Controls including pG_EAK alone and distilled water alone were measured at the same 
conditions. 
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IgG binding experiments 
Surface plasmon resonance  
Biacore T200 was used to conduct experiments with a CM5 chip at 25°C.  pG 
(25.3 kDa, 0.92 mg/mL stock concentration) were used as ligand to immobilize onto the 
CM5 sensor surface.  Ab-1 (mouse monoclonal IgG, 150 kDa, 3.3 µM stock 
concentration), Ab-2 (goat monoclonal IgG, 150 kDa, 6.7 µM stock concentration), and 
Ab-3 (rabbit IgG monoclonal, 150 kDa, 3.3 µM stock concentration) were used as 
analytes to flow over the ligand immobilized surface.  Flow Cell (FC) 1 was used as 
reference for FC2, and FC3 for FC4.  pH scouting of ligand was done and pH 4.0 was 
selected for pG as the immobilization pH value.  pG was diluted (1:500 dilution, 1.84 
µg/mL diluted concentration) in 10 mM sodium acetate buffer at pH 4.0 and immobilized 
onto FC4 to a level of ~300 RU, using standard amine coupling chemistry.  PBS-P (20 
mM phosphate buffer pH 7.4, 2.7 mM KCl, 137 mM NaCl, 0.05 % (v/v) surfactant P20) 
was used as the immobilization running buffer.  Based on the captured ligand response 
values, theoretical Rmax values were calculated.  The Rmax values assumed 1:1 
interaction mechanism.  Overnight kinetics were performed for all analytes binding to the 
ligands.  The kinetics experiments were performed in the presence of PBS-P.  The flow 
rate of all analyte solutions was maintained at 50 µL/min.  Association and dissociation 
times used for all analytes were 60 s and 600 s, respectively.  One 20s pulse of Glycine 
pH 1.5 was used to regenerate the sensor surface.  Injected compound concentrations 
were 0 µM, 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, and 100 nM.  Sensorgrams 
from the overnight kinetics were evaluated using 1:1 steady state affinity or 1:1 kinetics 
model fitting. 
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Loading of IgGFITC on pG hydrogel 
The binding of IgG to pG bioaffinity hydrogel was measured by determining the 
loading of IgG on the hydrogel.  Fluorescein (FITC) labeled IgG (Invitrogen) was used as 
the model IgG to provide the readout in the form of FITC fluorescence.  11.25 μg (75 
pmol) of IgGFITC was added to gel formed with 20 µL of 5 mg/ml EAK (60 nmol) and 
24.5 µL of 6.16 μM pG_EAK (150 pmol) (molar ratio of EAK : pG_EAK =  400 : 1).  
After incubated for 15 min, the sample was brought up to 100 µL with PBS.  The IgGFITC 
loaded hydrogel was collected by centrifugation and washed with 1ml of fresh PBS five 
times before re-suspended and transferred to black 96 well plate for FITC fluorescence 
measurement.  Control samples including IgGFITC loaded in hydrogel made of only EAK, 
IgGFITC mixed with only pG_EAK, or only IgGFITC were also prepared by replacing EAK 
with water and pG_EAK with PBS when either one is missing. 
Paper chromatography 
The binding of IgG to pG gel was examined using a thin layer chromatography 
based on the trapping of IgG on the path way of its migration driven by capillary action 
on a chromatography paper (WhatmanTM GE healthcare) and concentration gradient. 
Rabbit IgG800s (NOVUS biologicals, 1 mg/ml) were spotted horizontally (numbered 1-3 
from left to the right) near the bottom of the paper (leaving about 3 cm to the edge of the 
bottom) with different samples including PBS, EAK (5 µL of 5 mg/ml), or EAK and 
pG_EAK (5 µL of 5.46 μM) mixture spotted above the IgG spotting positions 
corresponding to each IgG spot vertically.  After the drying of the spots, the bottom of the 
chromatography paper was immersed in a reagent reservoir filled with PBS.  Allow the 
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liquid to migrate upward through capillary action and take the paper out of the PBS when 
the water front move up to the top of the paper.  Let the paper dry completely before 
imaging the migration of IgG800 in the path of convective flow using an Odyssey imager 
(Li-Cor, Inc., Lincoln, Nebraska) set at low intensity (L2.0) and focus offset of 3.2mm. 
Multi-IgGs loading on pG hydrogel 
The loading of three different IgGs on the pG hydrogel was verified by detecting 
the fluorescence spectra from three different dyes labeled to each of these three IgGs 
respectively.  Specifically, equal molar amount (25 pmol) of PerCP-Cy5.5 labeled rat 
anti-mouse CD4 IgG (BD Pharmingen), PE labeled rat anti-mouse IgG (BD pharmingen) 
and FITC labeled mouse IgG (Southern Biotech) were added to EAK and pG_EAK 
coassemblies (20 µL of 5 mg/ml EAK mixed with 24.5 µL of 6.16 μM pG_EAK) and 
EAK without pG_EAK as the control.  After one hour of incubation for the binding to 
reach equilibrium, the samples were washed five times with 1ml of fresh PBS and 
transferred to black 96 well plate to get the emission spectra from (495 nm to 800 nm) 
under the excitation of 488 nm.  The combination of the three IgG solutions was also 
included as the positive control to show the desirable peak locations as reference. 
FITC-IgG self-quenching after loaded to pG hydrogel   
The distribution of loaded IgG in pG hydrogel could be speculated by studying 
the quenching effect of FITC dye labeled on the loaded IgG.  Specifically, 22.5 µL of 0.5 
mg/ml mouse FITC-IgG (Southern Biotech) was added to the pG_EAK and EAK 
coassemblies (20 µL of 5 mg/ml EAK mixed with 24.5 µL of 6.16 μM pG_EAK) 
established at the bottom of black 96-well plate.  The fluorescence from FITC-IgG was 
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scanned from 500nm-800nm after excitation at 494 nm and compared to the fluorescence 
spectra from the same amount of FITC-IgG in aqueous solution or loaded in EAK gel.  
The single point measurement at its emission peak (520 nm) was also scanned separately 
for better comparison. 
In vitro IgG release 
The release kinetics of a fluorescein-labeled IgG (Pierce goat anti-human IgG) 
from pG bioaffinity hydrogel were determined by monitoring the cumulative 
fluorescence in release medium over 3 months.  IgG-loaded hydrogels were established at 
the bottom of MicroSert (inner diameter = 4.15 mm, maximum volume = 500 µL) by 
instilling a mixture of EAK (60 nmol), pG_EAK (150 pmol) and IgGFITC (75 pmol).  The 
55 µL mixture was incubated overnight at 37°C before adding 400 µL of PBS containing 
0.1% BSA, 0.024% NaN3 as the release medium.  The insert was placed in its receptacle 
vial and capped to prevent the medium evaporation.  The vial was put under 37°C for 
incubation.  At various time points, 200 µL of the release medium were collected for 
measurement using plate reader (Perkin Elmer 1420 Multilabel Counter VICTORTM, 
excitation = 485 nm; emission = 535 nm).  Aliquots of fresh release medium were added 
to restore the system to its initial volume. 
Mice and in vivo studies 
Six to eight week old female BALB/c or C57BL/6 mice were purchased from 
Hilltop Lab Animals (Scottdale, PA) and housed in the Duquesne University Animal 
Care Facility certified by the USDA. Animals were handled in accordance with protocols 
approved by Institutional Animal Care and Use Committee.  
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Retention after foot pad injection (preliminary test, no replicates) 
The injection mixture containing 60 nmol (in 20 µL) of EAK together with 150 
pmol of pG_EAK and 75 pmol of Dylight 800 4X PEG conjugated goat anti-rabbit IgG 
(Thermo Scientific) was drawn into 25G’ needled syringe and injected subcutaneously 
into one foot pad of the mouse while free IgG800 control was injected into the other foot 
pad of the same mouse when the mouse was anesthetized with isoflurane (induction 5%; 
maintenance 3%).  The mouse was sacrificed 2 days after the injection and foot pads 
were excised and imaged using an Odyssey imager (Li-Cor, Inc., Lincoln, Nebraska).  
The image captured from Odyssey was set at low intensity (L2.0) and focus offset of 
3.2mm.  This preliminary test was conducted to get a sense of the performance of pG gel 
in retaining IgG in foot pad (as tested in dL5 gel) before moving forward to the 
investigation of its performance in other subcutaneous location or inflammatory 
conditions. 
Stability after back injection 
Inject onto the back of C57BL/6 mice IgG800 (45 μg in 1 mg/mL goat anti-rabbit 
Dylight 800 4X PEG conjugate) or IgG800 displayed by pG hydrogel (80 µL of 10 mg/mL 
EAK and 82.4 µL of 14.556 μM pG_EAK) (4 replicates each).  The NIR signal at 800nm 
on the back was monitored at the local injection site using Li-Cor Pearl live imager 
before and over 2 days period after the injection.  At the end of day 2, all the mice were 
sacrificed for liver, spleen and lymph nodes scan using Odyssey imager at low intensity 
(L2.0) and the same focus offset (3.2mm). 
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Stability after undergraft injection 
To demonstrate the stability of the bioaffinity hydrogel under inflammatory 
conditions, we used a murine allogeneic skin transplantation model (donor: BALB/c; 
recipient: C57BL/6) and tracked its undergraft stability over 6 days after injection.  The 
procedure has been approved by the University IACUC.  Six- to eight-week old mice was 
purchased as certified pathogen-free from Hilltop Lab Animals (Scottdale, PA).  Mice 
were quarantined for at least five days prior to use in experiments.  Mice between the 
ages of 8-12 weeks were randomized into three groups in the transplant experiments.  
The procedure entailed harvesting skin grafts by euthanizing donor mice, making incision 
at the base of the ear and splitting the dorsal side from the base.  The dorsal layer was 
rinsed with sterile saline prior to the transplantation to serve as the donor.  Then a 0.5 cm 
incision was made in the left flank of a C57BL/6 mouse for placement of donor skin.  
Excess donor skin was trimmed so that transplant lies flatly within graft bed.  The 
recipient mouse was wrapped in sterile bandage and secured using a 7mm stainless steel 
wound clip (Reflex 7).  Recipient mice were recovered under heat lamp while waking up 
from anesthesia before placement in a clean cage.  Optical imaging of the mice was 
scanned using a Pearl Impulse (Li-Cor) small animal imaging system.  Pre-injection 
images were taken by placing the animals in the instrument chamber.  Post injection 
images were taken at specified time intervals.  To image in the near infrared range, the 
mice were kept under anesthesia and exposed to a 700 nm laser, followed by an 800 nm 
laser, and then a white light image was taken.  Grafting of BALB/c skins onto C57BL/6 
mice is a well-characterized model in studying acute rejection of allografts.  The full-
MHC (class I and II) mismatch renders consistent rejection in >90% of cases.       
 129 
In this in vivo undergraft stability test, IgG800 (11.24 μg in 1 mg/mL goat anti-
rabbit Dylight 800 4X PEG conjugate), IgG800 displayed by EAK hydrogel (20 µL of 10 
mg/mL EAK) or IgG800 displayed by pG hydrogel (20 µL of 10 mg/mL EAK and 5.5 µL 
of 54.577 μM pG_EAK) was injected subcutaneously underneath the skin graft (3 
replicates each) two days after the transplantation surgery.  Signals retained under the 
skin graft was recorded in real time using a Li-cor Pearl Impulse Imager before, right 
after and 2, 4, 6 days after the injection for each mouse.  NIR fluorescence intensity at 
different time points was quantified using Li-Cor Pearl imager software. 
Dual delivery of Fc-CTLA-4 and Fc-TGF-β1 in skin transplantation 
Skin transplantation surgery was performed in the same way as described in the 
previous undergraft stability test.  33 μg of TGF-β1 Fc (Chimerigen laboratories, 1 
mg/ml) and 33 μg of CTLA-4 (CD152) Fc non-lytic recombinant protein (ProSci, 1 
mg/ml) displayed by pG gel (20 µL of 10 mg/ml of EAK mixed with 4.34 µL of 69.2 μM 
of pG_EAK) or only the pG gel were injected underneath the skin graft two days after the 
surgery.  The same injection was repeated 3 days after the first injection.  Four days after 
the second injection, the mice were euthanized to collect the spleen.  The splenocytes 
were processed for in vitro re-stimulation with allogeneic antigen presenting cells from 
BALB/c spleen and cultured for 3 days before flow cytometry analysis for Treg cell using 
mouse regulatory T cell staining kit (eBioscience). 
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Results 
Confirmation of pG_EAK molecular mass 
pG_EAK recovered from nickel resins were further purified using endotoxin 
removal spin column (Pierce®, Thermo Scientific, 0.5ml).  The final eluent was analyzed 
using denaturing SDS-PAGE and mass spectrometry.  Electrophoretic image indicated a 
single band near the 35 kDa mark, and MALDI-TOF showed a singly-charged species 
with Mr of 25.3 kDa (Figure 4-3), consistent with the theoretical Mr of pG_EAK 
(predicted using ExPASy Bioinformatics Resource Portal).  In conjunction with 
functional studies that will be shown later in this chapter, it was concluded that the 
predicted protein pG_EAK was expressed and purified. 
 
Figure 4-3 MALDI-TOF mass spectroscopy of pG_EAK protein. 
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Co-assembly 
Gel electrophoresis was used to determine the fraction of pG_EAK incorporated 
into excess EAK.  The unincorporated portion of pG_EAK retained in the sup was 
reflected in the pG_EAK band on the SDS-PAGE gel after intermixing EAK16-II with 
pG_EAK at different ratios (Figure 4-4).  The ratio of 400:1 for EAK and pG_EAK 
resulted in 92% of the latter being incorporated into the final composite.  Therefore, 
except where stated otherwise, the experiments described in this chapter were conducted 
using gels admixed at the 400:1 molar ratio.   
The absorbance spectra for different components mixed with Congo red, the dye 
found to have a shift in its absorbance peak after binding to fibrils formed by β-sheet 
structure, were obtained.  After Congo red was added to samples containing pG_EAK 
alone, the samples exhibit the same absorbance peak as free Congo red at 486nm, 
indicating that pG_EAK does not self-assemble to form fibril itself.  In contrast, both 
Congo red added to EAK or the mixture of EAK and pG_EAK at ratio of 400:1 exhibit a 
red shift in absorbance peak, at 510nm and 506 nm respectively, indicating the fibril 
formation in those two samples. 
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Figure 4-4 Coassembly between EAK16-II with pG_EAK (a) SDS-PAGE analysis of 
incorporation of pG_EAK into EAK16-II fibrils. The protein bands in image represent 
the unincorporated, soluble fraction in the mixture of EAK : pG_EAK coassemblies at 
different ratios of the two. (b) Congo red absorbance spectra after added to different 
samples containing EAK, pG_EAK alone or the mixture of these two components at the 
ratio of 400:1 
 
Injectable composite 
The viscosity of the composite materials was determined using a microfluidic-
based measurement where the sample is injected at a constant flow rate through the flow 
channel, a rectangular slit constructed of borosilicate glass, of a measuring cell or chip.  
Samples of EAK, EAK intermixed with pG_EAK and pG_EAK alone were analyzed 
using a VISC module where multiple pressure sensors were mounted within the base to 
monitor the pressure drop from the inlet to the outlet of the channel.  The viscosity was 
calculated based on the shear rate and shear stress at the boundary wall which are 
correlated with the pressure drop, geometry of the rectangular slit and the flow rate. 
Solution dissolved with only pG_EAK exhibited baseline viscosity, at near that of 
water (1 mPa·s), confirming our previous observation that pG_EAK do not self-assemble 
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at the concentrations tested.  At shear rate of 4,000 s-1, the viscosity values of EAK and 
EAK mixed with pG_EAK registered 2.3 0.56 mPa·s and 2.5 0.24 mPa·s, respectively, 
indicating that the materials lack shear resistance and can be injected using conventional 
needled syringes.  At the low shear rate of 1200 s-1, EAK mixed with pG_EAK deviated 
from EAK, at 2.9  0.87 mPa·s and 4.4  0.32 mPa·s, respectively.  Yet pG gel holds 
sufficient mechanical strength to be suspended and adsorbed to a silica vessel and 
remained suspended for at least 24 h (Figure 4-5b). 
 
Figure 4-5 Viscosity profile of pG gel and its physical appearance visualized by Congo 
red (a) Viscosity of EAK16-II mixed with pG_EAK (400:1) at different shear rates 
compared with pG_EAK, EAK or deionized water alone. (b) pG gel stained with Congo 
red at the bottom of silica vessel inverted for 24 hours. 
 
Capture of IgG in pG gels in vitro 
The affinity and kinetic constants of IgG for pG_EAK were measured using 
surface plasmon resonance (Table 4-2).  Sonograms indicate that the fusion polypeptide 
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bound to IgG at high affinity.  The association (kon = 9.435 x 10
5 M-1s-1) and dissociation 
(koff = 21.81 x 10
-3 s-1) constants were also found in the same magnitudes of documented 
for the native proteins.  The apparent binding constant (Ka) for mouse IgG has been 
reported as strong (1.13 x 108 M-1), with association rate kon = 3.29 x 10
4 M-1s-1 and 
dissociation rate koff  = 2.90 x 10
-4 s-1 [49].  The Kd (8.8 nM) is close to the Kd tested in 
our measurement for mouse IgG (23.1 nM).  The differential affinities across the species 
documented in the literature were reproduced in that pG_EAK exhibited strong affinities 
for goat and rabbit IgG, but relatively weak for mouse IgG1.  These results show that 
pG_EAK associated and dissociated with IgG through specific interactions.  
Table 4-2 Binding and kinetic constants of pG_EAK 
 Kd (nM) kon (1/Ms) koff(1/s) 
Goat IgG polyclonal 0.005 3.658 * 105 2.0 * 10-6 
Rabbit IgG polyclonal 0.1 3.225 * 105 3.817 * 10-5 
Human IgG polyclonal 4.1 1.273 * 105 5.265* 10-4 
Mouse monoclonal IgG1  23.1 9.435 * 105 2.181 * 10-2 
     
To investigate the extent to which pG_EAK gel could display solvent-accessible 
Fc-binding sites, an in vitro pull-down assay was used to test capture of IgG molecules.  
A 3-fold higher fluorescent intensity was observed in samples in which IgGFITC was 
mixed with pG_EAK and EAK compared with EAK alone (Figure 4-6b).  Mixing the 
antibody with pG_EAK resulted in low amounts of fluorescent aggregates collected by 
centrifugation, consistent with the Congo red and viscosity measurements showing that 
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the lack of fibrillization of the polypeptide itself.  In addition, association of IgG and pG 
gel was examined in paper chromatograph under non-equilibrium conditions (Figure 
4-6c).  IgG800 accumulated at the pG_EAK/EAK spot in the pathway driven by capillary 
action verified the specific association between IgG and protein G.   
 
Figure 4-6 Capture of IgG in pG gels in vitro (a) Schematic depiction of the affinity 
hydrogel for retention of IgG and assay procedure. (b) Loading of FITC-labeled antibody 
on pG bioaffinity hydrogel compared with that on incomplete systems. (c) paper 
chromatography showing IgG800 migration driven by capillary action in paper 
chromatography with pG_EAK spot in path of convective flow 
 
As expected, pG_EAK gel can be used to capture three different antibodies in the 
same mixture simultaneously (Figure 4-7).  The crystal structures of protein G indicate a 
single α-helix stabilized by four β-strands.  One of the β-strands in protein G appears to 
interact with the β-strand in CH1 of IgG.  It may be deduced that in pG_EAK a trivalent 
(C1, C2 and C3) Fc-binding module displaying independent helix-β-strand structures.  
The data indicate that at least one of the C1, C2 and C3 segments was solvent accessible 
in the pG_EAK fibrillar gel network.   
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Figure 4-7 Emission scan of three different dye labeled (FITC, PE and PerCP-Cy5.5) 
IgGs on the pG hydrogel. 
 
A self-quenching phenomenon was observed for FITC-IgG loaded on pG gel 
(Figure 4-8).  Fluorescence quenching is the phenomenon where the quantum yield of a 
fluorophore is decreased, which is induced by the molecular interaction with quencher 
molecules.  Self-quenching takes place when the quencher molecule is the same 
fluorophore.  When the fluorophore molecules are in close proximity to each other, the 
manifested fluorescence intensity would be decreased due to self-quenching.  The 
observation of lower fluorescence intensity in sample where FITC-IgG was loaded to pG 
gel compared to the other two samples where the same amount of FITC-IgG was added 
to either aqueous solution or EAK gel, indicates that FITC-IgGs were highly 
concentrated by the IgG binding domain pG embedded in the gel matrix, causing the self-
quenching effect of the dye molecules labeled to IgG.  In contrast, free FITC-IgG 
exhibited the highest fluorescence intensity while the fluorescence of FITC-IgG loaded to 
non-specific EAK gel lies in between free FITC-IgG and FITC-IgG loaded in pG gel. 
The specific binding between FITC-IgG and pG was thereby verified. 
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Figure 4-8  Self quenching phenomenon of FITC-IgG loaded on pG gel (a) Emission 
fluorescence scan for FITC-IgG established in black 96-well plate together with pG 
hydrogel and compared that with free FITC-IgG or FITC-IgG nonspecifically trapped in 
EAK gel. (b) Emission fluorescence intensity of FITC-IgG at its maximum emission 
wavelength under the same setup as (a). 
 
In vitro IgG release 
To understand the microscopic properties of the bioaffinity interaction, release of 
antibodies from pG_EAK gel were monitored in vitro over a three-month period (Figure 
4-9).  The experiment was initiated by mixing IgGFITC with pG_EAK and EAK in a 
cylindrical vessel with defined dimensions.  In control experiments in which gels were 
made with only EAK, 85.2% ± 2.3% of the antibody loaded were released in the first 5 
days (Figure 4-9a).  In contrast, a slow rate of release was observed with pG gel; by day 
5, 2.7% ± 0.5% were released.  It was calculated that 82.7% of the IgG remained at the 
end of the 12-week period.  These data show that the pG_EAK module can be used to 
delay the release of antibodies from EAK gels.      
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Figure 4-9 In vitro release of IgG from the gel.  (a) Cumulative release of IgGFITC from 
pG gels (n = 3) or EAK gels (n = 3).  Each time point represents measurement from 
triplicate samples in gels setup in parallel. (b) initial release phase fitting to 1D unsteady 
state form of Fick’s second law of diffusion: 
𝑀𝑡
𝑀∞
=(
16 𝐷𝑎𝑝𝑝. 𝑡
𝜋 𝐻2
)
0.5
 by plotting fractional 
release vesus 𝑡0.5 for small values of t. 
 
The apparent diffusivity (Dapp) of IgG in pG gel was estimated by fitting the 
initial release to the non-steady state Fickian equation, relating Mt/M∞ as a function of 
t0.5.  Dapp of IgG in pG gel was determined to be 5.6 x 10
-15 m2 s-1, three orders of 
magnitude lower than Dapp of IgG embedded in the EAK gel (Table 4-3).  The analysis 
shows that incorporating pG_EAK served to retain a large fraction of the IgG loaded in 
the EAK matrix.  
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Table 4-3 Calculated apparent diffusion coefficients for both IgG displayed by EAK gel 
and pG gel and the IgG remaining in the gel at the end of release study. 
 Dapp (10-10 m2s-1) R2 IgG remained in gel (%) 
Control 0.0563 0.83 2.4 
System 0.0000564 0.77 82.7 
 
 
Mice and in vivo studies 
pG_EAK gel extends IgG localization in vivo  
The in vivo fate of antibodies co-injected with pG_EAK gel components into the 
subcutaneous space on the back was tracked in C57BL/6 mice real-time (Figure 4-10a).  
Superior local fluorescence was observed in mice injected with IgG800 mixed with 
endotoxin removed pG_EAK and EAK (test), compared to mice injected with the 
antibody in saline (9-fold on day one and 12-fold on day two) (Figure 4-10b).  Systemic 
distribution of the antibody was analyzed on day 2, based on fluorescent intensities in the 
liver, spleen and lymph nodes recovered from euthanized mice and measured ex vivo.  
IgG800 delivered in saline appeared in the liver, spleen, and brachial, inguinal and sciatic 
lymph nodes, while the same antibody injected in pG gel was restricted to the immediate 
draining branchial lymph nodes (Figure 4-10c).  pG_EAK also conferred superior IgG 
retention where the components were injected into mouse footpads (Figure 4-10d), which 
is consistent with the effects observed in the torso.  In addition, no immediate 
inflammatory reactions were observed in mice injected with pG_EAK, and low levels of 
IL-6 were detected incubating the peptide with freshly isolated mouse splenocytes in 
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vitro (Figure 4-11).  These results indicate pG gel impeded the draining and distribution 
of IgG deposited at the injection site.   
 
Figure 4-10 IgG retention in subcutaneous space after injection into the back of the mice. 
(a) Real time images of C57BL/6 mice injected with free IgG800 (control) and IgG800 
displayed by pG bioaffinity hydrogel (system) (n=4). (b) Quantification of the remaining 
NIR signal on the back of the mice over 2 days. (c) NIR signal distribution in liver, 
spleen and lymph nodes (axillary, inguinal and sciatic) at the end of day 2. (d) Image of 
mouse foot pads 2 days after injection with control (free IgG800) and test (IgG800 
displayed by pG hydrogel) hydrogel. 
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Figure 4-11 Interleukin 6 production. “EAK” represents cells added with EAK16-II (100 
µg/ml) alone.  Different concentrations (200 ng/ml, 2 µg/ml and 20 µg/ml) of endotoxin 
(LPS) were used as positive controls.  Splenocytes were harvested from a naïve C57BL/6 
mouse and cultured (106 cells/ml) for 24 h at 37°C in complete RPMI medium 
supplemented with 10% fetal bovine serum, and the substances indicated.  The BD 
Mouse IL-6 ELISA set was used to determine the concentration. 
 
Having established that the self-assembly and bioaffinity interactions took place 
in vivo in normal subcutaneous tissues, the capacity of pG_EAK gel to concentrate IgG 
in skin allografts was examined.  IgG co-injected into skin allografts with pG gel were 
retained locally in mice for at least 6 days (Figure 4-12), concentrating in the center of 
the wound bed.  This resulted in an average 2-fold higher exposure in terms of AUC 
compared to IgG delivered in saline control, with 229.1 v.s. 131.6, respectively. The 
higher graft retention coincided with reduced distribution to liver, lymph nodes, and 
spleen (Figure 4-12c).  Thus, the pG gel platform can be deployed in vivo for displaying 
antibodies in inflammatory tissues. 
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Figure 4-12 Retention of subcutaneously injected IgG800 under inflammatory condition 
(skin transplantation). (a) Real time images of C57BL/6 mice injected underneath the 
skin graft with free IgG800 (control 1), IgG in EAK gel (control 2) and IgG800 displayed 
by pG bioaffinity hydrogel (system) (n = 3). (b) Quantification of the remaining NIR 
signal under the skin graft of the mice over 6 days. (c) NIR signal distribution in liver, 
spleen and lymph nodes (brachial, axillary and inguinal) at the end of day 6. 
 
Dual delivery of Fc-CTLA-4 and Fc-TGF-β1 in skin transplantation 
It has been shown that TGF-β1 and CTLA-4 mutually support 
immunosuppression.  The capacities of Tregs to regulate naïve CD4+ T cells and DCs are 
primarily attributed to TGF-β1 and CTLA-4 [240].  These factors are best function in 
concert, and tolerance is acquired only if Tregs accumulate in skin allografts [241].  TGF-
β1, signature cytokine secreted by Tregs, convert naïve T cells to iTregs (induced Treg) 
by inducing Foxp3 [242].  In combination with IL-10, TGF-β1 facilitate the generation of 
tolerogenic DCs (tDCs) [243].  Host tDCs in turn secret IL-10, thereby driving cycles of 
suppressive milieu, promoting tolerance in direct and indirect recognition of alloantigens 
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[244].  Tregs constitutively express on the surface CTLA-4, which competes with CD28 
for B7 (CD80/CD86) molecules on DCs [245].  CTLA-4 ligation of B7 downregulates 
the costimulatory molecules, and suppresses production of IL-, TNFα and IL-6 in DCs 
[246].  Mice lacking the CTLA-4 gene display phenotypes that resemble Foxp3-deficient 
mice [247, 248].  We therefore postulate that sustained supply of CTLA-4 and TGF-β1 in 
grafts will raise the thresholds of Th1 activation, disrupt Th17 differentiation, increase 
Tregs, and generate tDCs [243, 244].            
Here we seek to recapitulate Treg functions in a cell-free system by concentrating 
Fc-tagged TGF-b and CTLA-4 in skin allografts shortly after transplantation during 
which T cells and DCs are polarized [243, 244].  Non-lytic, mouse Fc fusion proteins of 
TGF- (TGF-1/Fc, Mr=190 kDa), and CTLA-4 (CTLA-4/Fc, Mr=220) have been 
validated functionally in mice [249-254] and are available at high purity with endotoxin 
below 0.06 EU/µg (Chimerigen Laboratories, San Diego, CA).  While infusing all factors 
into patients would lead to detrimental immunosuppression, simply injecting Fc-proteins 
into skin grafts will not result in retention, as we have shown [202].  The targeted, 
localized approach proposed will increase the bioavailability of these factors at the 
transplant site, thereby sparing patients from systemic toxicities.  The clustered factors in 
protein G gel is expected to engage signaling pathways more efficiently by cross-linking 
cell surface receptors [255].  In this preliminary in vivo study for the demonstration of pG 
gel application, Fc fused CTLA-4 and TGF-β1 was multiplexed on pG gel and 
administered underneath the skin graft after the transplantation surgery.  An upregulation 
of regulatory T cells was observed in the flow cytometry analysis for the splenocytes 
collected from treated mice and restimulated with allogeneic antigen-presenting cells 
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(Figure 4-13).  The increase in the Treg population suggests sustained signaling of 
CTLA-4 and TGF-1 in the transplant microenvironment, most likely rendered by the 
affinity capture mechanism of the pG gel.  Additional experiments will be necessary to 
confirm this preliminary finding.  
 
Figure 4-13 representative flow cytometry plots of in vitro allogeneic re-stimulated 
splenocytes from mice treated with pG gel displayed Fc-CTLA and Fc-TGF-β1 (exp) or 
only pG gel (control) after allo skin transplantation surgery. (a) forward and side scatter 
plots for the gating of lymphocyte population P1; (b) histogram for the gating of CD4 
positive population M2; (c) dot plots showing Foxp3-A CD25 double positive cells gated 
on P1 and M2 indicating induced Treg population. 
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Discussion  
The data presented in this chapter support the notion of generating antibody 
depots in situ by intermixing IgG and pG_EAK with molar excess of EAK.  The system 
was designed around the concept of multivalent display of antibodies in vivo, employing 
a direct, specific and reversible binding interaction between the materials and antibodies.  
Derived from the partial sequence of Streptococcal protein G, consisting of the IgG-
binding C and D domains, without the albumin binding A and B domains, pG_EAK has a 
molecular weight of 25.3 kDa, a big reduction in molecular weight from dL5 complex 
with dL5_EAK of 28.4 kDa and pAGMG of 51 kDa.  The non-covalent interactions were 
also reduced from two to one.  This simplified system has the potential to increase the 
translational prospect due to the reduction of potential immunogenicity concerns and 
modeling complexity.   
The platform can be armed with multiple therapeutic antibodies, thereby enabling 
targeting distinct pathways simultaneously in pathogenic tissues and their draining lymph 
nodes.  In combination therapies, the prolonged concentration of antibodies in draining 
lymph nodes would enhance the synergistic impacts on multiple cellular and molecular 
entities driving pathogeneses.  The novelty of the system rests on the extent to which an 
antibody can be concentrated by varying the ratio of IgG and pG_EAK in the gels.  The 
simplified design facilitates the modeling of IgG release from the system by using 
reaction-diffusion model proposed by Lin and Metters [17, 256].   Two release 
mechanisms, the diffusion of the IgG from the hydrogel and the specific affinity 
interaction between the IgG and protein G, are controlling the release rate of IgG from 
the gel system.  This is manifested by three important parameters: IgG diffusivity (D), 
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IgG-pG dissociation constant (Kd) and IgG debinding rate constant (Koff).  Specifically, 
the release of free IgG from the bioaffinity pG gel is governed by Fick’s second law of 
diffusion and binding affinity between pG and IgG.  Kd determines the fraction of bound 
and free IgG in the gel throughout the release process and Koff determines the debinding 
rate.  The following equation could be used to describe the change in the IgG 
concentration within the hydrogel due to both diffusion and reversible binding to pG 
where 𝑥 is the spatial coordinate in the gel perpendicular to the gel surface (assuming 
one-dimensional release) and t is the time. 
𝜕[𝐼𝑔𝐺]
𝜕𝑡
= 𝐷 ∗
𝜕2[𝐼𝑔𝐺]
𝜕𝑥2
− 𝑘𝑜𝑛[𝐼𝑔𝐺][𝑝𝐺] + 𝑘𝑜𝑓𝑓[𝐼𝑔𝐺 − 𝑝𝐺] 
With specific values of these constants possibly obtained from SPR experiments 
for different antibody species and subtypes (example evidenced in Table 4-2), a time-
dependent distribution of [IgG], [pG] and [IgG-pG] within the gel should be able to be 
generated for a given IgG through numerical solution of the equation using finite-
difference method when the initial and boundary conditions describing the concentration 
changes of free IgG, unbound ligand and bound IgG-pG during the period of IgG release 
from the gel matrix is provided. 
The discordance between the in vitro release kinetics (Figure 4-9) and the in vivo 
retention profiles of IgG (Figure 4-10 and Figure 4-12) in pG gel can be attributed to 
several factors.  The ambient movements of the animals can disrupt the integrity of the 
localized soft gel, thereby increasing the rate of release.  The lack of a strong buffering 
system in the subcutaneous space may allow the pH to drift, perturbing the affinities of 
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pG for IgG in inflammatory tissues acidified by lactate [257].  The ionic strength may be 
depleted in vivo compared to the in vitro setting as the former may not be fully hydrated.  
pG_EAK and EAK may be degraded through proteolysis in the extracellular space and in 
intracellular organelles upon phagocytosis by macrophages, neutrophils and/or dendritic 
cells.  Multiple cleavage sites are embedded within the pG_EAK sequence for peptidase-
cleavage.  The low viscosity of the gel is conducive to such cellular uptake.  Eventually 
the materials will disintegrate after approximately 21 days [21], most likely due to a 
combination of proteolytic degradation and macrophage phagocytosis [228].  
For macromolecules such as IgG, lymphatic uptake is the main route of 
absorption from subcutaneous depots into the systemic circulation.  Preclinical studies 
indicate that diffusion of IgG through the extracellular matrix (ECM) is the rate-limiting 
step, given the relatively rapid transport from the lymph network to blood circulation.  In 
the ECM IgG are degraded by proteolytic enzymes [68].  This elimination pathway is 
compensated in part by endosomal recycling of IgG via neonatal Fc receptors (FcRn) 
expressed by local phagocytes, in which a fraction of the administered IgG is protected 
from proteases.  This is evidenced in that high doses of IgG (e.g. 40 mg/kg), however, 
can saturate FcRn in local tissues, thereby increasing the fraction vulnerable to 
proteolysis [69].  Mager and coworkers have demonstrated this by monitoring 
subcutaneous-administered rituximab in rats, in which they observed a reduction of 
bioavailability from 31% to 18% corresponding to increasing the dose from 10 mg/kg to 
40 mg/kg  [258].  We postulate that the pG_EAK gel depot mimics the protective effects 
of FcRn recycling in limiting the diffusion of IgG through the ECM. The system may be 
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analogous to biomolecular condensates discovered in eukaryotic cells, phase-separated in 
the cytoplasm, concentrating proteins and nucleic acids in a small finite volume [259].  
Conclusion 
The second generation bioaffinity hydrogel built on pG_EAK was demonstrated 
to be a simpler IgG local delivery platform involving less binding interactions in the 
design while retaining stable IgG binding capability to provide prolonged retention of 
IgG at both normal and inflammatory subcutaneous space.  The release rate could be 
modulated by varying the ratio of IgG and pG in the formulation.  The delivery of Fc 
fused immunosuppressive cytokines by pG gel underneath transplanted allogeneic skin 
graft has the potential to prolong the survival of the graft skin through upregulation of 
immunosuppressive T cell populations—regulatory T cells, which generally 
downregulate the induction and proliferation of effector T cells.  
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Appendix:  
Content for appendix includes 2 sections. The first section is the continuous 
miniaturization of IgG binding domain in the bioaffinity hydrogel design and the 
preliminary data generated regarding its application in neutrophil inhibition. The second 
part is focused on the application of these bioaffinity hydrogels as three-dimensional cell 
culture scaffold. The construction of thymus epithelium cells aggregates could be 
facilitated by the gels to promote T cell development in immunomodulatory deficient 
animals. 
I. Miniaturization of IgG Binding Domain in the Bioaffinity Hydrogel Design 
Z34c functionalized EAK gel 
The design of bioaffinity hydrogels has undergone progressive miniaturization in 
our lab, in using lower molecular weight Fc-binding domains, and reducing the number 
of non-covalent interactions, in order to simplify the optimization and reduce the 
potential immunogenicity.  Toward this goal, the construction and characterization of 
pG_EAK has been described in chapter 4.  Built on top of this pG_EAK design was the 
construction of another fusion protein Z34c_EAK for bioaffinity hydrogel formation 
(Figure 5-1).  Z34c_EAK consists of the B domain mimetic (4.18 kDa) of the 
Staphylococcal protein A (MW = 42 kDa) [260].  Generated through phage display 
randomization and point mutations from the earlier protein A mimetic Z38, Z34c is a 
disulfide-linked cyclic peptide consisting of two helices, analogous to helix-1 and helix-2 
of domain B in the native protein A [261].  The binding constants for IgG of Z34c and 
native protein A are comparable, both at approximately 20 nM [260], yet Z34c is 
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significantly smaller in size (4.18 kDa) compared to protein G domain (22 kDa) in 
pG_EAK.  Z34c_EAK was expressed in E.coli as well and Z34c is predicted to have low 
immunogenicity, with few potential MHC-II ligands [92] compared with other Fc binding 
domains (Table 5-1).  Specifically, Z34c_EAK has only one predicted ligand with 
smaller than 10th percentile while native protein A has 88 and pG_EAK has 62 predicted 
ligands with smaller than 10th percentile and smaller percentile rank indicates higher 
potential immunogenicity. 
 
Figure 5-1 Diagrams showing (a): the construct of Z34c_EAK and (b) coassembled Z34c 
gel displaying IgG molecules. 
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Table 5-1 immunogenicity prediction for different IgG binding domains based on MHC-
II ligand scanning using immune epitope database (IEDB)  
 Allele 
Predicted 
ligands 
10th 
percentile 
Peptide 
Percentile 
rank 
(consensus 
method) 
Native 
protein G 
HLA-
DRB1*0401 
137 VSDYYKNLINNAKTV 0.41 
Native 
protein A 
HLA-
DRB1*0401 
88 QNAFYQVLNMPNLNA 0.49 
pG_EAK 
HLA-
DRB1*0401 
62 GKTLKGETTTKAVDA 1.88 
Z34c_EAK 
HLA-
DRB1*0401 
1 QRRFYEALHDPNLINE 9.71 
 
Intermixing Z34c_EAK with molar excess of EAK resulted in gels that bind IgG 
antibodies which was reflected by the superior PE fluorescence signal from PE-IgG 
loaded in Z34c gels compared to other incomplete systems as well as the colocalization 
of IgG with the hydrogel fibril under fluorescence microscope by PE fluorescence from 
IgG and ThT fluorescence stained with EAK fibrils (Figure 5-2).   
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Figure 5-2 IgG loading on Z34c bioaffinity hydrogel and its colocalization with gel fibrils 
(a) Loading of PE-labeled antibody on Z34c bioaffinity hydrogel compared with that on 
incomplete systems. (b) florescence microscopy showing the colocalization of loaded 
IgG and gel fibrils reflected by the overlapping signal from PE fluorescence from labeled 
IgG and ThT fluorescence after binding to gel fibrils.  
 
In addition, Z34c is effective in increasing retention of IgG at host-graft interface 
in murine skin transplantation model after subcutaneous injection of IgG loaded on 
Z34c_EAK/EAK composite underneath the skin graft.  IgG displayed by Z34c gel 
retained better than free IgG control which diffuses away from the injection site fast.  
Relatively strong signal remained at the center of the graft for Z34c gel displayed IgG 2 
days after the injection at the host-graft interface of BALB/c donor skin on C57BL/6 
recipient mouse Figure 5-3.  Thus, we stabilized the antibody on the graft bed through 
Z34c gel. 
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Figure 5-3 The fluorescence decay over 2 days after injection of IgG800 with (test) or 
without (control) Z34c gel at the interface of host-skin graft. 
 
Inhibition of neutrophil trafficking in skin transplant model using anti-neutrophil 
surface marker IgGs displayed by Z34c gel  
One possible application of Z34c gel is to inhibit neutrophil trafficking in skin 
transplant model.  Neutrophil trafficking inhibition at the host-graft interface in allograft 
transplantation patients may play an important role in prolonging survival of skin 
allografts.  It could potentially limit fluid loss, prevent infection, decrease pain and 
promote wound healing.  We expect that neutrophil migration be impeded by antibody-
induced oligomerization of the cell-specific surface molecules Ly6G and CD11b.  The 
antibodies against those surface molecules (anti-Ly6G and anti-CD11b IgGs) can be 
displayed by our Z34c gel.  The 4.16 kDa mimetic of Staphylococcal protein A (Z34c), is 
a disulfide-linked cyclic peptide consisting of two helices.  It mimicks helix-1 and helix-2 
of domain B in the native protein A and possesses comparable affinity toward IgG to 
native protein A, but retains low immunogenicity and reduced steric hindrance during 
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coassembly with EAK16-II due to its relatively low molecular weight after fused to EAK 
(6.9 kDa).  Therefore, by displaying anti-Ly6G and anti-CD11b IgGs on Z34c gel, 
activated neutrophils can be intercepted locally and its infiltration to draining lymph 
nodes will be reduced, thus suppressing the following immune response and prolonging 
allograft survival (Figure 5-4). 
 
 
Figure 5-4 Schematic diagram showing the design of anti-neutrophil Z34c gel delivered 
at the interface of host-graft in skin transplant model  
 
The infiltration of neutrophils at the graft site were verified both ex vivo and in 
situ by detecting neutrophil elastase activity as the indicator, assuming more neutrophil 
infiltration would cause higher production of neutrophil elastase at the graft site.  For ex 
vivo assay (Figure 5-5a), neutrophil elastase was extracted from transplanted skin graft 
two days after transplantation and incubated with the fluorogenic elastase substrate 
MeOSuc-AAPV-AMC.  The fluorescence intensity generated after incubation was 
compared to that generated from elastase extracted from naïve ear skin without 
transplantation.  Higher elastase activity was detected in skin graft recovered from a 
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transplanted mouse compared to fresh ear skin reflected by higher fluorescence intensity 
detected from the former at varying time points resulting in a higher slope of the line 
fitting the data, which indicates a higher catalytic rate facilitated by more neutrophil 
elastase.  For in situ assay (Figure 5-5b), local administration of NE680, the agent which 
contains an elastase substrate that relieves the quenching of two conjugated dye when 
cleaved, was performed on the graft bed of transplanted mouse one day after the 
transplantation surgery.  The yielding fluorescence in the near infrared range on the graft 
bed after removal of the skin graft was monitored for 2 days and compared to the control 
fluorescence generated on the open wound on the same location without transplantation. 
Higher elastase activity detected on allo-transplanted mouse compared to control open 
wound is in agreement with the in situ assay. 
 
Figure 5-5 verification of neutrophil infiltration after skin transplantation surgery at the 
graft site (a) ex vivo assay determining the fluorescence intensity of the fluorogenic 
neutrophil elastase substrate after incubation with transplanted skin graft or naïve ear skin 
without transplantation. (b) in situ assay determining the near infrared signal after 
delivering signal generating neutrophil elastase substrate NE680 to the transplantation 
site and compared to open wounds without allo skin transplantation surgery. 
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After the elevated neutrophil infiltration level at the graft site after skin 
transplantation surgery was confirmed, the effect of anti-neutrophil antibody treatment 
displayed by the Z34c bioaffinity module was tested in vivo by injecting neutrophil 
specific, NIR fluorescent imaging agent cFLFLF-PEG-Cy7, which binds to formyl 
peptide receptor on activated neutrophil, through tail vein the second day after 
transplantation surgery and anti-neutrophil antibody treatment.  The signal accumulation 
at the graft site was compared to the control setup with the administration of only Z34c 
gel.  From the in vivo imaging scan, less neutrophil accumulation at transplantation site 
was observed in treated mouse, suggesting that this treatment could effectively impede 
continuous neutrophil infiltration after immobilizing first wave of neutrophil infiltration. 
 
Figure 5-6 Graft homing-neutrophil impediment at host-graft interface (a) diagram 
showing the treatment and injection regime after skin transplantation surgery. (b) NIR 
signal tracking after injection of neutrophil specific, NIR fluorescent imaging agent 
cFLFLF-PEG-Cy7. 
Meanwhile, this strategy can be coupled with anti-neutrophil elastase particles to 
counter tissue-destructive mechanism elicited by neutrophil elastase.  Alvelestat (AZD 
9668), a selective elastase inhibitor, can be loaded in PLGA particles and the particles 
could be trapped into the EAK gel matrix to work synergistically with the displayed 
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antibodies to constrain neutrophil effect.  The EAK gel could trap the particles and 
slowdown the release of the particles.  Transplant necrosis is expected to be reduced 
through this method.  DiR dye loaded PLGA particles was used as the model particles to 
demonstrate their entrapment effect in EAK gels.  The NIR dye DiR (ex/em: 
750nm/780nm) can provide a readout signal representative of the particle location.  The 
entrapment of DiR loaded PLGA particles in EAK was successfully verified by 
comparing the NIR signal distribution in systems with or without EAK.  A localized and 
concentrated NIR signal can be observed in system incorporating EAK (Figure 5-7). 
 
Figure 5-7 Odyssey scan (800nm channel) for particle distribution before and different 
time points after the addition of release medium to the system. DiR particles were set up 
at the bottom of the vials initially with (left) or without (right) EAK gels (first panel) and 
200 ul of PBS was added to each sample before inversion of the vials (system 
incorporating EAK gel shows on the right side for later time points) 
 
This is the demonstration of potential combination of anti-neutrophil antibodies 
treatment and anti-neutrophil elastase therapy facilitated by miniaturized bioaffinity 
hydrogel and small molecule weight drug incorporated particles trapped in the gel 
respectively.  The experiments described in this section are mainly preliminary data, most 
of which are still lack of replicates.  Further verification of the results would be required 
in the future by adding replicates.  In addition, the proposed combination use of 
bioaffinity hydrogel and particles is proof of concept where the entrapment of particles in 
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the gel was realized by using dye loaded particles.  The effectiveness of the 
combinational therapy needs further investigation by using real drug loaded particles. 
 
 
  
 160 
II. Bioaffinity Hydrogels for Cell Therapeutics 
3D cell culture facilitated by hydrogels 
Another application of the functionalized EAK based hydrogels is to facilitate 
three-dimensional (3D) cell culture for cell therapeutics in tissue engineering.  3D cell 
culture facilitated by hydrogels is a commonly exploited strategy in tissue engineering 
field to provide the cells with the mimetic microenvironment when they actually reside in 
tissue.  Hydrogel affords necessary geometry and provide similar environment to 
extracellular matrix (ECM) to facilitate cell survival or proliferation, allowing the cells to 
behave more reflective of their in vivo response [262].  In addition, the spatial 
organization of the cell surface receptors involved in the interactions of neighboring cells 
could be influenced and physical constraints will be exerted to the cells with the hydrogel 
facilitated 3D cell culture.  The potential application of the bioaffinity hydrogel was 
explored in the generation of mini functional thymic units which is essentially 3D culture 
of thymic epithelial cell (TEC) clusters.  The TEC clusters lie in the stroma of the 
thymus, the essential gland for adaptive immunity which is responsible for continuous 
generation of new T-lymphocytes to effectively respond to evading pathogens, while 
remaining unresponsive to self.  The epithelial cells in thymus is unique in that their 
functional and survival are relying on their 3D organization because TECs cultured in a 
2D monolayer display altered patterns of expression of key genes for TEC function and 
growth, thereby losing their ability to support T cell development [263].  
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Construction of mini thymus unit through bioaffinity hydrogel assisted 3D 
aggregates of thymus epithelium cells (TECs) 
The construction of mini artificial thymic units to support the development of 
mature T cells in immunomodulatory disorders can be achieved by 3D aggregation of 
thymus epithelium cells (TECs).  Formation of 3-D TEC clusters facilitated by anti-
EpCAM (TECs surface marker) IgG displayed EAK gel helps to retain the molecular 
properties of those cells, thus generating a functional mini thymus and supporting 
functional T cells development.  Anti-EpCAM antibodies could be displayed by any Fc-
binding domain functionalized EAK gel described previously including Z34c, protein G 
(pG), or protein A/G (pAG) either attached to EAK sequence directly or with the help of 
adaptor complex formation.   Figure 5-8 shows an example of one design incorporating 
coassembly of EAK16-II and its histidinylated analogue EAKIIH6, and the formation of 
adaptor complexes (pA/G loaded with both anti-His and anti-EpCAM IgGs) [264]. 
 
Figure 5-8 Schematic drawing showing the strategies to generate the TECs mini thymus 
unit. The tri-component adaptor complex was formed by mixing anti-EpCAM antibody 
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(Ab), anti-His Ab and recombinant protein A/G at 3:3:1 ratio. Isolated thymic epithelial 
cells (TECs) were stained with the adaptor complexes, and mixed with EAK16-II and 
EAKIIH6 mixture in 10% sucrose. Gelation was initiated by adding complete RPMI-10 
medium to the cell material mixture. 
 
As a demonstration of bioaffinity hydrogel application in cell therapeutics, 
primary medulla thymic epithelial cells were delivered in an anti-EpCAM antibody-
armed bioaffinity gel into nude mice.  The cells are expected to congregate into 
functional units in vivo, leading to emergence of CD4 positive and CD8 positive T cells 
in the mice.   Toward this goal, the 3D mini thymus unit was constructed in vitro by using 
the bioaffinity hydrogels described in Figure 5-8 to provide geometrical organization of 
the TECs in the 3D gel scaffold, thereby helping to establish proper TEC-TEC and TEC-
thymocyte interaction for successful thymopoiesis. 
In this design, the amphiphilic peptide EAK16-II co-assembles with its C-
terminal histidinylated analogue EAKII-H6 (AEAEAKAKAEAEAKAKHHHHHH) to 
generate the Histidine (His)-tags integrated, ionic strength responsive bioaffinity 
hydrogel.  This functionalized bioaffinity 3D scaffold provides a docking mechanism, 
with antibodies of interest being anchored to the gel with the help of a linker complex 
comprised of anti-His antibodies and the Fc-binding, recombinant protein A/G.  It was 
utilized to induce 3D aggregation of TECs for in vitro culture through the display of anti-
EpCAM IgGs which target the surface marker of TECs.  This bioaffinity hydrogel design 
based on EAKII-H6 was systemically characterized by previous member in our lab and is 
out of the scope of this dissertation.  However, its application in the cell therapeutics was 
explored here since the same principle could be applied to all the bioaffinity hydrogel 
designs described in this dissertation. 
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The high affinity interaction between the His-tag embedded in the bioaffinity 
hydrogel matrix and the anti-His IgG served as a molecular bridge to anchor the EpCAM 
expressing TECs on the EAK16II/EAKIIH6 structure through another high affinity 
interaction between protein A/G and anti-EpCAM/anti-His IgGs.  TECs formed clusters 
of 20-30 cells in the hydrogel matrix as shown in Figure 5-9a, suggesting that the 
EAK16-II and EAKIIH6 bioaffinity hydrogel system could induce the aggregation of 
TECs.  The viability of TECs embedded in the EAK16-II/EAKIIH6 bioaffinity hydrogel 
was examined using calcein-AM and ethidium homodimer-1 (EthD-1) staining.  The 
presence of green calcein-AM signal indicates live cells with intracellular esterase 
activity, whereas red-fluorescent EthD-1 is retained in dead cells with compromised 
plasma membrane integrity.  Most of the TECs remained alive after 3 days culture within 
the gel as shown in Figure 5-9b.  These image results, together with detection of 
expression of genes specific to thymic epithelium (EpCAM) and different TEC subsets 
(Krt5 and Krt14 for mTECs and Krt8 for cTECs) as well as transcriptions of TEC-
specific transcription factors (FoxN1 and Tbata) and expression of signaling molecules 
(CCL25) important for lympho-stromal interaction through RT-PCR, suggest that TECs 
embedded in the bioaffinity hydrogel as clusters not only can maintain their thymic 
epithelium identity in vitro, but also be able to retain their functionalities to support T cell 
development in vivo.  The EAK16-II/EAKIIH6 based mini-thymus units were 
transplanted underneath the kidney capsules of athymic B6.FoxN1-/- nude mice and flow 
cytometry analyses revealed the presence of circulating CD45+CD3+ T cells 5 weeks post 
operation.  Both CD3+CD4+ and CD3+CD8+ T cells were found to be present in 
secondary lymphoid organs.  Those T cells are capable of reacting to alloantigens but not 
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syngeneic antigens which was reflected by their proliferating response after mixed 
leukocyte reaction (MLR) assay where drastic proliferation was observed for T cells 
mixed with allogeneic antigen presenting cells while only limited, background levels of 
proliferation were observed for T cells when syngeneic antigen presenting cells were 
supplemented.  Therefore, the functionality of the mature T cells in the thymus 
reconstructed B6. Nude mice was confirmed to be similar to that of wild-type B6 mouse 
while staying self-tolerant.  The RT-PCR experiments in verifying the gene, transcription 
factors and signaling molecules expression levels in vitro, and flow cytometry analyses 
for in vivo T-lymphopoesis verification after transplantation of mini thymus units into 
athymic mice, were conducted by our collaborators at Allegheny General Hospital and 
documented in the paper published on clinical immunology.  Details of those experiments 
could be found in reference [264]. 
 
Figure 5-9 Generation of TECs mini thymus complex in vitro. (a) representative phase 
contrast microscopic image (50X) of TEC aggregations (arrows) in EAK16-II/EAKH6 
hydrogel. (b) representative fluorescent microscopic images of TEC aggregates in 
EAK16-II/EAKH6 hydrogel cultured in vitro for 3 days. Live cells were discriminated 
from the dead cells by their intracellular esterase activities to generate green fluorescen 
calcein-AM (green) and their capabilities to exclude the red fluorescent ethidium 
homodimer-1 (EthD-1, red) from entering the nucleus. Left panel, low magnification 
image (100X) of the TEC aggregates (white arrows). Right panel, high magnification 
image (400X) of the TEC aggregates. 
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Taken together, it was demonstrated that TECs anchored to EAK16-II/EAKIIH6 
bioaffinity hydrogel with anti-EpCAM IgG containing tri-component adaptor complex 
could self-assemble into 3D aggregates.  This 3D configuration could retain, to a certain 
degree, the properties of the TECs in vitro, and enable them to function as mini thymus 
units to support the development of mature T cells when engrafted into athymic nude 
mice.  The construction of mini thymus units, which is essentially TECs organized in the 
3D configuration, mimicking TECs cultured in the thymus stroma, could be extended to 
other bioaffinity hydrogel designs, including the ones described in chapter 3 and chapter 
4.   
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